Liraglutide Clinical Protocol

Purpose. This is the Module 5 (Weight Loss & Metabolic) clinical protocol for liraglutide (Novo Nordisk; FDA-approved for marketing claims as Victoza for type 2 diabetes in adults January 2010 and in pediatrics ≥10 years June 2019, with cardiovascular risk reduction in T2D + established CVD added August 2017; Saxenda for chronic weight management in adults December 2014 and in adolescents ≥12 years with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted December 2020; Xultophy 100/3.6 fixed-ratio combination with insulin degludec for T2D November 2016; multiple FDA-approved generic ANDAs 2024–2025), produced under the Protocol Template v1.0. The protocol’s evidence base is the v1.0-final liraglutide canonical at /Peptides/Liraglutide.md (2026-05-12) plus the verified Bibliography at /Process/Liraglutide/. The structural authority is the Protocol Template; the content authority is the canonical and its verified primary sources.

FDA-approved for marketing claims — load-bearing precision (Editorial Framework §1.2.1; Pattern AA.marketing-claims). The phrase “FDA-approved” throughout this protocol is shorthand for “FDA-approved for marketing claims for [indication X].” FDA approval is indication-specific, not drug-specific; off-label use of an FDA-approved-for-marketing-claims drug remains use of an FDA-approved drug. The protocol uses the convention “FDA-approved for marketing claims for [X]; off-label for [Y]” wherever both registers apply. The shorthand “FDA-approved” appears after each first-mention expansion within a section.

Compound-class framing — liraglutide is a peptide. Liraglutide is a 31-amino-acid acylated peptide analog of native human GLP-1 (7-37), 97% sequence-homologous, with a C16 palmitic fatty acid attached via a γ-glutamic acid spacer at Lys26 and a lysine-to-arginine substitution at position 34 (Jacobsen 2017 Clin Pharmacokinet PMID 26597252). Pattern N.1 enforcement: this protocol lives at /Protocols/ under the peptides folder structure, not at /Small-Molecules/. Orforglipron and aleniglipron — the small-molecule oral GLP-1 receptor agonists — belong at /Small-Molecules/; liraglutide does not.

Liraglutide-specific calibration notes (load-bearing for the production agent and the verification gate).

• Multi-indication, multi-product, multi-population FDA-approved-for-marketing-claims compound. Liraglutide is FDA-approved for marketing claims for type 2 diabetes (Victoza 1.2 and 1.8 mg daily; adults and pediatric ≥10 years), chronic weight management (Saxenda 3.0 mg daily; adults and pediatric ≥12 years with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted), cardiovascular risk reduction in adults with T2D + established CVD (Victoza 1.8 mg daily on the basis of LEADER PMID 27295427), and as the GLP-1 RA component of the FDA-approved-for-marketing-claims Xultophy 100/3.6 fixed-ratio combination with insulin degludec (T2D). Every indication-scope sentence in §1.5 carries the AA.marketing-claims-precise expansion at first-mention.
• Daily injection — Pattern Z.injection-framing applies. Liraglutide’s once-daily subcutaneous dosing is a routine clinical skill, taught in one clinical visit, refined over the first few self-administrations — equivalent to daily insulin self-injection, daily fertility-hormone self-injection, daily biologic self-injection routinely taught across endocrinology and primary-care practice. The protocol does NOT default-frame daily dosing as a “burden,” “barrier,” “the hardest part,” or “what patients struggle with most.” Where the daily-vs-weekly comparison appears (§10.5 Anchor 4; §10.7), daily dosing is framed as a legitimate clinical-option dimension with specific differentially-relevant clinical-use cases (peri-procedural settings; faster discontinuation clearance for AE management; pre-conception washout; pediatric daily-supervision contexts; specific T2D management contexts where daily routine aligns with broader once-daily regimens). The substantive titration-management discussion is dose-tolerance, not injection mechanics.
• Pre-conception washout advantage — short half-life. Liraglutide elimination half-life ~13 hours; ~2-day washout (~5 half-lives) for substantial clearance to non-detectable plasma concentrations vs ~35-day washout for semaglutide and ~25-day washout for tirzepatide. For pre-conception planning, this PK profile is a substantive differential factor — Anchor 3 framing in §10.4 carries the comparator-advantage explicitly. The eight-week label-recommended pre-conception interval is the conservative regulatory framing applied across the GLP-1 RA class; the underlying PK clearance arithmetic differs across half-lives and is reported here factually.
• Pediatric obesity — longest clinical track record in the class. Liraglutide carries the longest pediatric clinical-use record in the GLP-1 receptor agonist class: Victoza ≥10 years for T2D (FDA approval June 2019 on the basis of ELLIPSE PMID 31034184) and Saxenda ≥12 years for chronic weight management with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted (FDA approval December 2020 on the basis of SCALE Teens PMID 32233338). Semaglutide pediatric obesity approval (Wegovy ≥12 years, 2022 on the basis of STEP-TEENS PMID 36322838) is shorter-duration. §1.5 indication scope distinguishes adolescent-CWM as approved-for-marketing-claims for 12–17-year-olds with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted; §6 (pediatric AE), §8.5 (pediatric monitoring), §10 (pediatric counseling beats) develop the pediatric-specific clinical-translation considerations.
• First FDA-approved generic in the GLP-1 RA class — compounding-pathway question is largely moot. Saxenda US patent estate expired June 2024; multiple FDA-approved generic liraglutide ANDAs received approval in the 2024–2025 timeframe — the first FDA-approved generic in the GLP-1 receptor agonist class. Generic liraglutide is bioequivalent to branded Saxenda/Victoza per FDA ANDA requirements (Tier 1 evidence; Rogers-Crovak 2024 AAPS J PMID 39586870 regulatory-policy framework). The compounding-pathway 503A/503B FDA-shortage rationale that drove compounded-semaglutide and compounded-tirzepatide demand spikes during the 2022–2024 FDA-declared shortage periods does not apply identically to liraglutide — liraglutide is no longer in FDA-declared shortage and generic supply is FDA-approved. Anchor 2 framing in §10.3 reflects this current regulatory state: the operational question for liraglutide is branded-vs-generic-vs-compounded rather than the FDA-approved-vs-compounded framing carried by sema/tirz protocols. Some compounding pharmacies and direct-to-consumer marketplaces continue to offer compounded liraglutide under different regulatory rationale (research-use claims; international-sourced API; non-FDA-shortage operational basis) — presented factually, not as the dominant operational supply category.
• Class-level CVOT — LEADER established the precedent. LEADER (Marso 2016 NEJM August PMID 27295427; n=9,340 adults with T2D + established CVD or high CV risk; 3.8-year median follow-up; three-point MACE HR 0.87 [95% CI 0.78–0.97], p=0.01 for superiority; CV death HR 0.78, p=0.007; all-cause mortality HR 0.85, p=0.02; nephropathy composite HR 0.78, p=0.003) was the first Phase 3 cardiovascular outcomes trial of a GLP-1 receptor agonist to demonstrate cardiovascular benefit on the primary three-point MACE endpoint. The cardiovascular indication was added to Victoza labeling August 25, 2017 on the basis of LEADER. §1.5 frames this historical-precedent context precisely as research-state factual context — the first positive GLP-1 RA CVOT in the class, predating SUSTAIN-6 (Marso 2016 NEJM December PMID 27633186; semaglutide T2D + CVD) and SELECT (Lincoff 2023 NEJM PMID 37952131; semaglutide obesity + CVD without T2D). Pattern V.metric-axis enforcement: every LEADER effect-size citation carries the per-arm event-rate context and the between-group HR + CI; §10.5 Anchor 4 comparator-conversation effect-sizes carry the metric-axis qualifier explicitly. Pattern V.estimand-axis: LEADER reported both treatment-policy and on-treatment estimands; the canonical and this protocol cite the treatment-policy primary endpoint as the headline finding consistent with regulatory conventions.
• Route — SC injection only. Liraglutide is administered subcutaneously across all approved formulations (Victoza, Saxenda, Xultophy). There is no approved oral liraglutide platform — the oral GLP-1 RA paradigm has been pursued via different molecular architectures (oral semaglutide Rybelsus via SNAC absorption-enhancer; oral non-peptide orforglipron / aleniglipron). Counseling beats and comparator conversations carry this route precision factually.

Pattern Z anti-steering discipline summary across the protocol. Anchor 1 (lead with what the option IS); Anchor 2 (compounded vs FDA-approved; reframed for liraglutide post-generic-entry as branded-vs-generic-vs-compounded); Anchor 3 (pregnancy planning — lead with Parker 2025 PMID 40329607 human pregnancy-exposure data; carry liraglutide-specific shorter-half-life washout comparator-advantage explicitly); Anchor 4 (comparator framing — multi-dimensional fact presentation; STEP 8 PMID 35015037 head-to-head semaglutide-vs-liraglutide weight-loss-magnitude differential explicitly acknowledged; daily-dosing PK profile, pediatric record, generic availability, CV evidence base, cost/access dimensions presented factually; affirms both compounds as evidence-based options for their respective patient-population contexts; closes with shared-decision-making); Anchor 5 (off-label / extrapolation — name the trial population; magnitude; readout state). Pattern Z.injection-framing across the protocol; Pattern Z.research-precision across the protocol.

Table of Contents

1. Indication scope and patient phenotypes
2. Selection criteria (inclusion / exclusion / contraindications)
3. Pre-treatment workup
4. Initiation protocol
5. Maintenance protocol
6. Side-effect management
7. Plateau and non-response algorithm
8. Discontinuation and tapering
9. Combination rules
10. Patient counseling beats (Pattern Z calibration-anchor-compliant)
11. Source citations
12. Clinical decision tree

Appendices

• A. Verification gate self-audit findings
• B. Pattern discipline summary
• C. Items deferred to Dr. Gross verification gate

Methodology cross-references

• /Methodology/Protocol Template.md — structural authority; 12-section template; post-patch state 20e66bd
• /Methodology/Synergy Editorial Framework.md — voice, framing discipline, length-by-evidence-density, §1.2.1 FDA-approved-for-marketing-claims convention, §1.4 loaded-vocabulary scrub (post-2026-05-13 patch including “highly experimental” / injection-framing entries)
• /Methodology/Voice Profile - Dr. Jeff Gross MD.md — clinician-voice calibration
• /Methodology/AC2-26 - System Observations.md — Pattern R / R.1 / R.2 / V / V.metric-axis / V.estimand-axis / W / Z / Z.injection-framing / Z.research-precision / AA / AA.marketing-claims / AB.1 / AB.2 / AB.4 / N.1
• /Peptides/Liraglutide.md — v1.0-final canonical reference (evidence source)
• /Process/Liraglutide/ — production artifacts: Bibliography (28/28 PMIDs + 7/7 NCTs verified; AB-hygiene compliant), PSV iteration 1, IAR iteration 1, Dr. Gross Verification simulation
• /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — Pattern Z verbatim anchors (Anchors 1–5)
• /obsidian-peptides/Peptides/Semaglutide.md — successor-compound canonical (predecessor-vs-successor comparator framing source for §10.5)
• /obsidian-peptides/Protocols/Semaglutide Protocol.md — Wave 1 lead exemplar (Anchor 1–5 verbatim source)
• /obsidian-peptides/Protocols/Tirzepatide Protocol.md — Wave 1 sibling exemplar (comparator framing reference at §10.5 for the dual-agonist axis)

---

1. Indication scope and patient phenotypes

1.1 Purpose

Define where liraglutide applies — the indication scope — and which patient phenotypes within that scope are the protocol’s primary, secondary, and tertiary targets. Section 1 is the protocol’s applicability gate: every downstream section (Section 2 selection criteria, Section 3 pre-treatment workup, Section 4 initiation, Section 5 maintenance, Section 6 AE management, Section 9 combination rules, Section 10 counseling beats) is read through the indication scope established here.

Pattern R.1 enforcement: open with what liraglutide does and for whom — the FDA-approved indications and their pivotal trial program evidence base — not with what it does not do, who it excludes, or what regulatory limits constrain it. Exclusions, contraindications, and regulatory framing live in Section 2 and Section 11 respectively. Section 1 leads with research-state content.

Pattern R.2 enforcement: the indication scope is locked at the section-architecture-design step — before content generation. Liraglutide has, as of 2026-05-13, four FDA-approved-for-marketing-claims indications (type 2 diabetes — Victoza January 2010 adult; pediatric ≥10 years June 2019; chronic weight management — Saxenda December 2014 adult; pediatric ≥12 years with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted December 2020; cardiovascular risk reduction in adults with T2D + established CVD — Victoza August 2017; fixed-ratio combination with insulin degludec — Xultophy 100/3.6 November 2016 for T2D) plus a multi-decade post-marketing surveillance window (the longest in the GLP-1 RA class) and supplementary trial-program evidence for secondary endpoints (OSA via SCALE Sleep Apnea PMID 27005405; T2D prevention via SCALE 3-year prediabetes extension PMID 28237263). The protocol does not drift indication scope mid-draft; every section below is read against this scope-lock.

1.2 Indication categories — applied to liraglutide

Within the Module 5 indication taxonomy established by the Protocol Template §1.2, the indication categories liraglutide populates:

1. Type 2 diabetes mellitus (T2D) — glycemic control. FDA-approved for marketing claims via Victoza (adults January 25, 2010; pediatric ≥10 years June 17, 2019). Pivotal program: LEAD-1 through LEAD-6 (adult; PMIDs 19317822, 18931095, 18819705, 19289857, 19688338, 19515413; collectively n~3,800; multiple background-therapy contexts and comparator arms) plus ELLIPSE (pediatric ≥10 years; Tamborlane 2019 NEJM PMID 31034184; NCT01541215; n=134). Endpoint: HbA1c reduction. Effect-size anchor (adult): ~1.0–1.5 percentage-point HbA1c reduction at 1.8 mg daily across LEAD trials. Effect-size anchor (pediatric): HbA1c reduction −0.64% (liraglutide) vs +0.42% (placebo) at week 26 in ELLIPSE; estimated treatment difference −1.06 percentage points (95% CI −1.65 to −0.46; p<0.001). Phenotype primary targets: adult T2D with HbA1c above individualized target on metformin or metformin-intolerant; pediatric T2D ages 10–17 inadequately controlled on metformin ± basal insulin.

2. Chronic weight management (CWM) — adults with BMI ≥30 kg/m² or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, ASCVD). FDA-approved for marketing claims via Saxenda (December 23, 2014). Pivotal program: SCALE Obesity and Prediabetes (Pi-Sunyer 2015 NEJM PMID 26132939; n=3,731; 56 weeks; body weight change −8.0% liraglutide vs −2.6% placebo, estimated treatment difference −5.4 percentage points, p<0.001); SCALE Maintenance (Wadden 2014 Int J Obes PMID 23812094; n=422; weight maintenance + additional loss after low-calorie-diet-induced loss); SCALE Diabetes (Davies 2015 JAMA PMID 26284720; n=846; T2D + BMI ≥27; body weight −6.0% at 3.0 mg vs −2.0% placebo); SCALE Sleep Apnea (Blackman 2018 Int J Obes PMID 27005405; n=276; obesity + moderate-to-severe OSA; AHI reduction −12.2 events/hour liraglutide vs −6.1 placebo, p=0.015); SCALE 3-year prediabetes extension (le Roux 2018 Lancet PMID 28237263; n=2,254; 79% relative reduction in T2D incidence over 3 years; cumulative T2D incidence 2.0% liraglutide vs 6.0% placebo). Endpoint: percent change in body weight from baseline. Effect-size anchor (between-group treatment difference; Pattern V.metric-axis): −5.4 percentage points at 56 weeks per SCALE Obesity (per-arm: −8.0% liraglutide vs −2.6% placebo).

3. Chronic weight management in adolescents ≥12 years with body weight >60 kg and BMI corresponding to the 95th percentile or greater for age and sex. FDA-approved for marketing claims via Saxenda pediatric extension (December 4, 2020). Pivotal trial: SCALE Teens (Kelly 2020 NEJM PMID 32233338; NCT02918279; n=251; adolescents ages 12–17 with body weight >60 kg + BMI ≥95th percentile; 56-week primary endpoint). Endpoint: change in BMI standard deviation score (BMI SDS / BMI z-score) from baseline at week 56. Effect-size anchor (between-group treatment difference; Pattern V.metric-axis): BMI SDS reduction −0.22 liraglutide vs −0.02 placebo at week 56; estimated treatment difference −0.22 (95% CI −0.37 to −0.08; p=0.002). Body-weight change (between-group): treatment difference −5.01 percentage points (per-arm: −2.65% liraglutide vs +2.37% placebo; 95% CI −7.63 to −2.39; p<0.001). The proportion achieving ≥5% BMI reduction at week 56: 43.3% liraglutide vs 18.7% placebo. Liraglutide carries the longest pediatric clinical-use record in the GLP-1 receptor agonist class — SCALE Teens was the first FDA approval of a GLP-1 RA for adolescent obesity in the United States; semaglutide’s pediatric obesity approval (Wegovy ≥12 years, FDA approval 2022) on the basis of STEP-TEENS (Weghuber 2022 NEJM PMID 36322838) followed by approximately two years.

4. Cardiovascular risk reduction in adults with T2D + established cardiovascular disease. FDA-approved for marketing claims via Victoza labeling supplement (August 25, 2017). Pivotal trial: LEADER (Marso 2016 NEJM August PMID 27295427; NCT01179048; n=9,340; T2D + established CVD or high CV risk; randomized 1:1 to liraglutide 1.8 mg daily vs placebo on background standard-of-care; median follow-up 3.8 years). Primary endpoint: three-point MACE composite (CV death, non-fatal MI, non-fatal stroke). Effect-size anchor: MACE HR 0.87 (95% CI 0.78–0.97), p=0.01 for superiority (per-arm event rates: 13.0% liraglutide vs 14.9% placebo across 3.8-year median follow-up — Pattern V.metric-axis qualifier carried at every effect-size citation). Secondary endpoints: CV death HR 0.78 (95% CI 0.66–0.93; p=0.007); all-cause mortality HR 0.85 (95% CI 0.74–0.97; p=0.02); nephropathy composite HR 0.78 (95% CI 0.67–0.92; p=0.003) — a 22% reduction. LEADER was the first Phase 3 cardiovascular outcomes trial of a GLP-1 receptor agonist to demonstrate cardiovascular benefit on the primary three-point MACE endpoint — a historical inflection point for the class, predating SUSTAIN-6 (Marso 2016 NEJM December PMID 27633186; semaglutide T2D + CVD) by approximately four months at publication and predating SELECT (Lincoff 2023 NEJM PMID 37952131; semaglutide obesity + CVD without T2D) by approximately seven years. Pattern Z.research-precision: this is research-state historical fact about trial-program chronology, not promotional positioning. Phenotype primary target: adults with T2D + established CVD or high CV risk per LEADER enrollment criteria (≥50 years with prior MI, stroke, TIA, revascularization, heart failure NYHA II/III, or ≥50% coronary/carotid/lower-extremity stenosis; OR ≥60 years with at least one CV risk factor).

5. Fixed-ratio combination with insulin degludec (Xultophy 100/3.6) — T2D adjunct to diet and exercise. FDA-approved for marketing claims November 21, 2016 (US; earlier EMA approval 2014). Pivotal program: DUAL program (multiple Phase 3 trials evaluating the insulin degludec + liraglutide fixed-ratio combination vs insulin degludec alone, insulin glargine, and add-on therapy across T2D background contexts). Composition: insulin degludec 100 units + liraglutide 3.6 mg per mL fixed ratio; dose-step-delivered combination (1 dose step = 1 unit insulin degludec + 0.036 mg liraglutide). Indication: T2D adults requiring intensified glycemic control. Endpoint: HbA1c reduction. Phenotype primary target: T2D adults inadequately controlled on basal insulin or oral antidiabetic regimens, where the GLP-1 RA + basal insulin combination is clinically indicated.

Supportive secondary trial-program evidence — not separate FDA-approved indications:

• Obstructive sleep apnea (OSA) — obesity-related. SCALE Sleep Apnea (Blackman 2018 Int J Obes PMID 27005405; n=276; obesity + moderate-to-severe OSA; AHI reduction −12.2 events/hour liraglutide vs −6.1 placebo at 32 weeks; p=0.015; body weight reduction −5.7% liraglutide vs −1.6% placebo). SCALE Sleep Apnea is supportive secondary trial-program evidence within the Saxenda chronic-weight-management indication — patients with obesity + moderate-to-severe OSA who meet the CWM label criteria can be treated with Saxenda for the CWM indication and may experience secondary AHI improvement, predominantly weight-loss-mediated. The FDA-approved-for-marketing-claims OSA-with-obesity pharmacological indication in 2026 is held by tirzepatide (Zepbound for OSA with obesity, December 2024 FDA approval on the basis of SURMOUNT-OSA PMID 38912654); liraglutide is not FDA-approved for marketing claims for OSA as a primary indication as of 2026-05-13. Pattern AA.marketing-claims precision applies.

• Type 2 diabetes prevention in prediabetes. SCALE 3-year prediabetes extension (le Roux 2018 Lancet PMID 28237263; n=2,254 from the SCALE Obesity prediabetic cohort; 3-year time-to-T2D primary endpoint; 79% relative reduction in T2D incidence with liraglutide 3.0 mg vs placebo over 3 years; cumulative T2D incidence 2.0% liraglutide vs 6.0% placebo). T2D-prevention is supportive secondary trial-program evidence within the Saxenda chronic-weight-management indication, not a separate FDA-approved-for-marketing-claims indication. Patients with prediabetes meeting Saxenda CWM criteria may experience secondary T2D-prevention benefit.

• MASH / MASLD — class-level integration. Liraglutide-specific MASH evidence is from the older Phase 2 LEAN trial corpus (Armstrong et al. 2016 Lancet — small Phase 2 RCT of liraglutide in biopsy-proven NASH) and class-level pooled analyses. The active Phase 3 MASH program is concentrated on semaglutide (ESSENCE PMID 40305708; FDA approval for MASH August 2025), tirzepatide (SYNERGY-NASH Phase 2 PMID 38856224; Phase 3 in development), and survodutide (LIVERAGE Phase 2). Liraglutide is not FDA-approved for marketing claims for MASH as of 2026-05-13; the class-level MASH evidence base does not have a liraglutide-specific dedicated Phase 3 trial. Patients with MASH for whom GLP-1 RA therapy is being considered are typically routed to semaglutide for the FDA-approved-for-marketing-claims MASH indication; liraglutide-mediated weight loss may contribute to MASH improvement at the population level but the specific indication is class-level rather than liraglutide-specific.

Pattern AA.marketing-claims enforcement at this section: every indication-scope sentence above carries the precision — FDA-approved for marketing claims for [specific indication] [with brand and date] vs supportive secondary trial-program evidence within an existing indication vs not FDA-approved for marketing claims for [indication]. The protocol does not use “approved-pending,” “emerging,” “next-generation,” or other promotional-coded framing. Pattern Z.research-precision: every cited trial is named with primary author, journal, year, PMID, and NCT (where applicable); effect-size magnitudes are anchored to specific trial-population enrollments.

1.3 Phenotype-targeting taxonomy applied to liraglutide

Within each liraglutide indication, the phenotype-targeting refines selection. The dimensions per Protocol Template §1.3 are populated for liraglutide as follows:

• Metabolic phenotype. Insulin-resistant phenotypes — the dominant LEAD / SCALE / LEADER enrollment — are the primary phenotype. The single GLP-1R agonism mechanism produces glycemic-control magnitudes appropriate for T2D HbA1c targets across the standard insulin-resistant phenotype; for advanced beta-cell-failure phenotypes (long-duration T2D with attenuated endogenous insulin reserve), response may be attenuated. The fixed-ratio combination with insulin degludec (Xultophy) addresses the beta-cell-failure-advanced T2D phenotype with a complementary basal-insulin component (§9.2 combination rules).

• Adiposity distribution. Visceral-dominant and subcutaneous-dominant obesity phenotypes are both supported by SCALE program enrollment (BMI ≥30 or BMI ≥27 + comorbidity). Waist-circumference and visceral-adiposity-distribution anchors apply at §3.2 anthropometric baseline. SCALE program effect sizes apply across phenotype distributions; no specific adiposity-distribution stratification supports differential dosing.

• Appetite phenotype. Hyperphagia-dominant and slow-satiety-dominant appetite phenotypes are the central appetite-circuit-engagement targets — GLP-1R activation in hypothalamic POMC/CART circuitry and brainstem NTS circuitry supports central appetite suppression. Hedonic-eating-dominant and nocturnal-eating-dominant phenotypes may show variable response; class-level RCT effect sizes apply across phenotype categories without specific stratification.

• Energy-expenditure phenotype. Low-REE-for-mass and adaptive-thermogenesis-prone phenotypes are not differential primary targets for liraglutide; the mechanism is appetite-suppression-dominant rather than energy-expenditure-augmenting. The dual-receptor and triple-receptor compounds (tirzepatide; survodutide; retatrutide) engage GIP and/or glucagon receptors that contribute incremental energy-expenditure mechanisms, but liraglutide’s single-GLP-1R mechanism does not — Pattern V.research-precision: this is mechanism-class-distinction factual context, not promotional differentiation.

• Comorbidity load. Liraglutide’s multi-indication approval breadth supports both monocondition and polycondition phenotypes. The T2D + ASCVD polycondition phenotype is the LEADER-anchored indication. The T2D + obesity polycondition phenotype is SCALE Diabetes-anchored. The T2D + advanced glycemic-progression phenotype requiring basal insulin is Xultophy-anchored. Adolescent obesity (12–17 years with body weight >60 kg + BMI ≥the 95th percentile age-and-sex-adjusted) is a SCALE Teens-anchored phenotype.

• Pharmacologic history. Prior GLP-1 RA exposure (non-response, intolerance, or successful therapy with regain after discontinuation) is a frequent presentation. LEAD-6 (Buse 2009 Lancet PMID 19515413) demonstrated liraglutide 1.8 mg once daily produced superior HbA1c reduction vs exenatide 10 µg twice daily in T2D (−1.12% vs −0.79% at 26 weeks, p<0.0001). Prior bariatric surgery with weight regain is a phenotype where liraglutide CWM use may be appropriate per clinician judgment within label.

• Life-stage modifier. Reproductive-age female phenotypes are a Section 8 pre-conception-discontinuation-trigger phenotype with the liraglutide-specific shorter-half-life advantage (~2-day substantial-clearance washout vs ~35-day for semaglutide). Pediatric phenotypes (10–17 years for Victoza T2D; 12–17 years for Saxenda obesity) are FDA-approved indications with the deepest pediatric clinical-use record in the GLP-1 RA class — Sections 4.5, 4.6, 5.7 (pediatric AE), 8.5 (pediatric monitoring), 10 (pediatric counseling) develop. Geriatric phenotypes (≥65 years) are supported by LEAD / SCALE / LEADER subgroup analyses; specific data in ≥75 years is sparser and clinician judgment with attention to renal function trajectory and multi-drug-interaction context is warranted.

The protocol identifies which phenotype dimensions are primary targets (the indication-defining phenotypes the LEAD / SCALE / LEADER / ELLIPSE / SCALE Teens trial programs enrolled), secondary targets (phenotypes with supporting evidence but outside the indication label, e.g., OSA-related obesity within CWM), and tertiary / off-target (phenotypes excluded from trials or with negative-direction signal — Pattern V.estimand-axis applies for any extrapolation beyond trial-enrolled populations).

1.4 Cross-reference to case construction

Every worked clinical case in §4 initiation, §5 maintenance, §6 AE management, §7 plateau / non-response, §8 discontinuation, and §10 counseling beats is anchored to a §1.3 phenotype dimension. A case that presents a phenotype not anchored to the §1.3 taxonomy is a Pattern R.2 design-step failure — the case is generating phenotype categories rather than instantiating them.

1.5 Liraglutide indication scope — research-state-leading summary

Liraglutide (Novo Nordisk; NN2211 development code; second-generation acylated-analog GLP-1 receptor agonist) is FDA-approved for marketing claims across four indications spanning fifteen-plus years of regulatory expansion. The protocol’s indication scope locks here:

Indication 1 — T2D glycemic control (adults; FDA-approved for marketing claims via Victoza, January 25, 2010). Label: adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus. Pivotal program: LEAD-1 through LEAD-6 (collectively n~3,800; multiple background-therapy contexts). Effect-size anchor: HbA1c reduction ~1.0–1.5 percentage points at 1.8 mg daily across LEAD trials; LEAD-3 (Garber 2009 Lancet PMID 18819705) monotherapy −1.14% (1.8 mg) and −0.84% (1.2 mg) vs −0.51% glimepiride 8 mg at week 52; LEAD-6 (Buse 2009 Lancet PMID 19515413) head-to-head −1.12% liraglutide 1.8 mg daily vs −0.79% exenatide 10 µg twice daily at week 26 (p<0.0001 for superiority of liraglutide). Phenotype primary targets: T2D adults with HbA1c above individualized target; metformin-treated or metformin-intolerant. Pattern AA.marketing-claims precision: Victoza is FDA-approved for marketing claims for type 2 diabetes (adults 2010; pediatric ≥10 years 2019; cardiovascular risk reduction in T2D + established CVD 2017).

Indication 2 — T2D glycemic control (pediatric ≥10 years; FDA-approved for marketing claims via Victoza pediatric extension, June 17, 2019). Label: adjunct to diet and exercise to improve glycemic control in pediatric patients ≥10 years with T2D mellitus. Pivotal trial: ELLIPSE (Tamborlane 2019 NEJM PMID 31034184; NCT01541215; n=134 children and adolescents ages 10–17 with T2D inadequately controlled on metformin ± basal insulin; 26-week primary endpoint with 26-week safety extension). Effect-size anchor: HbA1c reduction at week 26 −0.64% (liraglutide) vs +0.42% (placebo); estimated treatment difference −1.06 percentage points (95% CI −1.65 to −0.46; p<0.001). Phenotype primary target: pediatric / adolescent T2D ages 10–17, on background metformin ± basal insulin. The first FDA approval of a GLP-1 receptor agonist for pediatric type 2 diabetes — research-state historical inflection point that extended GLP-1 RA clinical translation into pediatric populations.

Indication 3 — Chronic weight management (adults; FDA-approved for marketing claims via Saxenda, December 23, 2014). Label: adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with initial BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² (overweight) with at least one weight-related comorbid condition (hypertension, dyslipidemia, T2D, OSA, ASCVD). Pivotal program: SCALE Obesity and Prediabetes (Pi-Sunyer 2015 NEJM PMID 26132939), SCALE Maintenance (Wadden 2014 Int J Obes PMID 23812094), SCALE Diabetes (Davies 2015 JAMA PMID 26284720), SCALE Sleep Apnea (Blackman 2018 Int J Obes PMID 27005405), SCALE 3-year prediabetes extension (le Roux 2018 Lancet PMID 28237263). Effect-size anchor: body weight change at week 56 −8.0% (liraglutide 3.0 mg) vs −2.6% (placebo); estimated treatment difference −5.4 percentage points (per-arm vs between-group; Pattern V.metric-axis qualifier carried throughout); proportion achieving ≥5% body weight reduction 63.2% liraglutide vs 27.1% placebo; ≥10% body weight reduction 33.1% liraglutide vs 10.6% placebo. The first FDA-approved-for-marketing-claims GLP-1 receptor agonist for chronic weight management — research-state historical inflection point that established the GLP-1 RA-class obesity-pharmacotherapy use case subsequently extended by semaglutide Wegovy (2021) and tirzepatide Zepbound (2023).

Indication 4 — Chronic weight management (adolescents ≥12 years; FDA-approved for marketing claims via Saxenda pediatric extension, December 4, 2020). Label: adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older with body weight >60 kg and an initial BMI corresponding to obesity (≥the 95th percentile age-and-sex-adjusted). Pivotal trial: SCALE Teens (Kelly 2020 NEJM PMID 32233338; NCT02918279; n=251 adolescents 12–17 with body weight >60 kg + BMI ≥95th percentile; 56-week primary endpoint). Effect-size anchor: BMI SDS change at week 56 −0.22 (liraglutide 3.0 mg) vs −0.02 (placebo); estimated treatment difference −0.22 (95% CI −0.37 to −0.08; p=0.002). Body weight change −2.65% (liraglutide) vs +2.37% (placebo); estimated treatment difference −5.01 percentage points (95% CI −7.63 to −2.39; p<0.001). Proportion achieving ≥5% BMI reduction: 43.3% liraglutide vs 18.7% placebo; ≥10% BMI reduction: 26.1% liraglutide vs 8.1% placebo. The first FDA approval of a GLP-1 receptor agonist for adolescent obesity in the United States — pediatric clinical-use scope ages 12–17 with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted. Liraglutide’s pediatric clinical-use record (Victoza ≥10y T2D 2019 + Saxenda ≥12y obesity 2020) is the longest in the GLP-1 receptor agonist class as of 2026-05-13; semaglutide pediatric obesity approval (Wegovy ≥12 years 2022 on the basis of STEP-TEENS PMID 36322838) followed by approximately two years and provides additional class-level pediatric clinical-use evidence.

Indication 5 — Cardiovascular risk reduction in adults with T2D + established cardiovascular disease (FDA-approved for marketing claims via Victoza labeling supplement, August 25, 2017). Label: to reduce the risk of major adverse cardiovascular events in adults with T2D mellitus and established cardiovascular disease. Pivotal trial: LEADER (Marso 2016 NEJM August PMID 27295427; NCT01179048; n=9,340 adults with T2D + established CVD or high CV risk; randomized 1:1 to liraglutide 1.8 mg daily vs placebo on background standard-of-care; 3.8-year median follow-up). Primary three-point MACE composite: HR 0.87 (95% CI 0.78–0.97), p=0.01 for superiority (per-arm event rates: 13.0% liraglutide vs 14.9% placebo across 3.8-year median follow-up — Pattern V.metric-axis qualifier carried at every effect-size citation in this protocol). CV death HR 0.78 (95% CI 0.66–0.93; p=0.007). All-cause mortality HR 0.85 (95% CI 0.74–0.97; p=0.02). Nephropathy composite (new-onset persistent macroalbuminuria, persistent doubling of serum creatinine, end-stage renal disease, or renal death) HR 0.78 (95% CI 0.67–0.92; p=0.003) — a 22% reduction. LEADER was the first Phase 3 cardiovascular outcomes trial of a GLP-1 receptor agonist to demonstrate cardiovascular benefit on the primary three-point MACE endpoint — class-level historical inflection point. The semaglutide CVOTs SUSTAIN-6 (Marso 2016 NEJM December PMID 27633186; T2D + CVD; n=3,297; MACE HR 0.74 [95% CI 0.58–0.95]) and SELECT (Lincoff 2023 NEJM PMID 37952131; obesity + CVD without T2D; n=17,604; MACE HR 0.80 [95% CI 0.72–0.90]) followed LEADER in trial-program chronology — Pattern Z.research-precision: this is factual cross-trial chronology in the class-level CVOT evidence base, where the LEADER population (T2D + established CVD) is one of three distinct CVOT patient populations across the three trials. Direct cross-trial effect-size comparison between LEADER, SUSTAIN-6, and SELECT is methodologically inappropriate for clinical-decision-making at the patient level — the trials span different patient populations, different compounds, different doses, different follow-up durations, and different MACE event rates. The class-level CV-benefit framework supports each compound’s CV evidence base factually; the specific compound choice for an individual patient is informed by the patient’s population alignment with each trial’s enrollment criteria and by the multi-dimensional comparator framework (§10.5 Anchor 4). Phenotype primary target: adults with T2D + established CVD per LEADER enrollment criteria (≥50 years with prior MI, stroke, TIA, revascularization, heart failure NYHA II/III, or ≥50% coronary/carotid/lower-extremity stenosis; OR ≥60 years with at least one CV risk factor).

Indication 6 — Xultophy 100/3.6 fixed-ratio combination with insulin degludec (T2D adults; FDA-approved for marketing claims November 21, 2016). Label: adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus. Composition: insulin degludec 100 units + liraglutide 3.6 mg per mL fixed ratio; dose-step-delivered (1 dose step = 1 unit insulin degludec + 0.036 mg liraglutide); titrated by 2 dose steps twice weekly based on fasting plasma glucose targets per FDA labeling. Pivotal program: DUAL program. Phenotype primary target: T2D adults requiring intensified glycemic control where basal insulin + GLP-1 RA combination is clinically indicated; typically inadequately controlled on basal insulin or oral antidiabetic regimens. The Xultophy combination is a §9.2-relevant within-class combination addressed in detail in Section 9.

Generic-supply landscape (post-2024 FDA-approved generic ANDAs). Multiple FDA-approved generic liraglutide ANDAs received approval in the 2024–2025 timeframe (parallel ANDA pathways for Victoza-equivalent T2D and Saxenda-equivalent CWM). Bioequivalence to branded reference product is established per FDA ANDA requirements (Tier 1 evidence: pharmacokinetic bioequivalence within 80–125% confidence-interval range for AUC and Cmax). The FDA peptide-generic regulatory-policy framework (Rogers-Crovak 2024 AAPS J PMID 39586870) provides the analytical-method-based assessment of higher-order structure equivalence between generic and reference product. Liraglutide is the only FDA-approved generic GLP-1 receptor agonist on the US market as of 2026-05-13. Generic supply applies across all liraglutide indications (T2D adult; T2D pediatric ≥10y; CWM adult; CWM pediatric ≥12y; CV risk reduction); Xultophy is the only FDA-approved combination product in the liraglutide line and is not yet generic. §10.3 Anchor 2 framing in this protocol reflects the branded-vs-generic-vs-compounded operational landscape post-generic-entry.

Phenotype primary targets across the six approved indication contexts. The §1.3 phenotype-taxonomy dimensions populated heavily across the LEAD / SCALE / LEADER / ELLIPSE / SCALE Teens / DUAL trial programs: T2D adults with HbA1c above individualized target (LEAD; LEADER); T2D adults with established CVD (LEADER); BMI ≥30 or BMI ≥27 + comorbidity adults (SCALE Obesity, SCALE Diabetes, SCALE Sleep Apnea); pediatric T2D ages 10–17 (ELLIPSE); pediatric obesity ages 12–17 with body weight >60 kg + BMI ≥95th percentile age-and-sex-adjusted (SCALE Teens); T2D adults requiring basal-insulin intensification (DUAL). Phenotypes under-represented in the liraglutide trial program (and thus phenotype-tertiary in this protocol): MASH F2/F3 fibrosis (semaglutide ESSENCE-anchored; liraglutide MASH evidence is older Phase 2 LEAN-trial corpus); CKD-in-T2D with FLOW-equivalent dedicated trial (semaglutide FLOW PMID 38785209; liraglutide LEADER nephropathy-composite secondary endpoint provides supportive but not dedicated-trial evidence); HFpEF + obesity dedicated trial (semaglutide STEP-HFpEF PMID 37622681 supportive; no liraglutide HFpEF-dedicated trial); BMI <27 without comorbidity (CWM label excludes this group across the class); adolescent <12; pregnancy (Section 8 discontinuation trigger).

Pattern AB.4 standing scan applied to §1.5. Every NCT and PMID above was verified by content (sponsor, intervention, indication, phase, status; first author, journal, year, study type) against ClinicalTrials.gov and PubMed at PSV iteration 1 of the canonical (Phase 10.5 PSV iteration 1 CLEAN — 28/28 PMIDs + 7/7 NCTs verified per canonical front-matter). The protocol’s Bibliography (§11) carries the verified-identifier table.

---

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who liraglutide is for, who it is not for, and who it must not be given to. Section 2 operationalizes the indication scope from Section 1 into actionable clinical screening criteria. The section is structured into three sub-blocks: inclusion criteria (positive criteria — the patient phenotypes the trial program enrolled and the FDA label permits across the four FDA-approved indications), relative exclusion criteria (patients in whom benefit is uncertain or risk is elevated, requiring case-by-case clinician judgment), and hard contraindications (patients in whom liraglutide must not be used).

Pattern R.1 enforcement at this section: open with inclusion criteria — who liraglutide is for across the four FDA-approved-for-marketing-claims indications — before exclusions and contraindications. The Section 2 architectural ordering (2.2 inclusion → 2.3 relative exclusion → 2.4 contraindication) is the Pattern R.1 design-time enforcement; reversing the order steers clinicians away from the molecule before they have read the inclusion case.

Pattern AA.marketing-claims enforcement: every contraindication is anchored to its source — FDA boxed warning, FDA labeled contraindication, FDA labeled precaution, or post-marketing pharmacovigilance signal under evaluation — with primary-source citation. “Avoid in pancreatitis history” without a source classification (boxed warning vs labeled contraindication vs labeled precaution vs clinician-discretion) is Pattern AA-imprecise.

2.2 Inclusion criteria — the trial-enrolled and label-permitted phenotypes

Inclusion criteria are stated as the populations the pivotal LEAD / SCALE / LEADER / ELLIPSE / SCALE Teens / DUAL trial programs enrolled and the FDA label permits. The protocol specifies, for each indication, the inclusion criteria with primary-source anchoring:

T2D glycemic control (Victoza 1.2 or 1.8 mg daily; adults). Adults age ≥18 with T2D mellitus inadequately controlled on diet and exercise; metformin-treated, metformin-intolerant, or as part of an evolving T2D regimen per ADA/EASD guidance. Background-therapy contexts enrolled across the LEAD program included metformin (LEAD-2 PMID 18931095), sulfonylurea (LEAD-1 PMID 19317822), metformin + TZD (LEAD-4 PMID 19289857), metformin + sulfonylurea (LEAD-5 vs glargine PMID 19688338; LEAD-6 vs exenatide PMID 19515413), and monotherapy (LEAD-3 PMID 18819705). HbA1c thresholds varied across LEAD trials; the FDA label permits T2D inclusion at the clinician’s individualized HbA1c target. Cardiovascular indication eligibility (Victoza 1.8 mg) requires T2D + established CVD per LEADER enrollment criteria (above).

T2D glycemic control (pediatric ≥10 years; Victoza titrated to 1.2 or 1.8 mg daily). Children and adolescents ages 10–17 with T2D inadequately controlled on metformin ± basal insulin per ELLIPSE enrollment (PMID 31034184). Body weight, growth-trajectory, and pubertal-staging considerations apply at §3 pre-treatment workup and §5 maintenance monitoring; family-engagement framework applies at §10 counseling beats.

Chronic weight management (Saxenda 3.0 mg daily; adults). Adults age ≥18 with BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² (overweight) with at least one weight-related comorbid condition (hypertension, dyslipidemia, T2D, OSA, ASCVD) per Saxenda label. SCALE Obesity (PMID 26132939) enrolled adults BMI ≥30 or BMI ≥27 with comorbidity. SCALE Diabetes (PMID 26284720) specifically enrolled T2D + overweight/obesity. SCALE Sleep Apnea (PMID 27005405) specifically enrolled obesity + moderate-to-severe OSA.

Chronic weight management (Saxenda 3.0 mg daily; adolescents ≥12 years). Adolescents ages 12–17 with body weight >60 kg and BMI corresponding to obesity (≥95th percentile for age and sex) per SCALE Teens enrollment (PMID 32233338) and the Saxenda pediatric label. The body-weight >60 kg threshold and BMI ≥95th percentile age-and-sex-adjusted criteria are load-bearing — adolescents below these thresholds are outside the SCALE Teens enrollment and the Saxenda pediatric label.

Cardiovascular risk reduction (Victoza 1.8 mg daily). Adults with T2D + established CVD or high CV risk per LEADER enrollment (PMID 27295427): ≥50 years with prior MI, stroke, TIA, revascularization, heart failure NYHA II/III, or ≥50% coronary/carotid/lower-extremity stenosis; OR ≥60 years with at least one CV risk factor.

Xultophy 100/3.6 (T2D adults requiring basal-insulin + GLP-1 RA combination). Adults age ≥18 with T2D inadequately controlled on basal insulin or oral antidiabetic regimens, where the combination of basal insulin + GLP-1 RA is clinically indicated per DUAL program enrollment and Xultophy label.

Common inclusion considerations across indications.

• Age range as specified per indication (≥18 adult indications; ≥10 years Victoza pediatric T2D; ≥12 years Saxenda pediatric obesity with body weight >60 kg).
• Trial-enrollment laboratory thresholds (renal function bound — no specific eGFR cutoff in LEAD/SCALE but caution at eGFR <30 per label; hepatic function bound).
• Pregnancy / lactation status: pre-conception planning per §6.8 / §8.4 / §10.4 (Anchor 3) — the liraglutide-specific ~2-day substantial-clearance washout protocol supports more flexible pre-conception planning than the longer-half-life weekly compounds.

2.3 Relative exclusion criteria — clinician-judgment phenotypes

Relative exclusion criteria identify phenotypes where liraglutide is not contraindicated but where benefit is uncertain, risk is elevated, or trial data are sparse. The protocol’s structure for each relative exclusion: state the criterion; state the underlying concern; state the magnitude of trial evidence; state the recommended clinician-judgment posture.

• Severe gastroparesis or gastroparesis-predisposing comorbidity. GLP-1 RA mechanism includes delayed gastric emptying; in established gastroparesis, anatomical and symptomatic worsening risk is elevated. LEAD / SCALE / LEADER program enrollment typically excluded severe gastroparesis. Clinician-judgment posture: not initiated in severe gastroparesis; mild-to-moderate gastroparesis warrants individualized risk-benefit discussion with attention to the daily-dosing PK profile supporting faster discontinuation clearance if symptoms worsen (~3–5 days for liraglutide vs ~5 weeks for semaglutide — Pattern V.research-precision: comparator data on faster-clearance management of GLP-1 RA-mediated GI AE in pre-existing gastroparesis is research-state-incomplete; the PK advantage is mechanism-based rather than RCT-demonstrated).
• Active or recent (within 12 months) acute pancreatitis. Distinct from prior severe pancreatitis history (a §2.4 labeled-precaution consideration). Recent acute pancreatitis is a relative exclusion with clinician-judgment posture; deferred until at least 12 months stable post-event with alternative etiology characterization.
• Severe gastrointestinal disease (active inflammatory bowel disease flare; severe GERD with esophagitis). Relative — GLP-1 RA GI AE profile may exacerbate; clinician-judgment posture with gastroenterology co-management for advanced cases.
• Diabetic retinopathy with recent rapid HbA1c improvement risk. SUSTAIN-6 documented a retinopathy-complication signal with semaglutide in patients with rapid glycemic improvement; the LEADER program reported diabetic retinopathy events consistent with rapid-glycemic-control-mediated retinopathy progression patterns observed across diabetes-control interventions (insulin, GLP-1 RAs, others) rather than direct GLP-1 RA-mediated retinopathy progression. Ophthalmology pre-treatment evaluation for advanced background DR or proliferative DR per §3.3 / §3.7 with HbA1c-trajectory-aware monitoring at §5.5 maintenance.
• Severe renal impairment (eGFR <30) outside trial-enrolled range. Liraglutide is not renally cleared as intact compound (clearance via endogenous proteolysis); PK studies in renal impairment show modest changes in plasma exposure but no dose-adjustment requirement up to severe renal impairment. Limited clinical data in ESRD; clinician-judgment posture with nephrology co-management. The FLOW-equivalent dedicated kidney-outcomes trial is semaglutide-specific (Perkovic 2024 NEJM PMID 38785209); liraglutide’s nephropathy-composite secondary endpoint in LEADER (HR 0.78, p=0.003) provides class-level evidence but no liraglutide-specific dedicated CKD-in-T2D trial — Pattern Z.research-precision: extension to dedicated CKD therapeutic indication is research-state-incomplete; clinical use in CKD operates within the standard T2D + CV indication framework.
• Severe hepatic impairment (Child-Pugh C) outside trial-enrolled range. Liraglutide PK is minimally affected by hepatic impairment (peptide proteolysis rather than hepatic metabolism). Limited clinical data in severe hepatic impairment; clinician-judgment posture.
• Active eating disorder (anorexia nervosa, bulimia nervosa, binge eating disorder with active purging). The appetite-suppression mechanism is contraindicated in disordered eating; ARFID and BED-without-purging are clinician-judgment phenotypes routed to behavioral-health co-management before initiation.
• Active malignancy on therapy (other than the MTC/MEN-2 hard contraindication in §2.4). Trial programs typically excluded active cancer; clinician-judgment posture with oncology co-management for active-treatment phenotypes.

2.4 Hard contraindications — boxed warnings and labeled contraindications

Hard contraindications are absolute — liraglutide must not be initiated, and if discovered during therapy, liraglutide is discontinued. Each contraindication is documented with its source classification.

• Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning class-wide for GLP-1 RAs including liraglutide. The boxed warning originated from rodent C-cell findings (Bjerre Knudsen 2010 Endocrinology PMID 20203154) demonstrating that GLP-1 receptor agonists activate rodent thyroid C-cells producing calcitonin release and, at extended exposure, C-cell hyperplasia and C-cell adenomas/carcinomas. Human thyroid C-cells express GLP-1R at substantially lower density than rodent thyroid C-cells; the translational concern from rodent to human is debated, but the boxed-warning-mandated contraindication is absolute for the genetic-risk populations. LEADER MTC events: 1 in the liraglutide arm vs 0 in the placebo arm (n=9,340; 3.8-year median follow-up) — too few events for statistical inference. Silverii 2024 Diabetes Obes Metab PMID 38018310 class-level thyroid cancer SR + MA shows modest signal at low-to-very-low certainty tier across the GLP-1 RA class. Pattern AA.marketing-claims-precise framing: “FDA boxed warning for MTC and MEN-2” is the class-wide regulatory framing; not specific to liraglutide alone.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same source — boxed-warning-mandated absolute contraindication; MEN-2 carries elevated MTC risk and is the genetic-risk population the boxed warning is most operationally relevant for.
• Known serious hypersensitivity to liraglutide or any product excipient. Labeled contraindication. Serious systemic hypersensitivity reactions including anaphylaxis and angioedema have been reported in post-marketing pharmacovigilance; rare but absolute on identification.
• Severe prior pancreatitis history (severe acute pancreatitis or chronic pancreatitis with active sequelae). FDA-labeled precaution / cautionary use language (not labeled contraindication; not boxed warning). The class-level pancreatitis signal per Wen 2025 Endocrinol Diabetes Metab PMID 40988099 is modestly elevated relative to comparators with low absolute incidence. LEADER acute pancreatitis events: 18 (liraglutide) vs 23 (placebo) — no significant difference; lower in the liraglutide arm. Protocol posture: documented severe prior pancreatitis is a labeled-precaution consideration warranting individualized risk-benefit discussion; absolute prohibition depends on the severity, etiology characterization, and time-from-event of the prior pancreatitis.
• Pregnancy (for chronic weight management indications). Saxenda label specifies discontinuation upon pregnancy awareness. Pregnancy is a §8.4 discontinuation trigger, not a §2 inclusion-screen-only criterion — a patient on protocol who becomes pregnant transitions out of protocol immediately. Liraglutide’s ~13-hour half-life supports approximately 2-day substantial-clearance washout (~5 half-lives); inadvertent first-trimester exposure is captured in the Parker 2025 Diabetes Obes Metab PMID 40329607 pooled regulatory pregnancy-exposure dataset (§6.8 / §10.4 develop). Pattern AA.marketing-claims-precise framing: pregnancy is a labeled precaution / discontinue-upon-awareness directive — the load-bearing semantic is “discontinue upon pregnancy awareness” rather than “Category-X-prohibition.”

2.5 Worked example — liraglutide selection criteria across the four FDA-approved indications

Inclusion criteria (per indication).

Adult T2D glycemic control (Victoza 1.2–1.8 mg daily). Adults age ≥18 with T2D inadequately controlled per individualized HbA1c target; on metformin background or metformin-intolerant; or as part of a T2D regimen evolution per ADA/EASD framework. Effect-size anchor framing for the inclusion sub-population: LEAD-3 monotherapy −1.14% HbA1c (1.8 mg) at 52 weeks; LEAD-2 + metformin similar magnitude; LEAD-6 vs exenatide BID demonstrated liraglutide superior glycemic-control efficacy at 26 weeks.

Pediatric T2D ≥10 years (Victoza titrated to 1.2 or 1.8 mg daily). Children and adolescents 10–17 with T2D on background metformin ± basal insulin per ELLIPSE enrollment; HbA1c above individualized pediatric target. Effect-size anchor: ELLIPSE between-group HbA1c treatment difference −1.06 percentage points at week 26.

Adult chronic weight management (Saxenda 3.0 mg daily). Adults age ≥18 with BMI ≥30 (obesity) or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, ASCVD). SCALE Obesity-anchored effect size: between-group body weight treatment difference −5.4 percentage points at 56 weeks (per-arm −8.0% liraglutide vs −2.6% placebo). SCALE Diabetes-anchored effect size in T2D + overweight/obesity: between-group body weight treatment difference −4.0 percentage points (per-arm −6.0% vs −2.0%) at 56 weeks. SCALE Sleep Apnea-anchored effect on AHI: between-group treatment difference −6.1 events/hour at 32 weeks (per-arm −12.2 vs −6.1).

Adolescent chronic weight management (Saxenda 3.0 mg daily, ≥12 years). Adolescents 12–17 with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted. SCALE Teens-anchored effect size: BMI SDS between-group treatment difference −0.22 at week 56 (per-arm −0.22 liraglutide vs −0.02 placebo); body weight between-group treatment difference −5.01 percentage points (per-arm −2.65% vs +2.37%). Pediatric-specific clinical-translation considerations integrate growth-staging, pubertal-progression, family-engagement, transition-of-care, and school-day/extracurricular daily-injection logistics (§6 / §8.5 / §10).

Cardiovascular risk reduction (Victoza 1.8 mg daily). Adults with T2D + established CVD or high CV risk per LEADER enrollment. Effect-size anchor (Pattern V.metric-axis): MACE HR 0.87 (95% CI 0.78–0.97; p=0.01 for superiority; per-arm event rates 13.0% liraglutide vs 14.9% placebo at 3.8-year median follow-up). CV death HR 0.78; nephropathy composite HR 0.78.

Xultophy 100/3.6 (T2D adults requiring basal-insulin + GLP-1 RA combination). Adults age ≥18 with T2D inadequately controlled on basal insulin or oral antidiabetic regimens where basal insulin + GLP-1 RA combination is clinically indicated. Section 9.2 develops the combination-rules framing.

Relative exclusion criteria. Severe gastroparesis: not initiated; mild-to-moderate gastroparesis warrants individualized discussion with attention to faster-clearance advantage of liraglutide vs longer-half-life weekly compounds. Active or recent (within 12 months) acute pancreatitis: deferred until at least 12 months stable post-event with alternative etiology characterization. Diabetic retinopathy with rapid-HbA1c-improvement risk: ophthalmology pre-screening for proliferative DR or advanced background DR; HbA1c-trajectory-aware monitoring. Severe renal impairment eGFR <30: clinician judgment with nephrology co-management; limited data in ESRD. Severe hepatic impairment Child-Pugh C: clinician judgment; limited data. Active eating disorder: not initiated; routed to behavioral-health co-management; BED-without-purging and ARFID are clinician-judgment phenotypes. Active malignancy on therapy: oncology co-management. Pre-conception planning: §8.4 / §10.4 active-management criterion — liraglutide-specific ~2-day washout protocol applies, not a §2 inclusion exclusion.

Hard contraindications. Personal or family history of MTC: FDA boxed warning, class-wide for GLP-1 RAs including liraglutide; absolute contraindication. MEN-2: same boxed warning, absolute. Known serious hypersensitivity to liraglutide or excipient: labeled contraindication. Severe prior pancreatitis history: FDA-labeled precaution / cautionary use; individualized risk-benefit. Pregnancy (CWM indications, Saxenda): labeled — discontinue upon pregnancy awareness; ~2-day substantial-clearance washout per §8.4 arithmetic.

Pattern AA.marketing-claims precision in this section. “FDA boxed warning for MTC and MEN-2” — precise regulatory framing; class-wide for GLP-1 RAs; not specific to liraglutide alone. “Labeled contraindication” for hypersensitivity — precise label-language framing. “Labeled precaution / cautionary use” for severe prior pancreatitis — precise framing; not “labeled contraindication” and not boxed warning. “Discontinue upon pregnancy awareness” — precise labeled-precaution language for the CWM indication. Pattern V cross-check: the LEADER nephropathy-composite HR 0.78 finding (p=0.003) is a direction-of-effect verification anchor for the renal-protection class-level question; LEADER reported this as a pre-specified secondary endpoint, not as the basis for a dedicated CKD-in-T2D indication — that indication-extension was developed by semaglutide via FLOW. The protocol does not generalize LEADER nephropathy-composite finding into a liraglutide-specific dedicated CKD indication — Pattern Z.research-precision.

---

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before liraglutide initiation. Section 3 is the operational handoff between Section 2 (selection criteria) and Section 4 (initiation protocol): a patient who passes Section 2 screening enters Section 3 workup; only on workup completion does Section 4 dose initiation begin.

The liraglutide pre-treatment workup is structured into seven panels: standard metabolic (applies to every liraglutide initiation regardless of indication), diabetes-specific (applies when T2D indication or T2D comorbidity within CWM/CV indication), MASH-screen (applies when baseline MASH risk profile is present — typically T2D + obesity + elevated AST/ALT + waist circumference), kidney-specific (applies when baseline kidney function is borderline regardless of indication, or for CV-indication patients given LEADER’s nephropathy-composite secondary endpoint context), CV-risk-specific (applies when CV indication or when baseline ASCVD risk profile is high), organ-baseline (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs), and body-composition / pediatric-specific (applies to CWM indications and to pediatric patients per the comprehensive pediatric subsection at §3.8).

Pattern W cross-section consistency: every lab listed in §3.2–§3.8 is reconciled with the §5 maintenance monitoring intervals (§5 cannot recommend a monitoring lab not established as a baseline lab in §3) and with the §6 AE management triggers (§6 cannot anchor an AE response to a lab not in the workup or monitoring panel). The protocol cross-references the M5.9 Lab Panels — Patient Questions canonical and the canonical Section 8.5 laboratory framework.

3.2 Standard metabolic panel

Applies to every liraglutide initiation. Establishes baseline metabolic state, identifies undiagnosed comorbidity, and provides reference for monitoring.

• Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline.
• Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for CV-risk indication eligibility (LEADER context) and for monitoring metabolic improvement.
• Fasting glucose and HbA1c. Establishes glycemic baseline regardless of indication. For non-diabetic CWM patients, this screens for undiagnosed prediabetes (relevant for SCALE 3-year prediabetes extension context — T2D-prevention benefit per le Roux 2018 PMID 28237263) or T2D (which would expand the indication context).
• Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the visceral-adiposity-distribution anchor.
• Blood pressure (seated, two readings, standardized). Baseline for CV-risk indication eligibility and for monitoring. Liraglutide produces modest SBP reduction (~2–3 mmHg in LEAD/SCALE program) — baseline BP context shapes hypertension co-medication adjustment.
• Heart rate (resting). Liraglutide produces a modest persistent increase in resting heart rate (~2–3 beats/minute) — a class-level finding for GLP-1 RAs. Baseline heart rate documentation supports monitoring trajectory characterization.

3.3 Diabetes-specific panel (T2D indication; T2D comorbidity within CWM/CV indication; CKD-borderline patients regardless of primary indication)

Applies when the protocol indication is T2D glycemic control (Victoza adult or pediatric ≥10y), when the patient has T2D as a comorbidity within a CWM/CV indication (SCALE Diabetes / LEADER-anchored), or when baseline kidney function is borderline regardless of primary indication.

• HbA1c (above; standard panel). Confirms T2D diagnosis and severity.
• Fasting C-peptide. Establishes endogenous insulin reserve — distinguishes T2D from latent autoimmune diabetes of adults (LADA) and from advanced beta-cell-failure T2D where GLP-1 RA monotherapy response may be attenuated.
• GAD-65 antibodies and IA-2 antibodies (if LADA suspected — adult-onset diabetes with normal BMI, rapid progression to insulin requirement, or atypical clinical course). GLP-1 RAs are not first-line in confirmed autoimmune diabetes; misclassification of LADA as T2D is a Pattern V direction-of-effect risk.
• Diabetes complication screen (if not within the last 12 months): dilated retinal exam (also a class-wide pre-treatment requirement — §3.7), urine albumin-to-creatinine ratio (UACR) for diabetic nephropathy, monofilament / vibratory testing for diabetic neuropathy.
• CGM data review if available. Establishes time-in-range baseline and hypoglycemia frequency baseline. Relevant for §5 dose-adjustment triggers in patients on concurrent insulin or sulfonylurea (§6.7 hypoglycemia framework).
• Pediatric T2D-specific assessment (ELLIPSE-anchored): family history of T2D, MTC, MEN-2; pubertal-staging (Tanner); growth-chart documentation; pediatric mental-health and family-engagement assessment (§3.8 / §8.5 develop).

3.4 MASH-screen panel (MASH-risk profile)

Applies when baseline phenotype suggests MASH risk (T2D + obesity + elevated AST/ALT on standard panel + waist circumference ≥102 cm men / ≥88 cm women).

• AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline; AST/ALT ratio interpretation context.
• Platelet count. Component of FIB-4 calculation.
• FIB-4 score. Calculated non-invasive fibrosis score (age × AST / [platelets × √ALT]). Stratifies fibrosis risk: low <1.3, indeterminate 1.3–2.67, high >2.67.
• Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high. Liver stiffness measurement (kPa) plus controlled-attenuation parameter (CAP) for steatosis quantification.
• Hepatitis B surface antigen and Hepatitis C antibody. Rule out viral hepatitis as alternative or co-existing liver disease.
• Iron studies (ferritin, transferrin saturation). Rule out hereditary hemochromatosis; elevated ferritin is common in MASH but very high transferrin saturation suggests iron-overload alternative.

Pattern Z.research-precision: liraglutide is not FDA-approved for marketing claims for MASH. Patients with confirmed MASH F2/F3 for whom GLP-1 RA therapy is being considered for the MASH-specific indication are typically routed to semaglutide (Wegovy MASH indication August 2025 on the basis of ESSENCE PMID 40305708). The MASH-screen panel at §3.4 supports MASH-risk identification for clinical-context purposes (e.g., hepatology co-management; secondary MASH benefit at the population level from liraglutide-mediated weight loss) rather than indication-eligibility-screening for a liraglutide-specific MASH indication.

3.5 Kidney-specific panel (borderline baseline kidney function; CV indication)

Applies when baseline eGFR is 30–60 regardless of primary indication, or when LEADER-anchored CV indication is the protocol context (given LEADER’s nephropathy-composite secondary endpoint).

• Serum creatinine, eGFR. Standard renal-function baseline (also in §3.2 CMP).
• Cystatin C-based eGFR if creatinine-eGFR is discordant with clinical picture (e.g., low muscle mass elderly patient).
• Urine albumin-to-creatinine ratio (UACR). Quantifies albuminuria — LEADER pre-specified nephropathy-composite secondary endpoint context; FLOW-equivalent CKD-in-T2D enrollment criterion is semaglutide-specific.
• Urinalysis with microscopy. Rules out alternative kidney disease (active sediment, hematuria, proteinuria pattern).
• Renin-angiotensin system (RAS) blockade documentation. Standard background therapy for diabetic kidney disease per ADA/EASD guidance; relevant for §5 maintenance monitoring.
• Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. Chronic-kidney-disease-mineral-and-bone-disorder workup.

Pattern Z.research-precision: liraglutide does not have a dedicated FLOW-equivalent CKD-in-T2D Phase 3 trial. LEADER’s nephropathy-composite secondary endpoint (HR 0.78, p=0.003) supports class-level kidney-protection evidence; the dedicated CKD-in-T2D therapeutic indication is held by semaglutide via FLOW (Perkovic 2024 PMID 38785209). For T2D + CKD patients where dedicated FLOW-anchored therapy is clinically indicated, semaglutide is the trial-program-anchored choice; liraglutide use in T2D + CKD operates within the standard T2D + CV indication framework with the nephropathy-composite supporting evidence.

3.6 CV-risk-specific panel (CV indication; baseline ASCVD risk profile)

Applies when the protocol indication is CV risk reduction (LEADER-anchored Victoza 1.8 mg) or when baseline ASCVD risk profile is high regardless of primary indication.

• ECG (12-lead). Baseline rhythm and conduction status; baseline heart-rate documentation (per §3.2 — relevant for the class-level ~2–3 bpm resting heart rate increase).
• High-sensitivity troponin if symptomatic baseline. Rules out unstable ASCVD; ACS within 60 days is typically a relative exclusion pending CV stabilization.
• NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60). The STEP-HFpEF program (semaglutide; PMID 37622681) provides class-level supportive HFpEF data; liraglutide is not FDA-approved for marketing claims for HFpEF and does not have a dedicated HFpEF Phase 3 trial.
• Echocardiogram if HFpEF-suspect. LV ejection fraction, diastolic-function indices, LV-mass index.
• Lipid panel and ApoB (per §3.2; carried forward to CV-risk-specific monitoring).

3.7 Organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs)

Class-wide pre-treatment workup for any GLP-1 RA protocol, regardless of indication. Anchors to the §2.4 contraindications and to the §6 AE-management algorithms.

• Thyroid baseline. TSH at minimum; neck examination for thyroid nodules. If personal or family history of MTC or MEN-2 is identified at this step, this is a §2.4 hard contraindication and the protocol does not initiate. Routine calcitonin screening is not generally recommended — the boxed warning is based on rodent C-cell signal and human MTC signal is debated; routine calcitonin screening has high false-positive rate without proportionate predictive value (clinician-judgment, not protocol-mandated). LEADER calcitonin monitoring at baseline and during follow-up showed balanced elevations across arms with no signal supporting on-treatment C-cell proliferation.
• Pancreas baseline. Serum lipase, serum amylase (lipase is more pancreas-specific). Triglycerides (hypertriglyceridemic pancreatitis is a distinct etiology — addressed in §3.2). Severe prior pancreatitis history per §2.4 labeled-precaution framework.
• Ophthalmology — dilated retinal examination. Particularly for T2D patients per the §3.3 diabetes-complication-screen overlap. Pre-treatment dilated exam for any T2D patient with HbA1c ≥9.0 or with known background DR is the protocol-recommended posture. LEADER reported diabetic retinopathy events consistent with rapid-glycemic-control-mediated retinopathy progression patterns observed across diabetes-control interventions.
• NAION pre-screen (class-context per Lakhani 2025 PMID 40383360). Non-arteritic anterior ischemic optic neuropathy (NAION) class-context signal per Lakhani PR et al 2025 American Journal of Ophthalmology PMID 40383360 — 180-country population-based observational pharmacovigilance study using disproportionality analysis of spontaneous adverse-event reporting databases. The Lakhani 2025 publication is an observational pharmacovigilance study, not a meta-analysis (Pattern AB.4 publication-type precision). The study documented NAION signal for semaglutide and at similar magnitudes for the older-generation GLP-1 RAs (including liraglutide, exenatide, dulaglutide — class-shared signal characterization for the single GLP-1 RAs); NAION signal was absent for tirzepatide in the disproportionality analysis (class-differentiation finding between single GLP-1 RAs and the GLP-1/GIP coagonist mechanism class). Pattern AA.marketing-claims precision: the Lakhani 2025 signal is at the disproportionality-analysis tier (Tier 3 evidence per the canonical 11.1 framework), not at the RCT-pooled-SR tier; labeling actions for NAION-specific risk-communication are research-state-active as of 2026-05-13. Clinician-judgment pre-screen includes documentation of known optic-disc cupping (“disc-at-risk” anatomy), prior NAION, or unexplained visual symptoms; counseling beats in §10 frame the signal as “class-context signal under regulatory evaluation,” not as “established risk.”

3.8 Body-composition / pediatric-specific panels

Body-composition baseline (CWM indications; all adults). Applies to every Saxenda initiation.

• Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA). Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA more accurate; BIA more accessible. Establishes a baseline against which §5 maintenance monitoring tracks lean-mass preservation vs total-weight change.
• Hand-grip strength or sit-to-stand timed test. Functional strength baseline — particularly relevant for ≥65 age phenotype where sarcopenic-obesity differential framing applies during weight loss.

Pediatric-specific baseline (Victoza pediatric ≥10y T2D; Saxenda pediatric ≥12y obesity). Applies to every pediatric liraglutide initiation per Section 11A.5 pediatric research-protocol considerations.

• Growth-chart documentation: height, weight, BMI z-score; longitudinal growth-velocity history if available.
• Tanner staging: pubertal-progression assessment at baseline; longitudinal Tanner-staging at 6-month intervals.
• Family history of MTC, MEN-2, autoimmune endocrinopathies: elevated relevance in pediatric initiation given the long-horizon cumulative-exposure window.
• Mental-health screening adapted to pediatric population: PHQ-A or similar pediatric-adapted instrument; eating-disorder differential screening; weight-discourse-aware family-engagement framework.
• Pediatric assent + parental consent procedures: age-appropriate assent for the pediatric patient; parental consent documentation; family-engagement on the long-horizon clinical-translation considerations (growth and pubertal-stage; cancer-incidence surveillance research direction; transition-of-care framework at 18–21).
• School-day and extracurricular logistics assessment: parental-supervised-injection planning for younger pediatric patients (Victoza ≥10y); adolescent-self-administration planning for older pediatric patients (SCALE Teens ages 12–17).

3.9 Worked example — liraglutide pre-treatment workup

For a non-diabetic adult initiating Saxenda 3.0 mg for CWM (the most common Saxenda initiation phenotype): standard metabolic panel (§3.2), thyroid + pancreas baseline (§3.7), ophthalmology dilated exam if any visual-symptom history or first-degree NAION family history (§3.7), body-composition BIA or DEXA (§3.8). MASH-risk screen via FIB-4 calculation from standard panel; advance to elastography only if FIB-4 indeterminate or high (§3.4). HbA1c documented (screens for prediabetes — SCALE 3-year prediabetes extension context).

For a T2D adult initiating Victoza for glycemic control: add diabetes-specific panel (§3.3) including fasting C-peptide and dilated retinal exam, with HbA1c-determined urgency on the retinal exam (pre-treatment for HbA1c ≥9.0; within 6–12 months otherwise). UACR documented.

For an adult with T2D + established CVD initiating Victoza for LEADER-anchored CV-risk indication (Victoza 1.8 mg): add CV-risk-specific panel (§3.6). ECG baseline; troponin if symptomatic; echocardiogram if HFpEF-suspect; lipid panel. Nephropathy-composite baseline (UACR, eGFR) per §3.5 — supports LEADER nephropathy-composite-context monitoring.

For an adolescent (12–17 years; body weight >60 kg; BMI ≥95th percentile age-and-sex-adjusted) initiating Saxenda for adolescent CWM: standard metabolic panel (§3.2), thyroid + pancreas baseline (§3.7), pediatric-specific baseline (§3.8) including growth-chart documentation, Tanner staging, family history of MTC/MEN-2, pediatric mental-health screening, school-day/extracurricular logistics, pediatric assent + parental consent, body-composition baseline. Pediatric ophthalmology if T2D-comorbid.

For a pediatric patient (10–17 years) initiating Victoza for ELLIPSE-anchored pediatric T2D: standard metabolic panel + diabetes-specific panel (§3.3) including fasting C-peptide and dilated retinal exam (HbA1c-determined urgency), pediatric-specific baseline (§3.8) including growth-chart documentation, Tanner staging, family history, mental-health screening, parental-supervised-injection planning, pediatric assent + parental consent.

For an adult initiating Xultophy 100/3.6 for T2D requiring basal-insulin + GLP-1 RA combination: standard metabolic panel (§3.2), diabetes-specific panel (§3.3), pancreas + thyroid + ophthalmology baseline (§3.7), CV-risk-specific panel (§3.6) given the polycondition T2D + CV-risk context typical for the Xultophy initiation phenotype. Insulin-titration baseline (current basal-insulin dose; fasting plasma glucose targets) per Xultophy dose-step framework.

Pattern W cross-check applied to §3.9. Every lab in the worked-example panels above is reconciled with §5 monitoring intervals and §6 AE-trigger labs; the protocol’s §11 Bibliography anchors each pivotal-trial enrollment lab to its NCT and PMID with Pattern AB.4 standing-scan verification.

---

4. Initiation protocol

4.1 Purpose

Define the starting dose, titration schedule, and tolerability-management cadence for liraglutide initiation. Section 4 is the time-sequenced action plan from Day 0 (first dose) through approximately Week 5 (Saxenda target-dose attainment) or Week 2 (Victoza maintenance-dose attainment) — the period during which the patient transitions from naive to maintenance-stable.

Pattern Z.injection-framing enforcement at this section: the injection mechanics are presented as a routine clinical skill (subcutaneous self-injection at abdomen, thigh, or upper arm via dial-up multi-dose pen; same mechanics as daily insulin self-injection routinely taught across endocrinology and primary care). The substantive clinical-management discussion is dose-tolerance (GI AEs, dose-titration cadence), not injection mechanics. Self-injection is taught in one clinical visit, refined over the first few self-administrations.

Pattern Z calibration anchors apply throughout §4 — initiation is the conversational anchor for Anchor 4 (comparator framing) and Anchor 5 (off-label / extrapolation transparency) as developed in §10 counseling beats.

4.2 Starting dose

The starting dose is the lowest dose that has tolerability-acceptable trial-program data and serves as the titration starting point. For liraglutide across all indications, the starting dose is 0.6 mg subcutaneous daily for one week — sub-therapeutic by design and designed for GI-AE tolerability priming before escalation.

• Victoza T2D (adult and pediatric ≥10y): 0.6 mg daily for one week → 1.2 mg daily (maintenance for most patients) → optional escalation to 1.8 mg daily if additional glycemic control is needed (1.8 mg is the LEADER cardiovascular indication dose).
• Saxenda CWM (adult and adolescent ≥12y with body weight >60 kg and BMI ≥95th percentile age-and-sex-adjusted): 0.6 mg daily for one week → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg (maintenance target) across a five-week titration with weekly 0.6-mg increments.
• Xultophy 100/3.6: dose-step-delivered initiation per Xultophy label; 1 dose step = 1 unit insulin degludec + 0.036 mg liraglutide; titrated by 2 dose steps twice weekly based on fasting plasma glucose targets.

4.3 Titration schedule

Saxenda standard titration (label-recommended; CWM indication; five-week sequence to 3.0 mg target):

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 and thereafter: 3.0 mg daily (maintenance target)

Total titration: 5 weeks to 3.0 mg target. The week-by-week 0.6-mg increment is the FDA-labeled schedule designed to mitigate the dose-related GI AE profile.

Victoza standard titration (T2D indication):

• Week 1: 0.6 mg daily (tolerability priming; sub-therapeutic for glycemic control)
• Week 2 onward: 1.2 mg daily (maintenance for most patients)
• Optional escalation: 1.8 mg daily (LEADER CV indication dose; considered if additional glycemic control needed at the 1.2 mg dose)

Total titration: 1 week to 1.2 mg maintenance; optional second-step escalation to 1.8 mg.

Pediatric titration (Victoza ≥10y T2D; Saxenda ≥12y CWM with body weight >60 kg and BMI ≥95th percentile age-and-sex-adjusted). Same titration schedules as adult per ELLIPSE (Victoza pediatric T2D) and SCALE Teens (Saxenda pediatric obesity) — 0.6 mg daily week 1 → escalation per the same weekly increments to the indication-appropriate maintenance dose. Pediatric tolerance to GI AEs during titration may differ from adult tolerance; clinical practice supports flexible titration extension if needed (§4.4).

Slow-titration option (clinician-judgment within label). For patients with significant GI AE at any titration step, hold at the current dose for an additional 1–2 weeks before the next escalation. The slow-titration variant is within the FDA-labeled clinical-judgment latitude — Pattern AA.marketing-claims precision: clinician-judgment within label, not label-mandated. Some patients may not reach the 3.0 mg Saxenda maintenance dose due to GI AE tolerance and may maintain at 2.4 mg or 1.8 mg with reduced but real expected effect magnitude — clinician-patient shared decision-making determines the maintenance dose within the FDA-labeled dose range.

4.4 GI tolerability management at each titration step

Liraglutide’s dominant adverse-event profile is gastrointestinal — nausea, vomiting, diarrhea, constipation, eructation, abdominal pain — with the profile typically peaking at each dose escalation and attenuating within 1–2 weeks at stable dose. The protocol documents at each titration step the anticipated AE profile and the management algorithm:

• Nausea — first-line non-pharmacologic. Reduce meal size; slower eating pace; avoid greasy / high-fat meals; hydrate consistently. Patient counseling is the foundation of GI AE management.
• Nausea — first-line pharmacologic. Ondansetron 4 mg PRN; consider scheduled dosing for moderate-severity nausea. Cross-reference with QT considerations in concurrent medications.
• Vomiting — assessment. Distinguish protocol-related vomiting (expected during titration; attenuates with continued dosing) from acute-pancreatitis-suspect vomiting (severe abdominal pain, persistent, with lipase elevation) — §6.4 algorithm.
• Diarrhea / constipation. Bowel-pattern-specific management; loperamide PRN per standard dosing for diarrhea; osmotic laxative (polyethylene glycol) for constipation.
• Volumetric titration adjustment. Persistent moderate-to-severe GI AE at any step is the trigger for slow-titration (§4.3) — hold at current dose for an additional 1–2 weeks before next escalation, or step down to prior dose if tolerability does not stabilize.

Liraglutide-specific faster-clearance differential. Liraglutide’s ~13-hour half-life supports clearance to non-detectable plasma concentrations within ~3–5 days of discontinuation — a differential clinical-translation consideration for patients with severe GI intolerance where rapid clearance for AE management is preferred (vs ~5 weeks for semaglutide; vs ~25 days for tirzepatide). Pattern Z.research-precision: this is a mechanism-based PK consideration; comparator data on faster-clearance management of severe GLP-1 RA GI AE in real-world clinical contexts is research-state-incomplete.

Daily-injection routine — Pattern Z.injection-framing. The daily injection itself is taught at the initiation visit. The mechanics: dial the dose on the pre-filled multi-dose pen; pinch the injection site (abdomen, thigh, or upper arm — rotate sites weekly); inject subcutaneously; count to 6; remove. The procedure is the same as daily insulin self-injection that is routinely taught across endocrinology and primary care. The protocol does not pre-load this discussion with anxiety vocabulary. The substantive clinical-management discussion at the initiation visit is dose-tolerance (anticipated GI AE; non-pharmacologic and pharmacologic management; signal-and-escalation criteria), not injection mechanics.

4.5 Early monitoring cadence

The early-monitoring cadence is the contact frequency during the initiation period. Typical liraglutide protocol cadence:

• Week 2 contact (post-first-dose tolerability check): telehealth or in-person; assess GI AE tolerability at the 0.6 mg dose; address adherence and injection technique; reinforce non-pharmacologic GI AE management.
• Week 4–5 contact (mid-titration tolerability): telehealth or in-person; assess GI AE tolerability at the 1.2–2.4 mg doses (Saxenda) or at the 1.2 mg maintenance dose (Victoza); reinforce titration progression and AE management.
• Week 6–8 contact (target-dose attainment confirmation): in-person; weight, BP, heart rate; tolerability assessment at 3.0 mg Saxenda maintenance or at the Victoza maintenance dose; transition to §5 maintenance cadence.
• Pediatric cadence: same intervals with additional pediatric-specific assessments at each contact (parental-supervision injection check; school-day logistics; growth-trajectory if continuing past 8 weeks; family-engagement reinforcement).

Contact modality (in-person vs telehealth vs message) is practice-specific; the protocol documents the modality assumptions and the escalation triggers (any contact identifying severe GI AE, suspected pancreatitis, suspected gallbladder event, suspected acute monocular vision change, suspected NAION, or significant unintended weight loss → in-person evaluation within 48 hours).

4.6 Worked example — liraglutide initiation across indications

Worked example A — Saxenda 3.0 mg initiation for adult CWM. A 48-year-old female, BMI 34, no T2D, no prior weight-loss-pharm exposure, initiates Saxenda for CWM.

Starting dose. 0.6 mg subcutaneous daily Week 1 (tolerability priming). Standard titration (label-recommended). Week 1: 0.6 mg. Week 2: 1.2 mg. Week 3: 1.8 mg. Week 4: 2.4 mg. Week 5 onward: 3.0 mg (maintenance target). Tolerability management. Week 1 (0.6 mg) typically mild nausea — non-pharmacologic management (meal-size reduction, slow eating, low-fat meals, hydration). Week 2 escalation to 1.2 mg — nausea may recur; counsel that this is anticipated and typically attenuates within 5–7 days at the new dose; ondansetron 4 mg PRN if moderate. Subsequent escalations (1.8 → 2.4 → 3.0 mg) follow the same logic; if moderate-severity GI AE persists at any step, hold for additional 1–2 weeks before next escalation. Early monitoring cadence. Week 2 telehealth; Week 4–5 in-person or telehealth; Week 6–8 in-person with weight, BP, heart rate, tolerability assessment.

Effect-size anchor framing for the patient counseling (Pattern V.metric-axis; between-group treatment difference). SCALE Obesity (Pi-Sunyer 2015 PMID 26132939) demonstrated, in the trial-enrolled population (n=3,731 non-diabetic adults with BMI ≥30 or BMI ≥27 with comorbidity), mean body weight change at week 56 of −8.0% with liraglutide 3.0 mg vs −2.6% with placebo — estimated treatment difference −5.4 percentage points (p<0.001); 63.2% of liraglutide patients achieved ≥5% body weight reduction; 33.1% achieved ≥10%. The patient’s response trajectory is anchored to this SCALE Obesity effect-size with the trial-enrollment qualification.

Worked example B — Victoza 1.8 mg initiation for adult T2D + established CVD (LEADER-anchored). A 64-year-old male with T2D (HbA1c 8.4), prior MI 2 years ago, on statin + antiplatelet + metformin + RAS blockade.

Starting dose. 0.6 mg subcutaneous daily Week 1. Standard titration. Week 1: 0.6 mg. Week 2: 1.2 mg. Optional Week 4–8: 1.8 mg if additional glycemic control needed (1.8 mg is the LEADER CV indication dose). Tolerability management. Same framework as Saxenda. Hypoglycemia surveillance. Patient is metformin-treated; metformin is not hypoglycemia-inducing as monotherapy, so no specific concurrent-agent dose-adjustment is required at liraglutide initiation. If patient were on sulfonylurea or insulin, sulfonylurea dose typically reduced ~50% or discontinued; insulin typically reduced ~20% at GLP-1 RA initiation per §6.7 hypoglycemia framework. Early monitoring. Week 2 telehealth; Week 4 in-person with weight, BP, heart rate; Week 8 in-person; HbA1c at Month 3 (assessing glycemic-control response trajectory); transition to §5 maintenance cadence.

Effect-size anchor framing (Pattern V.metric-axis). LEADER (Marso 2016 PMID 27295427) demonstrated MACE HR 0.87 (95% CI 0.78–0.97; p=0.01 for superiority; per-arm event rates 13.0% liraglutide vs 14.9% placebo across 3.8-year median follow-up); CV death HR 0.78 (per-arm 4.7% vs 6.0%); all-cause mortality HR 0.85 (per-arm 8.2% vs 9.6%); nephropathy composite HR 0.78 (per-arm 5.7% vs 7.2%). Effect-size is anchored to the LEADER population (T2D + established CVD or high CV risk per enrollment criteria above); the patient’s response context is anchored to that population alignment.

Worked example C — Pediatric Saxenda 3.0 mg initiation for adolescent CWM (SCALE Teens-anchored). A 14-year-old male, body weight 95 kg, BMI 36 (well above the 95th percentile age-and-sex-adjusted), no T2D, school-going, with engaged parents.

Starting dose and titration. Same five-week schedule as adult Saxenda: Week 1: 0.6 mg → Week 5 onward: 3.0 mg. Pediatric tolerance considerations: clinical practice supports flexible titration extension if GI AE is significant at any step. Parental-supervision injection planning. The first few self-administrations are parental-supervised; adolescent-self-administration becomes practical as confidence develops. School-day logistics — daily injection typically administered at a consistent time (e.g., morning before school) to support routine. Early monitoring cadence. Week 2 contact with adolescent + parent; Week 4–5 in-person or telehealth; Week 6–8 in-person with growth-chart documentation (height, weight, BMI z-score), Tanner staging update, family-engagement reinforcement; transition to §5 pediatric maintenance cadence.

Effect-size anchor framing (Pattern V.metric-axis). SCALE Teens (Kelly 2020 PMID 32233338) demonstrated BMI SDS change at week 56 of −0.22 with liraglutide vs −0.02 with placebo (between-group treatment difference −0.22; p=0.002; per-arm −0.22 vs −0.02). Body weight change −2.65% liraglutide vs +2.37% placebo (between-group treatment difference −5.01 percentage points; p<0.001). 43.3% of liraglutide patients achieved ≥5% BMI reduction; 26.1% achieved ≥10% BMI reduction. Off-treatment follow-up (26 weeks) showed weight regain — consistent with class-level discontinuation patterns. Pattern Z.research-precision: present these magnitudes factually anchored to the SCALE Teens enrollment population.

Worked example D — Pediatric Victoza initiation for adolescent T2D (ELLIPSE-anchored). A 13-year-old female with T2D (HbA1c 8.1), on metformin, BMI 30, no insulin.

Starting dose and titration. Same as adult Victoza: Week 1: 0.6 mg → Week 2 onward: 1.2 mg → optional 1.8 mg if additional glycemic control needed. Parental-supervision injection planning. Younger pediatric population than SCALE Teens; parental-supervision injection is the typical operational pattern at Victoza ≥10y T2D. Effect-size anchor framing (Pattern V.metric-axis). ELLIPSE demonstrated HbA1c reduction at week 26 of −0.64% liraglutide vs +0.42% placebo (between-group treatment difference −1.06 percentage points; p<0.001). Fasting plasma glucose reduction −0.92 mmol/L liraglutide vs +1.43 mmol/L placebo.

Pattern V applied to §4.6. Effect-size anchors at liraglutide target dose are framed with primary-source anchor and trial-enrollment qualification per Pattern V; metric-axis disclosure (per-arm vs between-group) carried at every effect-size citation per Pattern V.metric-axis; estimand framing (treatment-policy vs on-treatment) per Pattern V.estimand-axis where the trial publication reports both — LEADER’s primary publication reports treatment-policy estimand as primary (consistent with regulatory conventions), with sensitivity analyses for on-treatment.

Pattern AA applied to §4.6. The label-recommended titration is “standard schedule” framing; the slow-titration variant is “clinician-judgment tolerability adjustment” framing — both within the FDA-labeled clinical-judgment latitude, not off-label. Pattern AA.marketing-claims distinguishes label-recommended specific titration from clinician-judgment within label. The 1.8 mg Victoza dose carries Pattern AA.marketing-claims precision: “Victoza 1.8 mg is FDA-approved for marketing claims for type 2 diabetes glycemic control and is additionally FDA-approved for marketing claims for cardiovascular risk reduction in adults with T2D + established CVD on the basis of LEADER PMID 27295427.”

---

5. Maintenance protocol

5.1 Purpose

Define the post-titration, target-dose-attained operating state of the protocol: target dose, monitoring intervals, dose-adjustment triggers, and the transition between maintenance and discontinuation (§8) or non-response algorithm (§7). Section 5 is the longest operational phase of a liraglutide protocol — for a patient who tolerates target dose and continues therapy, maintenance is open-ended for the duration of clinical benefit.

5.2 Target dose

The target dose is the dose at which the molecule’s primary effect (HbA1c reduction; weight loss; CV-event reduction; nephropathy-composite reduction) is demonstrated in the pivotal trial program.

• CWM indication (Saxenda): 3.0 mg daily (SCALE Obesity, SCALE Diabetes, SCALE Sleep Apnea, SCALE Teens target dose). Some patients may maintain at 2.4 mg or 1.8 mg if 3.0 mg is not tolerated, with attendant reduction in expected effect magnitude.
• T2D indication (Victoza): 1.2 mg or 1.8 mg daily. The 1.2 mg dose produces clinically-meaningful HbA1c reduction for most patients; 1.8 mg is considered if additional glycemic control is needed. The 1.8 mg dose is the LEADER cardiovascular indication dose.
• Cardiovascular indication (Victoza 1.8 mg): 1.8 mg daily — the LEADER-validated dose.
• Pediatric Victoza T2D ≥10y: same as adult — 1.2 mg daily for most patients; 1.8 mg if additional glycemic control needed (ELLIPSE titrated up to 1.8 mg).
• Pediatric Saxenda ≥12y CWM (with body weight >60 kg and BMI ≥95th percentile age-and-sex-adjusted): same as adult — 3.0 mg daily target (SCALE Teens-validated).
• Xultophy 100/3.6: continued dose-step titration per Xultophy label; fasting plasma glucose targets drive titration.

5.3 Monitoring intervals

Monitoring intervals for the maintenance phase reflect indication-specific and comorbidity-specific considerations:

Saxenda CWM maintenance. Monthly contact during the first 3–6 months on 3.0 mg target dose to monitor weight trajectory against the SCALE Obesity / SCALE Teens-anchored expectations; then quarterly during the remainder of the first year; biannual thereafter for stable patients. At each visit: weight, BP, heart rate, brief AE-and-adherence interview, body-composition reassessment (BIA or DEXA at 6-month intervals during year 1, annually thereafter). The labeled 16-week response threshold per Saxenda FDA labeling: patients not achieving ≥5% body weight reduction at 16 weeks on 3.0 mg target dose may be considered for therapy discontinuation per labeling guidance (§7 non-response algorithm framework).

Victoza T2D maintenance. HbA1c at Month 3 (assessing glycemic-control response trajectory); HbA1c at Month 6, then quarterly during the first year on target dose; biannually thereafter for stable patients. Lipid panel and UACR annually. eGFR if CKD-borderline or LEADER-anchored CV-indication context.

Victoza CV indication maintenance. Add scheduled CV-event surveillance and standard secondary-prevention monitoring (lipid panel, BP, cardiology coordination as applicable). LEADER-anchored monitoring framework.

Pediatric maintenance. Growth-chart tracking (height, weight, BMI z-score) at 3-month intervals — particularly during pubertal growth phases. Tanner staging at 6-month intervals. HbA1c at 3-month intervals for pediatric T2D (Victoza ≥10y); body-weight + BMI z-score monthly during the first 3–6 months for pediatric CWM (Saxenda ≥12y). Annual lipid panel, renal function, hepatic function. Mental health and weight-discourse engagement at 6-month intervals. Transition-of-care coordination beginning at ages 16–18 depending on healthcare system.

Class-wide GLP-1 RA monitoring (all indications). Lipase on symptom-prompted basis (abdominal pain), not on scheduled-interval basis — per the AC2-26-class system-observations precedent on not screening with low-specificity labs absent symptom. Annual reassessment of organ-baseline panels (§3.7) — thyroid examination; medication reconciliation. Symptom-driven surveillance for cancer-context concerns per §5 cancer-context framework in the canonical (LEADER MTC events 1 vs 0; LEADER pancreatic cancer numerical imbalance HR 2.59 not significant; Ko 2026 Ann Intern Med PMID 41359966 class-level SR shows moderate-certainty “little or no effect” on most cancer types).

5.4 Dose-adjustment triggers

Dose adjustment in the maintenance phase is driven by three trigger categories: target-not-met, target-overshoot, and AE-emergent.

Target-not-met (CWM). <5% body weight reduction at Month 4 (Saxenda labeled 16-week response threshold) on 3.0 mg target dose with documented adherence triggers transition to §7 non-response algorithm. Patients on 2.4 mg or 1.8 mg maintenance (lower than target due to GI AE tolerance) have proportionally reduced expected effect; the non-response algorithm at §7 applies on the basis of the patient’s actual maintenance dose vs the SCALE Obesity / SCALE Teens-anchored response trajectory.

Target-not-met (T2D). HbA1c above individualized target at Month 3 on 1.2 mg triggers consideration of escalation to 1.8 mg. Persistent above-target HbA1c at 1.8 mg at Month 6 triggers §7 non-response algorithm or transition to a different agent (typically tirzepatide given SURPASS-2 head-to-head head-to-head data — Pattern V direction-of-effect anchored; or basal insulin addition; or Xultophy fixed-ratio basal-insulin combination).

Target-overshoot. In CWM, rare; unintended weight loss below patient’s pre-specified target floor (e.g., BMI <22) triggers dose-down to 2.4 mg or to 1.8 mg with re-evaluation. In T2D, hypoglycemia on concurrent insulin or sulfonylurea is the most common overshoot pattern; protocol typically titrates down the concurrent agent rather than down-titrating liraglutide.

AE-emergent. Persistent moderate-severity GI AE on 3.0 mg Saxenda that does not respond to symptomatic management is the most common dose-down trigger — to 2.4 mg or 1.8 mg with reassessment at Month 3 (whether the lower dose maintains adequate weight-loss effect for the patient).

5.5 Worked example — liraglutide maintenance

Worked example — Saxenda 3.0 mg maintenance in adult CWM. A 48-year-old female (Worked Example A from §4.6), now at Month 6 on Saxenda 3.0 mg target dose; weight loss 7.5 kg (~8% of starting weight, on-trajectory for SCALE Obesity-anchored response — between-group treatment difference −5.4 percentage points at week 56; per-arm −8.0% liraglutide).

Monitoring at Month 6. Weight, BP, heart rate, brief AE-and-adherence interview. GI AE profile mild and tolerable. Body composition (BIA): lean mass preserved within normal proportion of total weight loss. Decision: continue 3.0 mg target dose. Next monitoring at Month 9 (quarterly during year 1). At Month 12, assess maintenance-trajectory and transition to biannual monitoring if stable.

Worked example — Victoza 1.8 mg maintenance in adult T2D + established CVD (LEADER-anchored, Worked Example B from §4.6). Now at Month 6 on Victoza 1.8 mg; HbA1c 6.9 (at individualized target). Weight loss 3.2 kg (small magnitude, consistent with the LEAD program ~2–4 kg body-weight reduction at Victoza doses). BP 128/78. Heart rate 76 (modest increase from baseline 72 — consistent with class-level ~2–3 bpm trajectory).

Monitoring at Month 6. Continue 1.8 mg dose (LEADER CV indication dose). HbA1c quarterly during year 1; lipid panel + UACR annually; eGFR quarterly. CV-event surveillance per LEADER monitoring framework. Pattern V.metric-axis: the LEADER MACE HR 0.87 finding applies to the individual patient’s projected risk-trajectory framing within shared decision-making, with the trial-population enrollment qualification.

Worked example — Pediatric Saxenda 3.0 mg maintenance in adolescent CWM (SCALE Teens-anchored). The 14-year-old male (Worked Example C from §4.6), now at Month 6 on Saxenda 3.0 mg; BMI z-score change −0.18 (close to SCALE Teens between-group treatment difference of −0.22 at week 56). Growth-chart tracking shows height velocity on-trajectory for pubertal stage; Tanner staging progression as expected. Family engagement reinforced at each visit; school-day logistics stable.

Monitoring at Month 6. Height, weight, BMI z-score (3-month intervals). Tanner staging (6-month intervals). Mental health and weight-discourse check-in. Transition-of-care planning will begin at ages 16–18. Next monitoring at Month 9 with growth-chart documentation.

Worked example — Pediatric Victoza 1.8 mg maintenance in adolescent T2D (ELLIPSE-anchored). The 13-year-old female (Worked Example D from §4.6), titrated to 1.8 mg for additional glycemic control; now at Month 6; HbA1c 6.8 (at individualized pediatric target). Growth-trajectory on-track. Parental-supervision injection has transitioned to adolescent-self-administration as confidence developed.

Monitoring at Month 6. HbA1c at 3-month intervals. Growth and Tanner staging at 6-month intervals. Annual lipid panel, renal function, hepatic function. Family-engagement and transition-of-care planning.

Pattern W cross-check at §5.5. Monitoring intervals are reconciled with the §3 pre-treatment panel (every monitoring lab is established as a baseline lab) and with the §6 AE-management algorithms (every AE-trigger lab is in the monitoring schedule). The protocol explicitly states: lipase is monitored on symptom-prompted basis (abdominal pain), not on scheduled-interval basis. Pattern V.metric-axis: every effect-size citation in maintenance discussion carries the metric-axis qualifier consistent with the §1.5 framing.

---

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the adverse-event categories that apply to liraglutide. Section 6 is the AE-by-AE-class operational reference for the practice — what to expect, when to escalate, when to discontinue. The section is structured by AE class (GI; gallbladder; pancreatitis; cardiovascular including heart-rate effect; ophthalmologic including NAION class-context; injection site; hypoglycemia in T2D with concurrent agent; pediatric-specific) with each AE class addressed in a standard sub-structure: anticipatory framing, identification, severity grading, first-line management, escalation triggers, discontinuation triggers.

Pattern R enforcement: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the trial program — before management. Opening with discontinuation triggers would steer clinicians (and through training materials, patients) toward fear-framed AE response rather than expectation-anchored AE response.

Pattern V enforcement: when an AE-class signal is post-marketing or under regulatory evaluation (e.g., NAION class-context per Lakhani 2025 PMID 40383360), the protocol documents the signal status precisely (post-marketing pharmacovigilance disproportionality analysis vs labeled warning vs labeled contraindication) and does not generalize signal direction beyond what is established.

Pattern Z.research-precision enforcement: bias-vocabulary like “highly concerning” / “alarming” / “dangerous” is not used. Where an AE class has a contested class-level signal, the protocol names the trial(s), magnitudes, certainty tiers, and current regulatory disposition factually.

6.2 GI AE class — the dominant AE class for liraglutide

Anticipatory framing. GLP-1R-mediated delayed gastric emptying via vagal afferent pathways, central appetite-pathway modulation via hypothalamic and brainstem GLP-1R circuitry, and direct GI-motility effects produce a characteristic AE profile: nausea, vomiting, diarrhea, constipation, eructation, abdominal pain, dyspepsia. The AE profile is typically peak-at-dose-escalation and attenuates within 1–2 weeks at stable dose. Trial-program prevalence in pivotal trials:

• SCALE Obesity (Pi-Sunyer 2015 PMID 26132939; n=3,731 non-diabetic adults with BMI ≥30 or BMI ≥27 + comorbidity; 56 weeks): nausea ~40% liraglutide 3.0 mg vs ~14% placebo; diarrhea ~21% vs ~10%; vomiting ~16% vs ~4%; constipation ~20% vs ~9%. Discontinuation due to GI AE in SCALE Obesity was approximately 6–8% of the liraglutide arm.
• LEAD program (T2D context; n~3,800 across LEAD-1 through LEAD-6): nausea ~30% liraglutide doses vs ~10% comparator arms; diarrhea ~15%; vomiting ~10%; most events transient and resolving with continued dosing.
• STEP 8 head-to-head (Rubino 2022 JAMA PMID 35015037): discontinuation rates due to adverse events were 13.5% (semaglutide 2.4 mg weekly) vs 27.6% (liraglutide 3.0 mg daily) — the higher discontinuation rate in the liraglutide arm reflects in part the longer daily-titration period vs the shorter weekly-titration period and the dosing-frequency-related adherence dynamics. Pattern V.research-precision: this is the head-to-head comparison fact; the trial-population context is non-diabetic adults with overweight/obesity at 68 weeks.

Identification. Patient-reported during early-monitoring contacts (§4) and maintenance visits (§5). Standardized severity grading via CTCAE: Grade 1 (mild, intervention not indicated), Grade 2 (moderate, minimal intervention indicated), Grade 3 (severe, hospitalization indicated), Grade 4 (life-threatening). Most protocol-relevant liraglutide GI AEs are Grade 1–2.

First-line management. Non-pharmacologic: meal-size reduction; slow eating pace; low-fat / non-greasy meal composition; hydration emphasis. Pharmacologic: ondansetron 4 mg PRN for nausea; loperamide PRN for diarrhea per standard dosing; osmotic laxative (polyethylene glycol) for constipation; reassurance and meal-pairing adjustments for eructation. Faster-clearance differential: liraglutide ~3–5 day clearance to non-detectable concentrations supports rapid AE de-escalation if discontinuation becomes necessary.

Escalation triggers. Grade 3 severity at any step (severe, hospitalization indicated). Persistent Grade 2 severity beyond 2 weeks at stable dose. Vomiting with severe abdominal pain (assess for pancreatitis — §6.4). Significant unintended weight loss exceeding the protocol’s target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference (a tolerable but unpleasant Grade 2 profile is a Pattern Z calibration point — the protocol does not override patient preference for discontinuation by framing tolerability as obligation).

6.3 Gallbladder AE class

Anticipatory framing. GLP-1 RA association with cholelithiasis and cholecystitis has been demonstrated across the trial program; mechanism is attributed to weight-loss-rate-related bile-supersaturation and to direct effects on gallbladder motility. Trial-program prevalence:

• SCALE Obesity (PMID 26132939): cholelithiasis 1.5% liraglutide vs 0.5% placebo; cholecystitis 0.6% liraglutide vs 0.2% placebo.
• LEADER (PMID 27295427): gallbladder events 3.1% liraglutide vs 1.9% placebo over 3.8-year median follow-up.
• SCALE 3-year prediabetes extension (PMID 28237263): cholelithiasis numerically higher in liraglutide arm consistent with sustained weight-loss-mediated pathophysiology.

The signal is dose-related and more pronounced at the Saxenda 3.0 mg dose than at Victoza doses given the larger weight-loss magnitude.

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound is the first-line imaging study; HIDA scan if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis and symptoms compatible with biliary colic: surgical consultation; typical management trajectory is laparoscopic cholecystectomy. Protocol decision: temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged.

Escalation triggers. Acute cholecystitis with systemic signs (fever, leukocytosis, sepsis). Choledocholithiasis suspected (LFT pattern + dilated CBD on imaging) requires urgent ERCP or surgical consultation.

Discontinuation triggers. Recurrent symptomatic gallstones post-cholecystectomy with bile-acid-related pattern: clinician judgment for protocol continuation. A single uncomplicated cholecystitis episode with cholecystectomy is not a permanent contraindication.

6.4 Pancreatitis AE class

Anticipatory framing. Acute pancreatitis signal in GLP-1 RA pharmacovigilance has been debated since exenatide-era reports. Pivotal-trial data for liraglutide:

• LEADER (PMID 27295427): acute pancreatitis events 18 in the liraglutide arm vs 23 in the placebo arm over 3.8-year median follow-up — no significant difference; lower in the liraglutide arm.
• LEAD program: rare; balanced across treatment arms.
• SCALE program: rare; some numerical imbalance favoring placebo in pooled analyses but not significant.
• Wen 2025 Endocrinol Diabetes Metab PMID 40988099 — class-level SR + MA of pancreatitis and pancreatic cancer events in GLP-1 RA RCTs: pancreatitis signal at the class level is modestly elevated relative to comparators but absolute incidence remains low (single-digit-per-thousand patient-years). Pattern V.research-precision: the Wen 2025 SR is the current load-bearing class-level synthesis; this is the framing.

Pattern V direction-of-effect at this section: “no established increased risk in LEADER population; class-level signal is modest per Wen 2025; severe prior pancreatitis is a labeled precaution (§2.4).” The pancreatitis-signal framing in counseling (§10) is anchored to “LEADER did not show increased risk; class-level Wen 2025 SR shows modest signal; severe prior pancreatitis warrants individualized risk-benefit discussion.”

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class (§6.2) typically does not produce severe persistent localized pain — protocol differentiates “GI AE expected at titration” from “pancreatitis-suspect abdominal pain” via persistence, severity, localization, and lipase.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue liraglutide pending evaluation — the ~3–5 day liraglutide clearance supports rapid pharmacokinetic clearance during the evaluation window.

Escalation triggers. Confirmed acute pancreatitis (clinical + lab + imaging) → hospitalization, supportive management per pancreatitis standard-of-care. Severity stratification via Ranson / BISAP / APACHE-II.

Discontinuation triggers. Confirmed acute pancreatitis attributable to liraglutide (excluding alternative etiology — gallstones, hypertriglyceridemia, alcohol) → permanent discontinuation; transition to non-GLP-1 alternative if Module 5 indication continues.

Pancreatic cancer surveillance — research-state framing. LEADER pancreatic cancer events: 13 in liraglutide arm vs 5 in placebo arm; HR 2.59 (95% CI 0.92–7.27) — a numerical imbalance with wide confidence interval and not statistically significant at conventional thresholds. Interpretation considerations: low absolute event rate; wide CI; reverse-causation/diagnostic-bias hypothesis (pancreatic-cancer-associated symptoms may have prompted GLP-1 RA initiation in some patients; alternatively, GLP-1 RA-induced GI symptoms may have prompted earlier evaluation for pancreatic-cancer-relevant symptoms in the liraglutide arm); detection bias. Subsequent meta-analytic re-examination including Wen 2025 has incorporated LEADER alongside other Phase 3 RCT pancreatic-cancer data and has not confirmed a class-level pancreatic-cancer signal at conventional certainty tiers. Pattern V.research-precision: the LEADER numerical imbalance warrants continued surveillance attention but does not currently support a class-level pancreatic-cancer-incidence-elevation framing for counseling beats.

6.5 Cardiovascular AE class (including heart-rate effect)

Anticipatory framing. LEADER (PMID 27295427) established positive cardiovascular safety profile for liraglutide in T2D + established CVD with net cardiovascular benefit (MACE HR 0.87, p=0.01 for superiority). The protocol’s cardiovascular safety framing is anchored to the LEADER trial findings.

Heart-rate effect. Liraglutide produces a modest persistent increase in resting heart rate (~2–3 beats/minute) — a class-level finding for GLP-1 RAs. The mechanism involves both direct cardiac effects and sympathetic-tone modulation. The heart-rate effect has been the subject of long-term cardiovascular implication research; LEADER’s positive MACE-reduction finding indicates that the heart-rate effect did not translate into net cardiovascular harm in the trial population. Monitoring: heart rate at every maintenance visit; clinical-judgment review of trajectory.

Blood pressure effect. Modest reduction in systolic blood pressure (~2–3 mmHg) — favorable for cardiovascular outcome. Hypertension co-medication adjustment may be appropriate if BP trends meaningfully below the patient’s targets.

Lipid effects. Modest reductions in LDL-C, triglycerides; small reductions in total cholesterol. Modest favorable lipid-profile effects contributing to the overall cardiovascular-protection profile.

Discontinuation triggers. Confirmed acute cardiovascular event during therapy → clinical judgment for protocol continuation; LEADER population continues to support continued therapy in T2D + established CVD context. Unexplained tachycardia or arrhythmia symptoms → cardiology evaluation; dose-down or hold pending evaluation.

6.6 Ophthalmologic AE class — NAION class-context signal under evaluation

Anticipatory framing. Non-arteritic anterior ischemic optic neuropathy (NAION) class-context signal per Lakhani PR et al. 2025 American Journal of Ophthalmology PMID 40383360 — 180-country population-based observational pharmacovigilance study using disproportionality analysis of spontaneous adverse-event reporting databases. The Lakhani 2025 publication is an observational pharmacovigilance study, not a meta-analysis (Pattern AB.4 publication-type precision). NAION signal documented for semaglutide; signal documented at similar magnitudes for the older-generation GLP-1 RAs including liraglutide; signal absent for tirzepatide (class-differentiation finding between single GLP-1 RAs and the GLP-1/GIP coagonist mechanism class).

Pattern AA.marketing-claims precision: the Lakhani 2025 signal is at the disproportionality-analysis tier (Tier 3 evidence per the canonical 11.1 framework), not at the RCT-pooled-SR tier. Labeling actions for NAION-specific risk-communication are research-state-active as of 2026-05-13 — it is not a labeled contraindication or labeled warning for liraglutide as of 2026-05-13. Counseling beats in §10 frame this as “class-context signal under regulatory evaluation; absolute risk in the populations studied appears small; clinician judgment in patients with disc-at-risk anatomy or prior NAION applies.”

Mechanism considerations. NAION pathophysiology involves optic nerve head ischemia. Hypotheses for the GLP-1 RA association include rapid glycemic-control improvement effects on optic nerve perfusion, hemodynamic effects, and other mechanisms — the mechanism is research-state-active.

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in the acute phase. Differential includes giant cell arteritis (arteritic AION, separate entity), retinal vascular occlusion, optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue liraglutide pending evaluation — the ~3–5 day liraglutide clearance supports rapid pharmacokinetic clearance. Cross-reference with ESR/CRP to rule out arteritic etiology.

Escalation triggers. Confirmed NAION → permanent discontinuation; ophthalmology co-management; consideration of contralateral-eye risk (NAION recurrence in fellow eye is the relevant ophthalmology-counseling beat post-event).

Discontinuation triggers. Confirmed NAION → permanent discontinuation regardless of indication continuation. Transition to non-liraglutide Module 5 alternative: cross-class direction-of-effect is not fully established but Lakhani 2025 documents tirzepatide signal-absence at the same analytical threshold (class-differentiation finding) — Pattern V: signal-absent-at-threshold does not equal signal-absent-in-population, and post-approval exposure-window asymmetry caveat (semaglutide ~82 months vs tirzepatide ~28 months at Lakhani 2025 cutoff) applies.

6.7 Diabetic retinopathy AE class

Anticipatory framing. Rapid glycemic-control improvement in patients with pre-existing severe diabetic retinopathy has historically been associated with transient retinopathy worsening across diabetes-control interventions (insulin, GLP-1 RAs, others). LEADER and SCALE Diabetes (PMID 26284720) trials reported diabetic retinopathy events; the class-level pattern is consistent with rapid-glycemic-control-mediated effects rather than direct GLP-1 RA-mediated retinopathy progression. Pattern V direction-of-effect: rapid HbA1c improvement context, not GLP-1 RA-specific mechanism.

Identification and management. Pre-treatment dilated retinal exam per §3.3 for any T2D patient with HbA1c ≥9.0 or with known background DR. Patients with proliferative DR or advanced background DR — ophthalmology pre-screening; HbA1c-trajectory-aware glycemic-control pacing during initiation; ophthalmology coordination during maintenance.

6.8 Injection-site AE class

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) occur in approximately 5% of patients on daily subcutaneous liraglutide; usually mild and self-resolving. Lipohypertrophy can develop with site rotation failure — counseling reinforces site rotation (abdomen, thigh, upper arm — alternate sites; rotate within sites).

Identification. Patient-reported or visit-observed. Photograph documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement. Topical hydrocortisone for pruritus. Discontinuation is rarely indicated for injection-site AE alone.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is a labeled contraindication (§2.4) and triggers permanent discontinuation. Anti-liraglutide antibody formation occurs in ~5–10% of patients (§6.12 of canonical) — generally low-titer, non-neutralizing, not associated with efficacy reduction or hypersensitivity; routine antibody monitoring is not part of clinical surveillance.

6.9 Hypoglycemia AE class (T2D indication with concurrent insulin or sulfonylurea)

Anticipatory framing. GLP-1 RA monotherapy is not a hypoglycemia-inducing class — the glucose-dependent insulin-secretion mechanism is protective against hypoglycemia in the absence of concurrent hypoglycemia-inducing agents. The hypoglycemia risk emerges when liraglutide is combined with insulin or sulfonylurea — in which case, the typical pivotal-trial protocol was to reduce the dose of the concurrent agent at GLP-1 RA initiation (insulin typically reduced approximately 20% at liraglutide initiation; sulfonylurea typically reduced approximately 50% or discontinued).

Identification. Patient-reported hypoglycemia events; CGM data if available; HbA1c trajectory below individualized target.

First-line management. Reduce concurrent insulin or sulfonylurea dose; reinforce hypoglycemia recognition and treatment counseling.

Discontinuation triggers. Hypoglycemia from liraglutide is not a discontinuation indication for liraglutide; it is a dose-adjustment indication for the concurrent agent.

6.10 Pediatric AE considerations — comprehensive

Liraglutide’s pediatric clinical-use scope (Victoza ≥10y T2D 2019 per ELLIPSE PMID 31034184; Saxenda ≥12y obesity 2020 per SCALE Teens PMID 32233338) is the deepest pediatric clinical-translation evidence base in the GLP-1 RA class. Pediatric-specific AE considerations layered onto the adult framework above:

ELLIPSE pediatric T2D safety profile (PMID 31034184): the dominant AE profile was GI (nausea, vomiting, diarrhea) — qualitatively similar to adult LEAD program profile. Hypoglycemia events were higher in the liraglutide + insulin subset (expected given combined glucose-lowering therapy). No medullary thyroid carcinoma events; calcitonin monitoring did not show signal for on-treatment C-cell proliferation.

SCALE Teens pediatric obesity safety profile (PMID 32233338): the dominant AE profile was GI — qualitatively similar to adult SCALE program profile. The five-week titration schedule was used; titration tolerability was generally acceptable. No medullary thyroid carcinoma events. Body weight regain occurred during the 26-week off-treatment follow-up phase (consistent with class-level discontinuation patterns).

Pediatric-specific clinical-translation considerations:

• Growth and puberty staging: chronic peptide therapeutic in pediatric populations during growth and puberty stages raises growth-trajectory considerations distinct from adult populations. ELLIPSE and SCALE Teens trial follow-on observation horizons (~5–7 years as of 2026-05-13) are accumulating growth-trajectory data. Pediatric clinical-monitoring includes growth-chart tracking at 3-month intervals during pubertal growth phases, Tanner staging at 6-month intervals, and longitudinal growth-velocity assessment.
• Long-term cancer-incidence surveillance research direction (canonical §5.7): pediatric clinical use with a class-level rodent-MTC signal raises long-horizon surveillance questions. Calcitonin biomarker surveillance protocols for pediatric populations are research-direction-active. Current FDA-labeled monitoring framework applies; routine calcitonin screening is not protocol-mandated.
• Transition-of-care from pediatric to adult clinical management: adolescent patients aging into adult clinical management (transition typically at ages 18–21 depending on healthcare system) require coordinated handoff. Long-term medication continuation, surveillance protocols, and clinical-decision-making frameworks transition with the patient.
• School-day and extracurricular daily-injection logistics: parental-supervision injection for younger pediatric patients (Victoza ≥10y); adolescent-self-administration for older pediatric patients (SCALE Teens ages 12–17). Daily-injection routine integrated with school schedule.
• Mental health and weight-management discourse: pediatric obesity is associated with substantial psychosocial stressors; pediatric weight-management pharmacotherapy operates within a broader mental health and family-discourse context. Mental-health-aware patient communication; family-engagement strategies; weight-discourse approaches that avoid stigmatization.
• Generic-availability implications for pediatric populations: FDA-approved generic liraglutide ANDAs (2024–2025) extend to both Victoza and Saxenda contexts and apply equally in pediatric clinical use. Pediatric prescription-coverage and access patterns are differentially affected by generic supply (§10.3 / §10.7 framing).

6.11 Worked example — liraglutide AE management

Worked example A — Saxenda 3.0 mg adult CWM with persistent moderate nausea at maintenance. A 48-year-old female on Saxenda 3.0 mg for 6 months for CWM; weight loss 7.5 kg (~8% of starting weight, on-trajectory for SCALE Obesity-anchored response); reports persistent moderate nausea (Grade 2; recurring most days but mild enough to maintain meal intake), early satiety, and otherwise tolerable AE profile.

Protocol response. Anticipatory framing: persistent Grade 2 nausea at maintenance dose is within the trial-program-typical AE profile; SCALE Obesity reported nausea ~40% liraglutide vs ~14% placebo. First-line management: meal-size and meal-composition reinforcement; consider scheduled (not just PRN) ondansetron 4 mg daily for symptomatic relief. Reassessment at Month 7 visit: if Grade 2 nausea remains and patient is on-trajectory for indication target (>5% weight loss at Month 4 achieved here), continue current dose; if Grade 2 nausea is unacceptable to patient (Pattern Z calibration: patient-preference-anchored, not clinician-override), dose-down to 2.4 mg with Month 9 weight-trajectory reassessment. Pattern V.research-precision: 2.4 mg maintenance produces proportionally reduced expected effect magnitude vs 3.0 mg target — counseling presents the trade-off factually.

Worked example B — Victoza adult T2D + acute pancreatitis suspected at Month 4. A 64-year-old male on Victoza 1.8 mg (LEADER-anchored CV indication, Worked Example B from §4.6); Month 4; presents with acute severe upper abdominal pain radiating to back, vomiting, hospitalized in ED. Lipase elevated to 5× upper limit normal; abdominal CT shows mild peripancreatic fat stranding without necrosis. Triglycerides 220 mg/dL (not severely elevated). No gallstones on imaging. No alcohol history.

Protocol response. Confirmed acute pancreatitis; alternative etiologies (gallstones, severe hypertriglyceridemia, alcohol) ruled out — liraglutide-attributable acute pancreatitis is the working diagnosis. Discontinue liraglutide; ~3–5 day clearance to non-detectable concentrations is anticipated. Supportive pancreatitis management per standard of care. Permanent discontinuation of liraglutide post-recovery; transition to non-GLP-1 T2D regimen — consider sitagliptin (DPP-4 inhibitor, distinct class; though Pattern V cautions — DPP-4 inhibitors also carry pancreatitis labeled cautionary use), pioglitazone, or SGLT2 inhibitor; counsel on T2D-progression context.

Worked example C — Saxenda adult CWM with acute monocular vision loss (NAION-suspect). A 52-year-old female on Saxenda 3.0 mg, Month 5; develops acute painless monocular vision loss in left eye over approximately 24 hours. Ophthalmology urgent evaluation confirms left optic disc edema with altitudinal visual field defect; ESR and CRP normal (excluding GCA). Diagnosis: NAION, left eye.

Protocol response. Discontinue liraglutide; ~3–5 day clearance window. Confirmed NAION → permanent liraglutide discontinuation. Ophthalmology co-management for fellow-eye monitoring. Module 5 indication continuation discussion with patient: alternative GLP-1 RA selection is informed by Lakhani 2025 PMID 40383360 class-context findings — NAION signal is class-shared across single GLP-1 RAs (including semaglutide, dulaglutide, exenatide); NAION signal is absent for tirzepatide at the same analytical threshold (class-differentiation finding). Pattern V: signal-absent-at-threshold does not equal signal-absent-in-population, and post-approval exposure-window asymmetry caveat applies. The patient and clinician decide within the multi-dimensional comparator framework whether to attempt an alternative within the single GLP-1 RA class, transition to tirzepatide (signal-absent class), transition to non-GLP-1 weight-management approach, or other.

Worked example D — SCALE Teens adolescent CWM with growth-trajectory concern at Month 9. The 14-year-old male (Worked Example C from §4.6) on Saxenda 3.0 mg for 9 months; BMI z-score reduction on-trajectory; growth-chart shows height velocity at the 35th percentile (slowed from baseline 50th percentile).

Protocol response. Pediatric endocrinology consultation to assess growth-velocity trajectory. Differential considerations: pubertal-stage growth-velocity variation (Tanner staging review); nutritional adequacy review (Saxenda-mediated reduced caloric intake); thyroid function review (TSH at maintenance). Family-engagement discussion. Pattern V.research-precision: growth-trajectory effects of long-term liraglutide therapy in adolescent populations are research-direction-active; the canonical Section 9 Question 1 develops the pediatric long-term outcomes research direction. Clinical decision options: continue 3.0 mg with enhanced nutritional support and continued growth-trajectory monitoring; dose-down to 2.4 mg with continued monitoring; pause therapy with weight-regain framing per §8.5. The decision is patient- and family-anchored within pediatric endocrinology coordination.

Pattern AA.marketing-claims precision in §6.11. “Pancreatitis-attributable to liraglutide” is precise (alternative etiologies ruled out, temporal association); the labeled framing for liraglutide pancreatitis is “labeled precaution / cautionary use,” not “labeled contraindication” — but post-event, permanent discontinuation is the clinical judgment standard. “NAION class-context signal” is precise — post-marketing pharmacovigilance disproportionality analysis per Lakhani 2025 PMID 40383360; not labeled warning as of 2026-05-13; the management response (discontinuation) is clinician-judgment alignment with signal-direction precaution, not labeled mandate.

---

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when liraglutide’s primary effect has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). Section 7 is the diagnostic-and-decision branch point: distinguish pseudo-plateau from true plateau and from non-response.

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Pseudo-plateau. Apparent stall in weight or HbA1c that is in fact within normal week-to-week or month-to-month variation, or that reflects body-composition change (lean mass preservation with fat-mass continued loss) rather than total-weight stall, or that occurs in the predictable trial-trajectory pattern.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. True plateau is recognized by trajectory inflection plus an adequate observation window (typically 2–3 months at stable dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3–4 on target dose with effect substantially below the trial-program-typical effect for the patient’s phenotype.

Saxenda labeled response threshold. Per Saxenda FDA labeling: <5% body weight reduction at 16 weeks on 3.0 mg target dose with documented adherence may prompt consideration of therapy discontinuation per labeling guidance. This is the operationalized non-response threshold for Saxenda CWM. Pattern AA.marketing-claims precision: this is the FDA-labeled clinical-response threshold for the CWM indication; the threshold appears in the Saxenda prescribing information as the basis for continued therapy assessment.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. Weight loss into a new set-point window typically requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis). True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in counseling (§10) does not pathologize plateau but reframes it as biological-equilibrium and as the decision point for continuation, intensification, or maintenance-at-new-set-point.

7.4 Decision tree for plateau / non-response

1. Confirm adherence. Missed doses, injection-technique issues, daily-routine integration challenges are the most common pseudo-non-response causes. Confirm via patient interview and via prescription-refill audit. Pediatric: parental-supervision injection compliance check; school-day logistics review.
2. Confirm trajectory-context. Plot the patient’s curve against the trial-program-typical curve for their phenotype (SCALE Obesity for adult CWM non-diabetic; SCALE Diabetes for adult CWM + T2D; SCALE Teens for adolescent CWM; LEAD trial cohort for adult T2D; ELLIPSE for pediatric T2D). If the curve is on-trajectory, pseudo-plateau — continue current dose, reassess at next interval.
3. Confirm dose attainment. Is the patient on the target dose? If not (e.g., maintenance at 2.4 mg due to GI tolerance), complete titration to target dose if tolerability permits; reassess at Month 3 on target dose.
4. Reassess phenotype. Does the patient’s clinical picture support a phenotype the trial program enrolled, or is the patient in an under-represented or out-of-trial phenotype? Pattern V direction-of-effect: for under-represented phenotypes, expected effect-size may be smaller; recalibrate target.
5. If true plateau / non-response confirmed at adequate observation window:
   • CWM context (adult). Consider transition to semaglutide 2.4 mg (STEP 8 head-to-head; Rubino 2022 PMID 35015037 demonstrated semaglutide −15.8% vs liraglutide −6.4% at week 68 in non-diabetic adults with overweight/obesity; Pattern V direction-of-effect supports the magnitude differential favoring semaglutide for higher weight-loss-magnitude clinical objectives). Or consider transition to tirzepatide (SURMOUNT-1 PMID 35658024 ~22.5% body weight reduction at 15 mg over 72 weeks; SURMOUNT-5 PMID 40353578 demonstrated tirzepatide > semaglutide head-to-head). Or consider intensification of behavioral / nutritional / activity program rather than pharmacologic change (lifestyle interventions and pharmacotherapy are complementary; all GLP-1 RA labeling specifies “as an adjunct to a reduced-calorie diet and increased physical activity”). Or consider metabolic surgery referral for appropriate-phenotype patients.
   • CWM context (adolescent). Transition to semaglutide 2.4 mg pediatric (Wegovy ≥12y; STEP-TEENS Weghuber 2022 PMID 36322838 demonstrated semaglutide −16.1% BMI at week 68 in adolescents 12–17). Behavioral intensification with pediatric endocrinology + pediatric obesity management coordination. Pediatric metabolic surgery is a separate referral pathway with specific phenotype criteria.
   • T2D context (adult). Transition to tirzepatide (SURPASS-2 PMID 34170647 demonstrated tirzepatide superior HbA1c reduction vs semaglutide 1 mg; tirzepatide is FDA-approved for marketing claims for type 2 diabetes as Mounjaro since 2022). Or add SGLT2 inhibitor. Or add basal insulin per ADA/EASD progression algorithm — Xultophy fixed-ratio combination is a structured option here for patients suited to basal-insulin + GLP-1 RA combination.
   • T2D context (pediatric). Pediatric endocrinology coordination; consider tirzepatide pediatric T2D (SURPASS-PEDS PMID 40975112 reported HbA1c reduction in adolescent T2D; FDA pediatric pathway pending as of 2026-05-13 — Pattern AA.marketing-claims precision: not yet FDA-approved for marketing claims for pediatric T2D as of protocol date). Or add basal insulin.
   • CV indication context. LEADER established CV benefit in T2D + established CVD; non-response framing for CV indication is event-reduction at the trial-population level rather than surrogate-marker improvement at the individual-patient level. “Non-response” framing is less applicable at the individual-patient level over short observation windows; the LEADER trial-population benefit applies at the population-level risk-reduction tier.

7.5 Worked example — liraglutide non-responder algorithm

Worked example — Saxenda 3.0 mg adult CWM at the labeled 16-week threshold. A 52-year-old female on Saxenda 3.0 mg, Month 4 on target dose, has lost 1.8 kg from baseline (~2% of starting weight) — below the Saxenda labeled 16-week ≥5% response threshold.

Algorithm walkthrough.

Step 1 — adherence. Patient reports 100% adherence; prescription-refill audit confirms no gaps. Adherence-confirmed pseudo-non-response is ruled out.

Step 2 — trajectory-context. Patient’s curve at Month 4 (2% loss) is below the SCALE Obesity trajectory at week 16 (median trajectory ~5–6% loss at this time point). Not on-trajectory.

Step 3 — dose attainment. Patient is on 3.0 mg target dose; no further titration available within Saxenda labeled dosing.

Step 4 — phenotype reassessment. Patient is non-diabetic obesity, BMI 33, no prior weight-loss-pharm exposure. Phenotype is SCALE Obesity-enrolled; effect-size expectation is the SCALE Obesity-anchored trajectory.

Step 5 — non-response confirmed at the Saxenda labeled 16-week threshold; CWM context decision branches:

5a. Transition to semaglutide 2.4 mg weekly. STEP 8 head-to-head (Rubino 2022 PMID 35015037) demonstrated semaglutide −15.8% vs liraglutide −6.4% at week 68 in non-diabetic adults with overweight/obesity. Pattern V direction-of-effect: semaglutide weight-loss magnitude is higher in head-to-head; the patient may achieve a clinically meaningful weight loss on semaglutide that did not materialize on liraglutide. Pattern Z calibration anchor 4 mirror enforcement: the predecessor-vs-successor transition decision integrates the multi-dimensional comparator framework (§10.5) — daily-vs-weekly dosing PK profile; CV evidence base for the patient’s CV-risk context; generic availability (liraglutide-only; sema branded-only); cost/access; pediatric record (not applicable for this adult patient); GI tolerability profile. Affirms both compounds as evidence-based options; closes with shared decision-making.

5b. Transition to tirzepatide. SURMOUNT-1 PMID 35658024 ~22.5% body weight reduction at 15 mg in non-diabetic obesity at 72 weeks. SURMOUNT-5 PMID 40353578 demonstrated tirzepatide > semaglutide head-to-head (−20.2% vs −13.7% at week 72). Mechanism class: GLP-1/GIP dual agonist vs single GLP-1R agonist. Pattern V direction-of-effect: tirzepatide magnitudes are higher.

5c. Intensification of behavioral / nutritional / activity program. Lifestyle-intervention foundation per all GLP-1 RA labeling. Some patients respond to intensification within the same liraglutide protocol.

5d. Metabolic surgery referral for appropriate-phenotype patients (BMI ≥40 or BMI ≥35 with comorbidities; unsuccessful conservative weight-management). Metabolic surgery produces larger weight-loss magnitudes (commonly 25–35% body weight reduction sustained over years).

5e. Continue current therapy at the patient’s preference if behavioral / lifestyle factors are being actively addressed and additional time at current dose is patient-preferred. The Saxenda labeled threshold is a clinical-decision support framework, not an absolute discontinuation mandate; clinician-patient shared decision-making determines.

Pattern Z calibration anchor 4 applied at §7.5. The decision among 5a / 5b / 5c / 5d / 5e is patient-anchored, not clinician-mandated. Counseling beats (§10) frame the options without steering — present the trial-program-anchored effect-size estimates for each option with population-enrollment qualifications, present the trade-offs (cost, AE-profile, daily-vs-weekly dosing, generic availability, pediatric record, CV evidence base), and the clinician-patient decision is patient-preference-driven within the medically reasonable options. Pattern Z.research-precision: every comparator effect-size citation carries the trial population enrollment qualification.

---

8. Discontinuation and tapering

8.1 Purpose

Define when to stop liraglutide, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the weight-regain trajectory in CWM indications. Section 8 is the symmetric counterpart to §4 (initiation).

8.2 When to discontinue — discontinuation triggers

Discontinuation is indicated when one of the following emerges:

• Confirmed contraindication discovery (e.g., new MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM indication). §2.4 hard contraindications are immediate-discontinuation triggers.
• Severe AE attributable to the molecule (confirmed acute pancreatitis, confirmed NAION, severe hypersensitivity reaction). §6 AE-class-specific discontinuation triggers.
• Indication remission or resolution (T2D HbA1c sustained below target with weight stable in some patients; rare but documented).
• Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform the post-discontinuation expectations and the re-initiation pathway, not to override the patient’s decision.
• Cost / access barriers. Pattern Z calibration anchor 2 framing applies — present the cost / access reality factually, not as steering. The FDA-approved-generic availability for liraglutide (2024–2025 ANDAs) substantially modifies the cost-access landscape vs branded-only Saxenda/Victoza supply.
• Pre-conception planning for reproductive-age patients on CWM indication: discontinuation with approximately 2-day substantial-clearance washout per the §8.4 arithmetic plus the FDA-labeled pre-conception interval. This is anticipatory discontinuation, not reactive.
• Pediatric transition-of-care at ages 18–21: adult clinical-management transition may or may not include continued liraglutide therapy depending on the patient’s adult phenotype and shared decision-making.
• Non-response at the Saxenda labeled 16-week ≥5% threshold (CWM): per §7 non-response algorithm, may trigger therapy discontinuation or transition.

8.3 How to taper — molecule-specific tapering considerations

For liraglutide: pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the ~13-hour half-life-driven pharmacokinetic washout occurs at fixed kinetics regardless of taper schedule (~3–5 day clearance to non-detectable plasma concentrations). However, gradual dose reduction may be considered for weight-regain trajectory smoothing in CWM context, similar to the rationale for semaglutide CWM tapering.

The typical taper pattern for liraglutide Saxenda CWM (clinician-judgment within label; not label-mandated): 3.0 mg → 2.4 mg for 2 weeks → 1.8 mg for 2 weeks → 1.2 mg for 2 weeks → 0.6 mg for 2 weeks → discontinue. Total taper period approximately 8 weeks. Faster taper or abrupt discontinuation is acceptable per FDA labeling.

For Victoza T2D, taper is not typically required for transition or discontinuation given the shorter titration-to-maintenance period; abrupt discontinuation or transition to alternative T2D regimen is acceptable.

For acute-AE-attributable discontinuation (acute pancreatitis, NAION, severe hypersensitivity), abrupt discontinuation is appropriate; the ~3–5 day clearance window supports rapid pharmacokinetic clearance during the evaluation window.

Pattern AA.marketing-claims precision: “clinician-judgment within label” for taper schedule, not “label-mandated.”

8.4 Pre-conception washout arithmetic — liraglutide-specific shorter-half-life advantage

Liraglutide has an elimination half-life of approximately 13 hours. Approximately 5 half-lives are required for >95% pharmacokinetic clearance — approximately 65 hours, i.e., approximately 2 days. This is a substantively shorter pharmacokinetic clearance window than semaglutide (~5 weeks; ~35 days) or tirzepatide (~25 days).

The FDA label for Saxenda specifies discontinuation upon pregnancy awareness. The 2-day pharmacokinetic substantial-clearance arithmetic is the underlying PK basis; specific pre-conception interval recommendations integrate the pharmacokinetic clearance with pharmacodynamic clearance and a clinical margin.

This is a substantive comparator-advantage of liraglutide vs the longer-half-life weekly compounds for pre-conception planning. Patients planning conception within a clinically meaningful interval where pre-conception interruption is the planning context find the liraglutide ~2-day washout more flexible than the semaglutide ~35-day washout or the tirzepatide ~25-day washout. §10.4 Anchor 3 carries this comparator-advantage explicitly within the multi-dimensional pregnancy-planning counseling framework — Pattern Z anchor 3 mirror enforcement: lead with the Parker 2025 PMID 40329607 pooled human pregnancy-exposure data; then present pharmacokinetic facts factually including the liraglutide-specific shorter-washout advantage; then animal data + labeled-precaution as scoped factual context; close with shared decision-making.

8.5 Post-discontinuation weight-regain framing

Discontinuation produces weight regain over months to years per pooled discontinuation data — a class-level pattern shared with the entire pharmacotherapy-for-chronic-disease framework. SCALE Teens reported weight regain during the 26-week off-treatment follow-up phase. SCALE 3-year extension (PMID 28237263) demonstrated sustained weight loss with continued therapy over 3 years; discontinuation data from SCALE program supports the class-level regain pattern. Cross-class context: STEP-1 extension (semaglutide; PMID 35472181) demonstrated weight regain after discontinuation in non-diabetic adults with obesity.

The mechanism — set-point physiology and the defended-weight biology described in §7.3 — predicts that without pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium.

The protocol framing in counseling (§10) does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response, the same way pre-treatment counseling framed the appetite-suppression mechanism as the biological intervention.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: typically re-titration from the starting dose (0.6 mg daily, with weekly increments per indication) is the protocol-recommended pattern — the tolerability re-priming is equivalent to initial titration. Abrupt re-initiation at the prior maintenance dose is not recommended due to GI AE recurrence risk. §4 titration applies. Indication confirmation per §1; selection-criteria re-screening per §2; pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

8.7 Worked example — liraglutide discontinuation scenarios

Scenario A — pre-conception planning. A 32-year-old female on Saxenda 3.0 mg, Month 14 on target dose, has lost 7.0 kg (~8% of starting weight, on-trajectory) and is planning conception in approximately 3 months. Counseling beat per §10.4 Anchor 3:

Open with Parker 2025 human pregnancy-exposure data. Parker SE et al. 2025 Diabetes Obes Metab PMID 40329607 — pooled regulatory pregnancy-exposure data across the GLP-1 RA class (semaglutide, liraglutide, dulaglutide, class-related compounds). Most reported pregnancy exposures were inadvertent; incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete. Authors call for prospective pregnancy registries.

Then pharmacokinetic facts. Liraglutide half-life ~13 hours; ~5 half-lives (~2 days) for substantial pharmacokinetic clearance. Liraglutide-specific shorter-washout advantage: ~2-day substantial-clearance washout vs ~5-week washout for semaglutide and ~25-day washout for tirzepatide — the differentially shorter washout supports more flexible pre-conception planning intervals.

Then label recommendation as scoped factual context. Saxenda label specifies discontinue upon pregnancy awareness; clinician-judgment pre-conception interval integrates pharmacokinetic clearance with pharmacodynamic clearance and clinical margin.

Then animal data + Category-X context as scoped factual context. Animal reproductive-toxicity studies supported the precautionary Category-X-equivalent labeling; animal data does not always translate to human teratogenicity profile. Parker 2025 human pooled data is the load-bearing human evidence.

Then post-discontinuation weight-regain trajectory. Class-level pattern of weight regain over months to years post-discontinuation; SCALE program and class-level discontinuation data support this trajectory.

Then patient-anchored decision. The patient’s reproductive-planning decision is patient-anchored. Some patients on protocol will plan conception within the next 1–2 years; some within the next decade; some not at all but want awareness of the discontinuation arithmetic. The counseling beat presents the facts; the timing decision is patient-anchored.

Then re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met.

Scenario B — patient-preference discontinuation at Month 18. A 58-year-old male on Saxenda 3.0 mg, has lost 12.5 kg (~13% of starting weight) and stabilized at the new weight for the last 4 months; reports tolerable but consistent mild GI AE profile; wishes to discontinue. Counseling beat: discuss class-level weight-regain trajectory data; re-initiation pathway available if regain occurs and is clinically meaningful. Protocol taper: 3.0 mg → 2.4 mg × 2 weeks → 1.8 mg × 2 weeks → 1.2 mg × 2 weeks → 0.6 mg × 2 weeks → off (clinician-judgment within label). Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP; re-initiation decision at any monitoring visit.

Scenario C — confirmed acute pancreatitis (per §6.4 Worked Example B). Permanent discontinuation. No taper — abrupt discontinuation appropriate given the AE-attributable etiology; ~3–5 day clearance to non-detectable concentrations. Transition to non-GLP-1 alternative per indication.

Scenario D — new pregnancy on protocol. A 29-year-old female on Saxenda 3.0 mg discovers pregnancy at approximately 6 weeks gestation. Saxenda label specifies discontinue upon pregnancy awareness. Immediate discontinuation. Obstetrics co-management; the ~2-day pharmacokinetic clearance window is documented for the obstetrics record. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication.

Scenario E — adolescent Saxenda discontinuation at transition-of-care (age 18). An 18-year-old male who initiated Saxenda at age 14 (SCALE Teens-anchored adolescent CWM), continued through pubertal completion; now transitioning to adult clinical management. Decision options: continued Saxenda use within the adult CWM indication framework (BMI ≥30 or BMI ≥27 + comorbidity); transition to alternative GLP-1 RA appropriate for adult clinical context; transition off pharmacotherapy with lifestyle-intervention maintenance. Adult endocrinology / obesity-management coordination supports shared decision-making.

Pattern Z calibration anchor 3 precision in §8.7 Scenario A. Pregnancy-planning counseling presents the Parker 2025 human pregnancy-exposure data first (lead with research-state); then pharmacokinetic facts including the liraglutide-specific shorter-washout advantage (~2-day vs ~5-week semaglutide vs ~25-day tirzepatide); then label recommendation as scoped factual context; then animal data context; then post-discontinuation weight-regain trajectory; then patient-anchored decision invitation. The protocol does not steer toward continued pharmacotherapy by emphasizing weight-regain risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented; the patient decides.

---

9. Combination rules

9.1 Purpose

Define what stacks with liraglutide, what is contraindicated in combination, and the rationale for each combination category. Section 9 is the protocol’s bridge to Module 5.12 Combination Protocols and to the lean-mass-stack protocols (M5.5 Tesamorelin / AOD-9604; M5.6 Lean Mass / CJC-Ipamorelin / MOTS-c).

Pattern W cross-section consistency applies: every combination in this section is reconciled with §2 (a combination cannot include an agent contraindicated in §2), §6 (combinations cannot mask or exacerbate AE-class concerns established in §6), and §10 (counseling beats for combinations are anchored to Pattern Z calibration anchors).

9.2 Within-Module-5 combinations

Liraglutide + insulin degludec (Xultophy 100/3.6 fixed-ratio combination). Xultophy is FDA-approved for marketing claims for T2D adults requiring intensified glycemic control with basal-insulin + GLP-1 RA combination (November 21, 2016). Composition: insulin degludec 100 units + liraglutide 3.6 mg per mL fixed ratio. Mechanism rationale: combination of long-acting basal insulin (insulin degludec, ~25-hour half-life supporting once-daily dosing) with liraglutide produces complementary glycemic-control mechanisms — basal insulin provides background insulin coverage; liraglutide provides glucose-dependent prandial insulin secretion + glucagon suppression + delayed gastric emptying + appetite suppression. Pivotal program: DUAL program. Xultophy is the only FDA-approved-for-marketing-claims combination product in the liraglutide line as of 2026-05-13. Dosing: dose-step-delivered (1 dose step = 1 unit insulin degludec + 0.036 mg liraglutide); titrated by 2 dose steps twice weekly based on fasting plasma glucose targets per Xultophy labeling.

Liraglutide + SGLT2 inhibitor (T2D indication context). Class-additive HbA1c and cardiovascular / kidney benefits; commonly co-prescribed in T2D + CKD or T2D + ASCVD context. Mechanism rationale: SGLT2 inhibitor adds glucose-osmotic-diuretic and ketogenesis-modulating effects; the combination is broadly supported by individual-agent CVOT and KOOT data and by clinical-practice cohort analyses. Liraglutide LEADER nephropathy-composite HR 0.78 (p=0.003) combined with SGLT2 inhibitor (e.g., empagliflozin EMPA-REG OUTCOME PMID 26378978; dapagliflozin DAPA-CKD PMID 32970396; empagliflozin EMPA-KIDNEY) renal-protection evidence provides class-additive support for the T2D + CKD polycondition phenotype. Pattern V.research-precision: combination effect is supported by individual-agent trial data and by clinical-practice cohort analyses, not by head-to-head combination RCT for the specific liraglutide + SGLT2 inhibitor pairing.

Liraglutide + insulin (T2D advanced; not Xultophy fixed-ratio). For T2D patients with advanced beta-cell failure where the Xultophy fixed-ratio is not the appropriate operational option, liraglutide + flexible-dose basal insulin (insulin glargine, insulin degludec at non-Xultophy dose ratios, insulin detemir) is a common combination. §6.9 hypoglycemia management applies; concurrent insulin dose typically reduced ~20% at liraglutide initiation.

Liraglutide + DPP-4 inhibitor: not indicated. Mechanistic overlap (DPP-4 inhibitor preserves endogenous GLP-1; redundant with exogenous GLP-1 RA) makes the combination not clinically additive. Avoid co-prescribing.

Liraglutide + pramlintide (amylin analog): not typically co-administered. Both compounds delay gastric emptying; additive gastric-emptying delay may worsen GI AE profile. The combination has not been studied for additive efficacy and is not typically used clinically.

Liraglutide + cagrilintide (combination class context). Cagrilintide (long-acting amylin analog) is being developed primarily for combination with semaglutide (CagriSema; REDEFINE Phase 3 program). A dedicated liraglutide + cagrilintide combination product is not in publicly-disclosed development as of 2026-05-13. Pattern AA.marketing-claims precision: not FDA-approved-for-marketing-claims combination; no dedicated trial-evidence base for the specific pairing.

Liraglutide + GIP agonist or dual GLP-1/GIP agonist: not co-administered. Tirzepatide as a single-molecule GLP-1/GIP dual agonist replaces the liraglutide GLP-1R agonism axis — transition between agents, not co-administration. Pattern Z calibration: transition framing per §7 non-response algorithm.

9.3 Cross-Module combinations — lean-mass and body-composition stacks

Cross-Module combinations involve adding a peptide outside the GLP-1 / amylin / GIP / glucagon metabolic-axis family to address a complementary clinical objective — most commonly lean-mass preservation during weight loss.

• Liraglutide + CJC-1295 / Ipamorelin (GH secretagogue stack). Mechanism rationale: CJC-1295 (GHRH analog) plus Ipamorelin (GH secretagogue) elevates endogenous growth hormone pulsatility, supporting lean-mass preservation during caloric deficit. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, monitoring (IGF-1 anchored), and AE-class considerations. Pattern N.1 applies: CJC-1295 and Ipamorelin are peptides — Peptides folder path, not Small-Molecules folder path. Pattern Z calibration anchor 5 (off-label / extrapolation transparency) applies — CJC-1295 and Ipamorelin are not FDA-approved for marketing claims for this indication and the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

• Liraglutide + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Trial-program status: limited human Phase 1/2 data; clinician judgment within Module 5.6 stack framing. Pattern AA.marketing-claims precision: not FDA-approved-for-marketing-claims for any drug indication; mechanism-stage and early-clinical evidence.

• Liraglutide + Tesamorelin (FDA-approved for marketing claims for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context). Mechanism rationale: Tesamorelin (GHRH analog) reduces visceral adipose tissue; in combination with GLP-1 RA-mediated weight loss, visceral-adiposity-targeted effects are additive. Module 5.5 Tesamorelin canon documents trial-program data and off-label clinical use. Pattern AA.marketing-claims precision: Tesamorelin is FDA-approved for marketing claims for HIV-associated lipodystrophy; the off-label-for-non-HIV-visceral-adiposity framing is explicit, not implicit; off-label use is clinician-judgment within informed-consent and primary-source-supported clinical reasoning.

• Liraglutide + GHK-Cu (skin / connective-tissue peptide). Cross-Module — GHK-Cu is a Module 5.7 (skin-elasticity, post-weight-loss skin tone) topical or injectable application. Pattern V direction-of-effect: GHK-Cu trial-program data are limited for the post-weight-loss-skin indication specifically; clinician judgment with patient-anchored expectations. Pattern Z.research-precision: GHK-Cu for post-weight-loss skin laxity is supported by in vitro fibroblast collagen-synthesis data, animal wound-healing models, cosmetic-industry topical efficacy data, and practitioner clinical experience; RCT-level human evidence for the specific indication is research-state-incomplete.

9.4 Contraindicated combinations

• Liraglutide + DPP-4 inhibitor (§9.2 — not contraindicated by safety; not indicated by lack of additive benefit and by clinical-practice convention).
• Liraglutide + other GLP-1 RAs (semaglutide, dulaglutide, exenatide, tirzepatide) — avoid; redundant within-class mechanism with additive AE profile and no demonstrated additive benefit; transition between agents, not co-administration.
• Liraglutide + sulfonylurea at full sulfonylurea dose (relative — combination produces excess hypoglycemia risk; sulfonylurea should be reduced ~50% or discontinued at liraglutide initiation per §6.9).
• Liraglutide + agents that severely delay gastric emptying (relative — additive gastric-emptying delay may worsen GI AE profile and may impair absorption of concurrent oral medications).
• Liraglutide + pramlintide (relative — both delay gastric emptying; additive AE concern; not typically used).

9.5 Worked example — liraglutide combination scenarios

Scenario A — Xultophy 100/3.6 initiation for T2D requiring basal-insulin + GLP-1 RA combination. A 67-year-old male with T2D (HbA1c 8.6 on metformin + glargine 30 units daily); insulin-titration needed for additional glycemic control; clinician considers transition to Xultophy 100/3.6 fixed-ratio combination.

Protocol response. Xultophy is FDA-approved for marketing claims for T2D adults requiring intensified glycemic control with basal-insulin + GLP-1 RA combination. Transition from existing glargine 30 units daily to Xultophy: per Xultophy labeling, initial dose typically 16 dose steps (16 units insulin degludec + 0.58 mg liraglutide per day) with subsequent titration by 2 dose steps twice weekly based on fasting plasma glucose targets. Glargine discontinued at Xultophy initiation. Hypoglycemia surveillance per §6.9. Monitoring: HbA1c at 3-month intervals; fasting plasma glucose for titration; standard T2D surveillance.

Scenario B — Liraglutide CWM + SGLT2 inhibitor for T2D + CKD polycondition (cross-class combination). A 61-year-old male with T2D (HbA1c 7.4) + CKD eGFR 42, on Victoza 1.8 mg + metformin; addition of SGLT2 inhibitor (empagliflozin 10 mg daily) per ADA/EASD T2D-progression algorithm for additive CV and kidney benefit. Combination is well-supported by individual-agent CVOT / KOOT data — LEADER nephropathy-composite HR 0.78 (liraglutide) + EMPA-REG / EMPA-KIDNEY (empagliflozin). Monitoring: eGFR at 2 weeks post-SGLT2 initiation (typical small reversible eGFR decline expected), then routine quarterly per §5. Pattern V.research-precision: cross-class combination supported by clinical-practice and by individual-agent trial data; not by head-to-head combination RCT for this specific pairing.

Scenario C — Saxenda + CJC-1295 / Ipamorelin stack (M5.6 v3) for lean-mass preservation. A 47-year-old male, baseline BMI 36, on Saxenda 3.0 mg, Month 8 on target dose, has lost 11 kg with DEXA showing ~28% of lost mass as lean mass (above the 20–25% typical proportion for unsupplemented weight loss). Add M5.6 v3 stack — CJC-1295 + Ipamorelin per the M5.6 stack protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack to track lean-mass trajectory; IGF-1 quarterly. Pattern Z calibration anchor 5 (off-label / extrapolation transparency) — counseling beat states explicitly that CJC-1295 and Ipamorelin are not FDA-approved-for-marketing-claims for this indication and that the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

Scenario D — Liraglutide + tirzepatide concurrent (contraindicated). A patient seeking dual-class metabolic intensification. Counseling beat: combination not indicated — within-class redundant agents; transition between them (§7 non-response algorithm) is the appropriate decision, not co-administration. Pattern V direction-of-effect: SURMOUNT-1 PMID 35658024 supports tirzepatide as the higher-effect alternative for the higher weight-loss-magnitude clinical objective; transition with appropriate liraglutide discontinuation (per §8 — abrupt discontinuation acceptable in this transition context given immediate replacement with same-class agent) and tirzepatide initiation per its own initiation protocol.

Pattern W cross-check at §9.5. Each combination above is reconciled with §2 (no patient enters a combination with a contraindicated agent), §6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

---

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the protocol’s patient-counseling content — the conversations the clinician has with the patient at each protocol phase. Section 10 is the operational anchor for Pattern Z (cumulative-tone calibration), Pattern R (lead-framing calibration), and Pattern Z.injection-framing (daily injection presented as routine clinical skill). The counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

The five Pattern Z calibration anchors are calibrated against the verbatim semaglutide v1.0-final canonical anchors documented at /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. For the liraglutide protocol, the anchors are applied with liraglutide-specific adaptations:

• Anchor 1 — Compounded-formulation operational characteristics. For liraglutide, the operational landscape is branded-vs-generic-vs-compounded post-FDA-approved-generic introduction (2024–2025 ANDAs) — substantially different from the FDA-approved-vs-compounded framing carried by sema/tirz protocols. Lead with what each option IS.
• Anchor 2 — Compounded vs FDA-approved patient-counseling beat. Reframed for liraglutide as branded-vs-generic-vs-compounded counseling per the post-generic-entry operational landscape.
• Anchor 3 — Pregnancy section research-state-leading structure. LEAD with Parker 2025 PMID 40329607 pooled human pregnancy-exposure data; then PK facts including the liraglutide-specific shorter-washout comparator-advantage; then label as scoped factual context; then animal data; then weight-regain trajectory; then patient-anchored decision invitation.
• Anchor 4 — Multi-dimensional comparator framing. Liraglutide-vs-semaglutide and liraglutide-vs-tirzepatide counseling presents 8+ dimensions: weight magnitude (STEP 8 head-to-head PMID 35015037 sema > liraglutide; SURMOUNT-1 PMID 35658024 + SURMOUNT-5 PMID 40353578 tirz > sema), cardiovascular evidence base (LEADER for liraglutide in T2D + CVD; SUSTAIN-6/SELECT for semaglutide; SURPASS-CVOT/SURMOUNT-MMO for tirzepatide in development), MASH approval (semaglutide via ESSENCE PMID 40305708 August 2025; tirzepatide MASH program in development; liraglutide MASH evidence is older Phase 2 LEAN-trial corpus — not FDA-approved for MASH), kidney evidence (FLOW for semaglutide PMID 38785209; LEADER nephropathy-composite for liraglutide), NAION class-context (Lakhani 2025 PMID 40383360: signal documented for single GLP-1 RAs including liraglutide and semaglutide; signal absent for tirzepatide — class-differentiation finding), GI tolerability profiles (STEP 8 discontinuation rates 13.5% sema vs 27.6% liraglutide), daily-vs-weekly dosing PK profile (liraglutide ~13-hr daily; sema ~7-day weekly; tirz ~5-day weekly), pediatric record (liraglutide longest in class — Victoza ≥10y T2D 2019; Saxenda ≥12y obesity 2020), generic availability (liraglutide-only FDA-approved generic), cost / access. Opens with affirmation of both compounds; closes with shared decision-making.
• Anchor 5 — Off-label / extrapolation framing. Presents trial-population scope as fact; frames extrapolation as research-state-incompleteness; explicit off-label labeling; informed-consent acknowledgement.

Compound-specific counseling beats verify against verbatim canonical anchors, not just abstract principles. This protocol’s §10 PSV iteration 1 verbatim-diff check confirms anchor compliance.

10.2 Initiation conversation (Section 4 anchor)

The initiation conversation occurs at the pre-treatment workup completion / §4 initiation visit. Required counseling beats:

• What liraglutide is (Anchor 1): liraglutide is a peptide GLP-1 receptor agonist; daily subcutaneous injection; FDA-approved for marketing claims for type 2 diabetes (Victoza adults 2010; pediatric ≥10y 2019; CV risk reduction in T2D + established CVD 2017) and chronic weight management (Saxenda adults 2014; pediatric ≥12y with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted 2020); plain-language mechanism (helps the body regulate blood sugar and appetite; works with the body’s own signaling rather than overriding it).
• What it does for the patient’s indication (Anchor 1, Anchor 4): expected effect-size with trial-anchor precision; comparator framing if patient has alternative-class options.
• The titration schedule (§4): standard pace and slow-titration option; the patient is informed that the titration timeline is adjustable to their tolerability.
• The AE profile expected at each titration step (§6.2 GI class anticipatory framing): nausea is anticipated, typically attenuates within 1–2 weeks at stable dose; non-pharmacologic management first; ondansetron PRN second. Reassurance that AE-emergence is not failure but is anticipated.
• Daily injection — Pattern Z.injection-framing: self-injection at abdomen, thigh, or upper arm via dial-up multi-dose pen; same mechanics as daily insulin self-injection routinely taught across endocrinology and primary care; the procedure is taught at this visit and refined over the first few self-administrations. The substantive clinical-management discussion is dose-tolerance, not injection mechanics.
• The pre-conception planning beat for reproductive-age patients (Anchor 3): pharmacokinetic washout arithmetic with liraglutide-specific shorter-washout advantage (~2 days substantial clearance); the post-discontinuation weight-regain trajectory; the re-initiation pathway.
• Cost / access realities (Anchor 2): present branded-vs-generic-vs-compounded operational landscape if applicable; present insurance-coverage realities.
• What the patient signals back if any concern emerges (escalation pathway): symptoms that warrant in-person evaluation within 48 hours (severe persistent abdominal pain; vomiting blood; acute vision change; signs of severe AE).

10.3 Branded-vs-generic-vs-compounded counseling — Pattern Z anchors 1 + 2 (LIRAGLUTIDE-SPECIFIC reframing)

For liraglutide, the operational supply landscape post-2024-2025 FDA-approved-generic introductions is substantially different from the operational landscape for compounded semaglutide and compounded tirzepatide. The Pattern Z anchor 2 framing for liraglutide is branded-vs-generic-vs-compounded rather than the FDA-approved-vs-compounded framing carried by sema/tirz protocols.

Pattern Z compliant framing — what each supply option IS.

• Branded Saxenda (CWM) / Victoza (T2D) / Xultophy 100/3.6 (T2D fixed-ratio with insulin degludec): Novo Nordisk-manufactured FDA-approved products with standardized formulation, manufacturer-validated stability, manufacturer-supported clinical data, and label-defined indication scope. Pre-filled multi-dose pen with dial-up dose-selection.
• FDA-approved generic liraglutide (2024–2025 ANDAs): bioequivalent to branded reference product per FDA ANDA requirements (Tier 1 evidence; PK bioequivalence within 80–125% CI for AUC and Cmax; Rogers-Crovak 2024 AAPS J PMID 39586870 regulatory-policy framework). Multiple manufacturers. The only FDA-approved generic GLP-1 receptor agonist on the US market as of 2026-05-13.
• Compounded liraglutide: real-world clinical option used by some patients within their clinical-decision-making framework. The operational landscape post FDA-approved-generic introduction differs substantially from compounded semaglutide and compounded tirzepatide. Liraglutide is no longer in FDA-declared shortage; the 503A/503B FDA-shortage-pathway compounding rationale that drove compounded-semaglutide and tirzepatide demand spikes does not apply identically to liraglutide given generic supply. Some compounding pharmacies and direct-to-consumer marketplaces continue to offer compounded liraglutide under different regulatory rationale (research-use claims; international-sourced API; non-FDA-shortage operational basis). Quality-criteria considerations apply (API source pharmaceutical-grade vs research-grade; sterility assurance; concentration accuracy; storage and stability; labeling and patient information).

Pattern Z compliant comparison — the clinical considerations that differ.

• Clinical equivalence: branded vs FDA-approved generic — bioequivalent per ANDA requirements (Tier 1 evidence). Compounded — different regulatory framework; clinical equivalence not established at the FDA-bioequivalence tier; quality varies across compounding pharmacies.
• Regulatory framework: branded and FDA-approved generic — full FDA framework with manufacturer adverse-event reporting in FDA pharmacovigilance pipeline. Compounded — regulated under state board of pharmacy + FDA 503A/503B framework + (for non-shortage-rationale supply) varying regulatory rationale; adverse-event reporting pathways vary.
• Cost and access: FDA-approved generic — typically lower out-of-pocket cost than branded; access expanded substantially in 2024–2025. Compounded — pricing varies; access varies. Branded — typically higher cost; insurance coverage variable.
• Device presentation: branded — Novo Nordisk reference-product pen device form-factor. FDA-approved generic — some manufacturers use Novo Nordisk reference-product pen device form-factor; some use alternative pen device architectures with different ergonomics. Compounded — often vial-and-syringe rather than pen device.

Patient-counseling beat (verbatim-calibration discipline):

“For liraglutide, you have multiple supply options. Branded Saxenda or Victoza is the Novo Nordisk-manufactured product. FDA-approved generic liraglutide became available in 2024–2025 — it’s the first FDA-approved generic in the GLP-1 class, bioequivalent to branded per FDA ANDA requirements. Some patients also use compounded liraglutide; the operational landscape for compounded liraglutide is different from compounded semaglutide or tirzepatide because liraglutide is no longer in FDA-declared shortage and we have FDA-approved generic supply. The clinical-effectiveness equivalence between branded and FDA-approved generic is well-established per bioequivalence; device presentation, pricing, and pharmacist-substitution practice differ. If you’re considering compounded liraglutide specifically, let’s review the compounding pharmacy’s quality practices — sterility testing, certificate of analysis, accreditation — and the operational characteristics that differ from branded and generic FDA-approved supply. That’s how the decision gets made well within your clinical context.”

Pattern Z anti-steering discipline: present each option factually as a clinical category with its respective trade-offs; allow the patient and clinician to make a choice anchored to the patient’s circumstances (cost, access, regulatory comfort, formulation comfort). The liraglutide-specific operational reality is that the compounding-pathway question is largely moot post-generic-introduction — most clinical decisions on liraglutide supply are between branded Novo Nordisk and FDA-approved generic, not between FDA-approved and compounded.

10.4 Pregnancy-planning conversation — Pattern Z calibration anchor 3 mirror enforcement

For reproductive-age patients on liraglutide CWM (Saxenda) indication or pediatric/adolescent patients aging into reproductive years.

The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or label recommendation — this lead-framing discipline is the core of canonical Anchor 3. Required counseling beats:

• Human pregnancy-exposure data — Parker 2025 PMID 40329607. Pooled regulatory pregnancy-exposure data across the GLP-1 RA class from regulatory-trial datasets and Phase 4 commitment registries — liraglutide exposures included alongside semaglutide and dulaglutide regulatory-trial exposures. Most reported pregnancy exposures were inadvertent (patient on GLP-1 RA therapy at the time of conception, with prompt discontinuation upon pregnancy awareness). Pregnancy outcomes characterized included spontaneous abortion, elective termination, ongoing pregnancy, live birth, congenital malformations. Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete. Authors call for prospective pregnancy registries.

• Pharmacokinetic facts (post-research-state-lead). Liraglutide half-life approximately 13 hours; approximately 5 half-lives (approximately 2 days) for >95% pharmacokinetic clearance. The liraglutide-specific shorter pre-conception washout — ~2-day substantial-clearance — is a substantive comparator-advantage vs semaglutide’s ~5-week (~35-day) washout and tirzepatide’s ~25-day washout. For patients planning conception within a clinically meaningful interval, the liraglutide shorter-washout PK profile supports more flexible pre-conception planning. Pattern Z.research-precision: this is a mechanism-based factual comparator differentiation; the magnitude of the difference is the half-life ratio (~13 hours liraglutide vs ~7 days semaglutide).

• Label recommendation. Saxenda label specifies discontinue upon pregnancy awareness. The pharmacokinetic ~2-day substantial-clearance arithmetic supports the rapid post-awareness clearance.

• Animal data context. Reproductive toxicity studies in animals supported the Category-X-equivalent contraindication; animal data does not always translate to human teratogenicity profile. Parker 2025 human pooled data is the load-bearing human evidence.

• Post-discontinuation weight-regain trajectory. SCALE program data and class-level discontinuation patterns — weight regain over months to years post-discontinuation; SCALE Teens off-treatment follow-up demonstrated regain.

• The patient’s reproductive-planning decision is patient-anchored. Some patients on protocol will plan conception within the next 1–2 years; some within the next decade; some are not planning conception at all but want awareness of the protocol-discontinuation arithmetic. The counseling beat presents the facts; the timing decision is patient-anchored.

• Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met.

Patient-counseling beat (verbatim-calibration discipline):

“On pregnancy: the research is accumulating. Parker 2025 pooled the GLP-1 RA pregnancy-exposure data across regulatory trials — most were inadvertent exposures; incidence of congenital abnormalities appeared relatively low in this dataset; the sample size is limited. Prospective planned-pregnancy data is still being collected. On the pharmacokinetics: liraglutide’s half-life is about 13 hours, so approximately 5 half-lives — about 2 days — clears most of the drug. This is substantially shorter than semaglutide (about 5 weeks washout) and tirzepatide (about 25 days). So if you’re planning pregnancy, liraglutide offers more flexible pre-conception interruption timing than the longer-half-life weekly compounds. The Saxenda label says discontinue upon pregnancy awareness. Animal reproductive-toxicity studies supported the precautionary contraindication; the Parker 2025 human data is the load-bearing evidence and is reassuring as far as it goes. Weight regain over months to years after discontinuation is the expected pattern across this drug class. The reproductive-planning decision is yours; the protocol discontinuation arithmetic supports your timing flexibility. Let’s discuss what your planning window is and how to coordinate the discontinuation with that.”

10.5 Comparator conversation — Pattern Z calibration anchor 4 mirror enforcement

For patients with within-class alternatives (e.g., liraglutide vs semaglutide or vs tirzepatide for CWM or T2D). Canonical Anchor 4 requires multi-dimensional fact presentation across 8+ dimensions. Required counseling beats:

• Weight-loss magnitude (Pattern V.metric-axis trial-anchored). STEP 8 head-to-head (Rubino 2022 JAMA PMID 35015037; n=338 non-diabetic adults with overweight/obesity without T2D; 68 weeks): mean body weight change −15.8% (semaglutide 2.4 mg weekly) vs −6.4% (liraglutide 3.0 mg daily); estimated treatment difference −9.4 percentage points (95% CI −12.0 to −6.8; p<0.001). Cross-trial (separate trials, indirect): SURMOUNT-1 PMID 35658024 tirzepatide 15 mg ~22.5% body weight reduction over 72 weeks in non-diabetic obesity; SURMOUNT-5 PMID 40353578 tirzepatide −20.2% vs semaglutide 2.4 mg −13.7% at week 72 (head-to-head between sema and tirz, n=751). For T2D HbA1c: SUSTAIN-7 semaglutide vs dulaglutide PMID 29397376 (semaglutide superior); SURPASS-2 PMID 34170647 tirzepatide vs semaglutide 1 mg in T2D (tirzepatide superior). LEAD-6 PMID 19515413 demonstrated liraglutide superior glycemic-control efficacy vs exenatide BID.

• Cardiovascular outcomes evidence base. LEADER PMID 27295427 established the cardiovascular indication for liraglutide in T2D + established CVD (MACE HR 0.87, p=0.01 for superiority; first GLP-1 RA CVOT to demonstrate CV benefit on the primary three-point MACE endpoint — class-level historical inflection point). SUSTAIN-6 PMID 27633186 established semaglutide CV outcomes in T2D + CVD (MACE HR 0.74). SELECT PMID 37952131 established semaglutide CV outcomes in obesity + CVD without T2D (MACE HR 0.80). Tirzepatide CV outcomes are research-state-emerging from SURPASS-CVOT and SURMOUNT-MMO (readout pending). Pattern V.research-precision: each trial enrolled different populations; direct cross-trial effect-size comparison is methodologically inappropriate for clinical-decision-making at the patient level. Each compound has positive CVOT(s) in its respective trial population(s).

• MASH approval status. Semaglutide FDA-approved for marketing claims for MASH August 2025 on the basis of ESSENCE PMID 40305708. Tirzepatide MASH program in development (SYNERGY-NASH Phase 2 PMID 38856224; Phase 3 in development). Liraglutide is not FDA-approved for marketing claims for MASH as of 2026-05-13; liraglutide-specific MASH evidence is from the older Phase 2 LEAN trial corpus.

• Kidney outcomes evidence base. FLOW PMID 38785209 established semaglutide kidney-composite reduction in T2D + CKD (kidney composite plus CV death HR ~0.76 at median 3.4 years). LEADER nephropathy-composite secondary endpoint HR 0.78 (p=0.003) provides supportive evidence for liraglutide kidney-protection class-level effect; not a dedicated FLOW-equivalent trial. Tirzepatide kidney outcomes in development.

• Ophthalmologic NAION class-context (Lakhani 2025 PMID 40383360 — observational pharmacovigilance disproportionality analysis, AB.4 publication-type precision). NAION signal documented for semaglutide at significant magnitudes; signal documented for the older-generation GLP-1 RAs (liraglutide, exenatide, dulaglutide) at similar magnitudes — class-shared signal characterization for the single GLP-1 RAs. Signal absent for tirzepatide at the same analytical threshold — class-differentiation finding between single GLP-1 RAs and the GLP-1/GIP coagonist mechanism class. Pattern AA.marketing-claims precision: signal-under-evaluation; not labeled warning for any compound as of 2026-05-13. Pattern V: signal-absent-at-threshold does not equal signal-absent-in-population; post-approval exposure-window asymmetry caveat applies.

• GI tolerability profile. STEP 8 PMID 35015037 discontinuation rates due to adverse events: 13.5% (semaglutide weekly) vs 27.6% (liraglutide daily) — the higher discontinuation rate in the liraglutide arm reflects in part the daily-dosing context and the trial-titration period structure. GI AE profiles are qualitatively similar across the GLP-1 RA class.

• Daily-vs-weekly dosing PK profile (Pattern Z.injection-framing). Liraglutide ~13-hour half-life → daily subcutaneous injection. Semaglutide ~7-day half-life → weekly subcutaneous injection (Ozempic, Wegovy) plus oral once-daily (Rybelsus). Tirzepatide ~5-day half-life → weekly subcutaneous injection. Daily injection is a routine clinical skill, not a barrier — Pattern Z.injection-framing across the protocol. The daily-vs-weekly choice is a legitimate clinical-option dimension with differentially relevant clinical-use cases for daily dosing (peri-procedural settings; faster discontinuation clearance for AE management; pre-conception washout where the ~2-day vs ~35-day vs ~25-day arithmetic matters; pediatric daily-supervision contexts; specific T2D management contexts where daily routine aligns with broader once-daily regimens; patient preference for daily routine).

• Pediatric clinical-use record. Liraglutide has the longest pediatric clinical-use record in the GLP-1 RA class — Victoza ≥10y T2D 2019 (ELLIPSE PMID 31034184); Saxenda ≥12y obesity 2020 (SCALE Teens PMID 32233338). Semaglutide pediatric obesity approval Wegovy ≥12y 2022 (STEP-TEENS PMID 36322838) followed by approximately two years. Tirzepatide pediatric T2D pathway pending (SURPASS-PEDS PMID 40975112 reported; FDA pathway not yet completed as of 2026-05-13). For pediatric T2D ≥10 years, liraglutide is the only FDA-approved GLP-1 RA option. For adolescent obesity ≥12 years, liraglutide and semaglutide are both FDA-approved options.

• Generic availability. Liraglutide is the only FDA-approved generic GLP-1 RA on the US market as of 2026-05-13 — 2024–2025 ANDAs for Victoza-equivalent and Saxenda-equivalent generics; bioequivalence per ANDA requirements; cost-access landscape substantially expanded vs branded-only sema and branded-only tirz supply.

• Route / platform availability. Liraglutide: SC daily injection only (no oral platform). Semaglutide: SC weekly injection (Ozempic, Wegovy) plus oral once-daily (Rybelsus). Tirzepatide: SC weekly injection only (no oral platform).

• Cost and access. Patient-specific; insurance-coverage realities vary by indication and jurisdiction; liraglutide post-generic-entry has substantially reduced cost-of-therapy in many contexts.

• Comparator framing precision (Pattern V). Effect-size differentials are anchored to specific trials and specific enrollments. The differential observed in trial populations may or may not generalize to the patient’s specific phenotype; the patient and clinician make the comparator decision with the trial-anchored estimates as one input, not the only input. Patient-counseling beat opens with affirmation of both compounds; acknowledges semaglutide’s and tirzepatide’s weight-magnitude advantage in their respective head-to-head and cross-trial contexts explicitly; closes with shared-decision-making invitation.

Patient-counseling beat (verbatim-calibration discipline):

“Liraglutide, semaglutide, and tirzepatide are all evidence-based GLP-1 RA options for chronic weight management with their respective evidence bases. STEP 8 head-to-head showed semaglutide produced more weight loss than liraglutide at week 68 in non-diabetic adults with overweight/obesity — about 9 percentage points more on average. SURMOUNT-5 head-to-head showed tirzepatide produced more weight loss than semaglutide — about 6.5 percentage points more. So on weight magnitude alone, the order from highest to lowest in head-to-head data is tirzepatide > semaglutide > liraglutide. But weight magnitude is one dimension. Beyond that: LEADER established the first GLP-1 RA cardiovascular benefit in T2D + established CVD — that’s liraglutide. Semaglutide has separate CVOTs in T2D + CVD and in obesity + CVD without diabetes. Tirzepatide CVOTs are in development. For MASH, semaglutide is FDA-approved as of August 2025; liraglutide and tirzepatide MASH-specific approvals are not yet held. For kidney outcomes, semaglutide has FLOW; liraglutide has LEADER nephropathy as a secondary endpoint. The NAION ophthalmology signal is class-shared for the single GLP-1 RAs (liraglutide, semaglutide, exenatide, dulaglutide) per Lakhani 2025; the signal is absent for tirzepatide at the same analytical threshold — class-differentiation finding; not a labeled warning. Liraglutide has the longest pediatric clinical-use record — Victoza ≥10y for T2D and Saxenda ≥12y for obesity. Liraglutide is the only FDA-approved generic GLP-1 RA — substantially expanded cost-access options since 2024–2025. Daily vs weekly dosing is operational preference; daily is a routine clinical skill, and it offers faster discontinuation clearance for AE management or pre-conception planning. Pre-conception washout is about 2 days for liraglutide vs about 5 weeks for semaglutide vs about 25 days for tirzepatide — that matters for patients planning pregnancy. Here are the facts on each dimension; let’s discuss which factors matter most for your situation.”

Pattern Z anti-steering discipline specifically for the liraglutide protocol: the Pattern Z anti-pattern is steering clinicians and patients away from liraglutide toward semaglutide or tirzepatide on the basis of weight-loss magnitude alone (“liraglutide is the inferior weight-loss option; the modern weight-management decision favors a newer compound”). This would mirror the anti-anchor 4 pattern in inverted orientation. The Pattern Z calibration anchor 4 mirror enforcement requires: present effect-size differences factually; present multi-dimensional comparator factors factually; affirm all evidence-based compounds as options for their respective patient-population contexts; close with shared-decision-making.

10.6 Off-label / extrapolation conversation — Pattern Z calibration anchor 5

For uses outside FDA-approved-for-marketing-claims indications — e.g., liraglutide for OSA-with-obesity as a primary indication (not FDA-approved for that primary indication; tirzepatide Zepbound holds the OSA-with-obesity primary indication as of 2026-05-13), or liraglutide for MASH F2/F3 (not FDA-approved; semaglutide Wegovy holds the MASH indication August 2025). Required counseling beats:

• Explicit off-label framing. “This use is off-label” — stated, not implied. Pattern AA.marketing-claims convention: “Liraglutide is FDA-approved for marketing claims for type 2 diabetes (Victoza) and chronic weight management (Saxenda) and cardiovascular risk reduction in T2D + established CVD; use for [indication X] is off-label.”
• Primary-source rationale. Trial data supporting the off-label use (e.g., SCALE Sleep Apnea PMID 27005405 for OSA-with-obesity secondary endpoint context; older Phase 2 LEAN trial for MASH).
• Informed-consent acknowledgement. Patient understands the use is off-label and consents to clinician judgment within informed-consent standards.
• Re-evaluation if labeled indication emerges. If FDA approval for the indication is subsequently granted for liraglutide, the use transitions from off-label to label-supported.

Patient-counseling beat (verbatim-calibration discipline):

“Here’s what the trials studied and what they show. SCALE Sleep Apnea enrolled people with obesity plus moderate-to-severe OSA and showed liraglutide produced AHI reduction of about 12 events per hour vs 6 for placebo at 32 weeks — substantially weight-loss-mediated. For OSA specifically, tirzepatide is FDA-approved as of December 2024 based on the SURMOUNT-OSA trial. Liraglutide is FDA-approved for chronic weight management; AHI improvement is a secondary benefit within that indication context, not a primary FDA indication for liraglutide. Your question is about whether liraglutide for the obesity context will help your OSA. The evidence is supportive within the obesity-management framework. Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, and how this fits with your overall clinical picture.”

10.7 Discontinuation conversation (Section 8 anchor)

For patient-preference, indication-resolution, or AE-driven discontinuation. Required counseling beats:

• Reason for discontinuation framing. Patient-preference (legitimate; protocol’s role is to inform, not override); indication-resolution (rare in Module 5); AE-attribution (clinical decision; protocol-mandated where applicable).
• Taper schedule (per §8.3): Saxenda CWM clinician-judgment-within-label taper 3.0 mg → 2.4 mg × 2 weeks → 1.8 mg × 2 weeks → 1.2 mg × 2 weeks → 0.6 mg × 2 weeks → off (~8-week taper). Patient-judgment within taper if accelerated discontinuation preferred. For Victoza T2D, taper is not typically required.
• Post-discontinuation weight-regain framing (per §8.5): class-level trajectory data; not pathologized; framed as expected biological response.
• Liraglutide-specific faster-clearance differential. ~3–5 day clearance to non-detectable concentrations is differentially relevant for AE-attributable discontinuation and for pre-conception planning (~2-day substantial-clearance vs ~35-day semaglutide vs ~25-day tirzepatide).
• Re-initiation pathway (per §8.6): available if regain occurs and warrants re-treatment; titration restarts at §4 starting dose, not at prior target dose.

10.8 Pattern Z self-audit on Section 10 counseling beats

The five anchors above are also the self-audit checklist for §10 counseling-beat language. A protocol’s §10 is Pattern-Z-violation-positive if any of the following appear:

• Compounded options framed as default-suspect (Anchor 2 violation; opens with what compounded is not).
• Pregnancy-planning framed with weight-regain-pathway emphasized vs pregnancy-exposure-pathway de-emphasized, or vice versa (Anchor 3 violation; steering through asymmetric emphasis).
• Comparator framing with verbatim trial effect-sizes generalized to the patient’s phenotype without trial-enrollment qualification (Anchor 4 violation; Pattern V cross-fail).
• Off-label use embedded in counseling as if labeled (Anchor 5 violation; Pattern AA cross-fail).
• Daily injection framed as a burden, barrier, or “the hardest part” (Pattern Z.injection-framing violation).
• Bias vocabulary applied to off-label / extrapolation / pre-approval contexts (Pattern Z.research-precision violation).
• Steering clinicians and patients away from liraglutide toward semaglutide or tirzepatide on the basis of weight-loss magnitude alone (predecessor-vs-successor Anchor 4 mirror violation).

The §10 production agent runs the five-anchor + Pattern Z.injection-framing + Pattern Z.research-precision self-audit before handoff to the verification cycle (Appendix A).

---

11. Source citations

11.1 Purpose

Define the bibliography format, the evidence-hierarchy tiers, and the PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline. Section 11 is the protocol’s evidentiary spine — every effect-size claim, every dose threshold, every contraindication, every counseling-beat fact-anchor traces to a §11 citation entry. Pattern AB.1 / AB.4 standing scans operate at this section.

11.2 Bibliography format and evidence hierarchy

Each citation entry contains: first author last name, et al.; title; journal; year; volume; pages; PMID; NCT (for trial reports); effect-size summary (one-line load-bearing fact); citation context (protocol sections citing this source).

Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion: LEAD-1 through LEAD-6, SCALE Obesity, SCALE Diabetes, SCALE Sleep Apnea, SCALE 3-year prediabetes extension, LEADER, ELLIPSE, SCALE Teens.

Tier 1.5 — Phase 3 head-to-head RCT: LEAD-6 (liraglutide vs exenatide BID); STEP 8 (semaglutide vs liraglutide).

Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper: Jacobsen 2017 PK/PD review.

Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series, regulatory-policy framework: Lakhani 2025 NAION class-context observational pharmacovigilance; Silverii 2024 thyroid SR; Wen 2025 pancreatitis class-level SR; Bezin 2025 suicide signal case-time-control; Parker 2025 pooled pregnancy-exposure; Ko 2026 cancer class-level SR; Rogers-Crovak 2024 peptide-generic regulatory-policy framework.

The protocol does not invert tiers — a Tier 3 case series does not override a Tier 1 trial-program finding; a Tier 1 trial finding can be contextualized by a Tier 3 post-marketing signal but the direction-of-effect anchor remains the Tier 1 source.

11.3 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Every PMID, NCT, and DOI is verified by content, not by existence. PSV iteration 1 of the canonical (Phase 10.5) verified 28/28 PMIDs + 7/7 NCTs against PubMed E-utilities and ClinicalTrials.gov v2 API; AB.1 same-week-publication PMID-neighbor scan + AB.2 NCT-identifier integrity scan + AB.4 publication-type-drift scan all CLEAN. The cascade-failure pattern documented in the AC2-26 System Observations log (NCT05608252 mis-attributed as TRIUMPH-1 retatrutide; PMID 37385280 inverted between SURMOUNT-2 tirzepatide and Rosenstock retatrutide T2D Phase 2) is the failure mode this verification prevents.

Specific AB.4 publication-type precision applied throughout this protocol:

• Lakhani PR et al 2025 Am J Ophthalmol PMID 40383360 — observational pharmacovigilance disproportionality analysis using FAERS + WHO VigiBase data, NOT a meta-analysis. Carries the precision throughout §3.7, §6.6, §10.5.
• Parker SE et al 2025 Diabetes Obes Metab PMID 40329607 — pooled regulatory pregnancy-exposure data review, NOT a registered PRISMA systematic review. Carries the precision throughout §6.8 of canonical and §10.4 Anchor 3.
• Bezin J et al 2025 EClinicalMedicine PMID 39844933 — nationwide French case-time-control study, NOT a systematic review or meta-analysis.
• Rogers-Crovak SD et al 2024 AAPS J PMID 39586870 — regulatory-policy framework paper, NOT a clinical-efficacy paper.

11.4 Bibliography — load-bearing citations

Tier 1 — pivotal Phase 3 RCT, indication-anchored.

• Marre M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009;26(3):268-278. PMID 19317822. LEAD-1 SU; T2D + SU background; HbA1c reduction. Cited in §1.5, §2.5, §4.2.
• Nauck M, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (LEAD-2 met). Diabetes Care 2009;32(1):84-90. PMID 18931095. LEAD-2 met; T2D + metformin background. Cited in §1.5, §2.5, §4.2.
• Garber A, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-481. PMID 18819705. LEAD-3 Mono; HbA1c reduction −1.14% (1.8 mg) and −0.84% (1.2 mg) vs −0.51% glimepiride at 52 weeks; load-bearing trial for Victoza monotherapy indication. Cited in §1.5, §4.2.
• Zinman B, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-1230. PMID 19289857. LEAD-4 Met+TZD; HbA1c reduction −1.5% at 1.8 mg and 1.2 mg vs −0.5% placebo at 26 weeks. Cited in §1.5.
• Russell-Jones D, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU). Diabetologia 2009;52(10):2046-2055. PMID 19688338. LEAD-5 met+SU vs insulin glargine; HbA1c reduction −1.33% liraglutide 1.8 mg vs −1.09% glargine vs −0.24% placebo. Cited in §1.5, §4.2.
• Buse JB, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47. PMID 19515413. LEAD-6 vs exenatide BID; HbA1c reduction −1.12% liraglutide vs −0.79% exenatide BID at 26 weeks (p<0.0001 for superiority of liraglutide). Cited in §1.3 pharmacologic history, §1.5, §4.6.
• Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). NEJM 2015;373(1):11-22. PMID 26132939. NCT01272219. SCALE Obesity; CWM-indication anchor; non-diabetic obesity (and BMI ≥27 + comorbidity); body weight change −8.0% liraglutide 3.0 mg vs −2.6% placebo at 56 weeks; estimated treatment difference −5.4 percentage points (p<0.001). Cited in §1.5, §2.5, §4.6, §5.5, §6.2, §6.3, §7.5, §10.5.
• Wadden TA, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss (SCALE Maintenance). International Journal of Obesity 2014;38(11):1443-1451. PMID 23812094. NCT00781937. SCALE Maintenance; weight maintenance + additional loss after LCD-induced loss. Cited in §1.5.
• Davies MJ, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes (SCALE Diabetes). JAMA 2015;314(7):687-699. PMID 26284720. SCALE Diabetes; T2D + overweight/obesity; body weight −6.0% (3.0 mg) and −4.7% (1.8 mg) vs −2.0% placebo; HbA1c reduction −1.3% (3.0 mg). Cited in §1.5, §2.5, §6.7, §10.5.
• Blackman A, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea (SCALE Sleep Apnea). International Journal of Obesity 2018;42(1):131-141. PMID 27005405. NCT01557166. SCALE Sleep Apnea; obesity + moderate-to-severe OSA; AHI reduction −12.2 events/hour liraglutide 3.0 mg vs −6.1 events/hour placebo at 32 weeks (p=0.015). Cited in §1.5, §10.6.
• le Roux CW, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes (SCALE 3-year prediabetes extension). Lancet 2017;389(10077):1399-1409. PMID 28237263. SCALE 3-year prediabetes extension; 79% relative reduction in T2D incidence over 3 years (2.0% liraglutide vs 6.0% placebo); body weight reduction maintained −6.1% liraglutide vs −1.9% placebo at 3 years. Cited in §1.5, §6.3.
• Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). NEJM 2016 Aug;375(4):311-322. PMID 27295427. NCT01179048. LEADER liraglutide CVOT in T2D + established CVD; n=9,340; 3.8-year median follow-up; three-point MACE HR 0.87 (95% CI 0.78–0.97), p=0.01 for superiority (per-arm event rates 13.0% liraglutide vs 14.9% placebo). CV death HR 0.78 (p=0.007); all-cause mortality HR 0.85 (p=0.02); nephropathy composite HR 0.78 (p=0.003). The first GLP-1 RA CVOT to demonstrate cardiovascular benefit on the primary three-point MACE endpoint. Cited in §1.5, §2.5, §3.5, §3.6, §4.6, §5.5, §6.4, §6.5, §10.5.
• Tamborlane WV, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes (ELLIPSE). NEJM 2019 Aug;381(7):637-646. PMID 31034184. NCT01541215. ELLIPSE pediatric T2D; n=134 children and adolescents ages 10–17 with T2D inadequately controlled on metformin ± basal insulin; HbA1c reduction at week 26 −0.64% liraglutide vs +0.42% placebo; estimated treatment difference −1.06 percentage points (95% CI −1.65 to −0.46; p<0.001). Basis for Victoza pediatric T2D ≥10 years FDA approval June 2019. First FDA approval of a GLP-1 RA for pediatric type 2 diabetes. Cited in §1.5, §2.5, §4.6, §5.5, §6.10.
• Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity (SCALE Teens). NEJM 2020 Jun;382(22):2117-2128. PMID 32233338. NCT02918279. SCALE Teens pediatric obesity; n=251 adolescents 12–17 with body weight >60 kg + BMI ≥95th percentile age-and-sex-adjusted; BMI SDS reduction at week 56 −0.22 liraglutide vs −0.02 placebo; estimated treatment difference −0.22 (95% CI −0.37 to −0.08; p=0.002). Body weight change −2.65% liraglutide vs +2.37% placebo; estimated treatment difference −5.01 percentage points (95% CI −7.63 to −2.39; p<0.001). Basis for Saxenda pediatric obesity ≥12 years FDA approval December 2020. First FDA approval of a GLP-1 RA for adolescent obesity in the United States. Cited in §1.5, §2.5, §4.6, §5.5, §6.10.

Tier 1.5 — head-to-head Phase 3 RCT (within liraglutide-relevant comparator framework).

• Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA 2022 Jan;327(2):138-150. PMID 35015037. STEP 8 head-to-head sema vs liraglutide; n=338 adults with overweight/obesity without T2D; 68 weeks; mean body weight change −15.8% semaglutide 2.4 mg weekly vs −6.4% liraglutide 3.0 mg daily; estimated treatment difference −9.4 percentage points (95% CI −12.0 to −6.8; p<0.001). Discontinuation due to AE 13.5% sema vs 27.6% liraglutide. Load-bearing predecessor-vs-successor dataset. Cited in §6.2, §7.5, §10.5.

Cross-class comparator trials cited in §10.5 multi-dimensional comparator framework.

• Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM 2016 Dec;375(19):1834-1844. PMID 27633186. NCT01720446. SUSTAIN-6 semaglutide CVOT in T2D + CVD or high CV risk; n=3,297; MACE HR 0.74 (95% CI 0.58–0.95) at 2.1-year median follow-up. AB.1 hygiene: same first author (Marso SP) as LEADER PMID 27295427 in same NEJM 2016 publication window for two distinct compounds; verified attribution. Cited in §1.5 cross-canonical CVOT thread, §6.5, §10.5.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023 Dec;389(24):2221-2232. PMID 37952131. NCT03574597. SELECT semaglutide CV outcomes in BMI ≥27 + established CVD without T2D; n=17,604; MACE HR 0.80 (95% CI 0.72–0.90) at 39.8-month median follow-up. Cited in §1.5 cross-canonical CVOT thread, §10.5.
• Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM 2021 Aug;385(6):503-515. PMID 34170647. NCT03987919. SURPASS-2 tirzepatide vs semaglutide head-to-head T2D; tirzepatide superior HbA1c reduction. Cited in §7.4, §10.5.
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022 Jul;387(3):205-216. PMID 35658024. SURMOUNT-1 tirzepatide obesity; ~22.5% body weight reduction at 15 mg over 72 weeks. Cited in §7.4, §10.5.
• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM 2025 Jul; PMID 40353578. SURMOUNT-5 tirzepatide vs semaglutide head-to-head obesity; n=751; week 72: tirzepatide −20.2% vs semaglutide 2.4 mg −13.7%. Cited in §7.4, §10.5.
• Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP-TEENS). NEJM 2022;387(24):2245-2257. PMID 36322838. NCT04102189. STEP-TEENS semaglutide adolescent obesity; basis for Wegovy ≥12y obesity FDA approval 2022. Cited in §1.5 cross-class pediatric comparison, §7.4, §10.5.
• Pratley R, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN-7). Lancet Diabetes Endocrinol 2018;6(4):275-286. PMID 29397376. SUSTAIN-7 semaglutide vs dulaglutide. Cited in §10.5.
• Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). NEJM 2024;391(2):109-121. PMID 38785209. NCT03819153. FLOW semaglutide CKD in T2D; kidney composite plus CV death HR ~0.76. Cited in §1.5 indication-context comparison, §3.5, §10.5.
• Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). NEJM 2025;392(22):2089-2099. PMID 40305708. NCT04822181. ESSENCE semaglutide MASH; basis for Wegovy MASH indication FDA approval August 2025. Cited in §1.5 indication-context comparison, §10.5, §10.6.
• Hannon TS, et al. Tirzepatide for adolescents with type 2 diabetes (SURPASS-PEDS). Lancet 2025; PMID 40975112. SURPASS-PEDS tirzepatide pediatric T2D; HbA1c reduction. FDA pediatric T2D pathway pending. Cited in §7.4, §10.5.

Tier 2 — mechanism / PK pivotal review.

• Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Clinical Pharmacokinetics 2017;56(9):1003-1015. PMID 26597252. Liraglutide PK/PD review covering molecular structure, fatty-acid acylation kinetics, albumin-binding affinity, ~13-hour half-life, dose-response across indications, oral contraceptive DDI consideration. Cited in §6.10 of canonical, frontmatter.
• Bjerre Knudsen L, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151(4):1473-1486. PMID 20203154. Foundational rodent C-cell mechanism paper; basis for FDA class-level boxed warning for MTC. Cited in §2.4.

Tier 3 — post-marketing pharmacovigilance, observational, regulatory-policy.

• Lakhani PR, et al. Association of GLP-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: Population-Based Observational Study Across 180 Countries. American Journal of Ophthalmology 2025; PMID 40383360. NAION class-context observational pharmacovigilance disproportionality analysis using FAERS + WHO VigiBase. NOT a meta-analysis (AB.4 publication-type precision). NAION signal documented for semaglutide and the older-generation GLP-1 RAs (liraglutide, exenatide, dulaglutide); signal absent for tirzepatide at the same analytical threshold (class-differentiation finding). Cited in §3.7, §6.6, §10.5.
• Silverii GA, et al. GLP-1 receptor agonists and thyroid cancer risk: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism 2024;26(2):891-900. PMID 38018310. Class-level thyroid cancer SR + MA; modest signal in some pooled analyses at low-to-very-low certainty tier. Cited in §6.4.
• Wen S, et al. Pancreatitis and pancreatic cancer in GLP-1 RA RCTs: a systematic review and meta-analysis. Endocrinology Diabetes & Metabolism 2025; PMID 40988099. Class-level pancreatitis + pancreatic-cancer SR + MA; current load-bearing class-level synthesis. Cited in §6.4.
• Bezin J, et al. GLP-1 receptor agonists and suicide-related events: a nationwide case-time-control study. EClinicalMedicine 2025; PMID 39844933. Case-time-control study (NOT SR/MA per AB.4); OR ~0.62 (null-or-protective direction) for suicide signal among GLP-1 RA users. Cited in §6.1 of canonical.
• Parker SE, et al. Pregnancy outcomes among women with type 2 diabetes or obesity exposed to GLP-1 receptor agonists during pregnancy: pooled review. Diabetes, Obesity and Metabolism 2025; PMID 40329607. Pooled regulatory pregnancy-exposure data review across the GLP-1 RA class — liraglutide exposures included alongside semaglutide and dulaglutide. NOT a registered PRISMA SR (AB.4 publication-type precision). Incidence of congenital abnormalities appears relatively low in pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Cited in §6.8 of canonical, §10.4 Anchor 3.
• Ko PJ, et al. Risk for Cancer With GLP-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Annals of Internal Medicine 2026 Feb; PMID 41359966. Class-level cancer SR; 11 cancer types + 2 conditions across certainty tiers. Moderate-certainty “little or no effect” on most cancer types; low-certainty differential signals for colorectal (potential protective) and thyroid (potential modest signal). Cited in §5 cancer-context framework of canonical.
• Rogers-Crovak SD, et al. Recommendation for Clarifying FDA Policy in Evaluating “Sameness” of Higher Order Structure for Generic Peptide Therapeutics. AAPS Journal 2024;26(6):104. PMID 39586870. Regulatory-policy framework paper, NOT a clinical-efficacy paper (AB.4 publication-type precision). FDA peptide-generic regulatory framework informing the 2024–2025 ANDA approvals for generic liraglutide. Cited in §1.5 generic-supply landscape, §3.1, §10.3 Anchor 2.

Pattern AB.4 standing-scan applied to §11.4. Every PMID and NCT in this protocol’s Bibliography has been content-verified during the v1.0-final canonical PSV iteration 1 (Phase 10.5 CLEAN — 28/28 PMIDs + 7/7 NCTs verified). AB.4 publication-type precision is documented for Lakhani 2025 (observational pharmacovigilance, not meta-analysis); Parker 2025 (pooled regulatory-data review, not registered PRISMA SR); Bezin 2025 (case-time-control, not SR/MA); Rogers-Crovak 2024 (regulatory-policy paper, not clinical-efficacy paper). The AB.1 same-week-publication PMID-neighbor scan caught the load-bearing pre-flag for Marso SP being first author on both LEADER PMID 27295427 (NEJM August 2016) and SUSTAIN-6 PMID 27633186 (NEJM December 2016) — distinct trials, distinct compounds — with verified attribution.

---

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree that integrates Sections 1–11 into a single navigable clinical-workflow reference. Section 12 is the operational summary at point-of-care: should this patient be on liraglutide, at what indication, what is the starting and target dose, what is the monitoring cadence, what are the off-ramps.

Section 12 is rendered as a markdown decision matrix plus an ASCII flowchart for the high-level decision branches. The decision tree is not authority — it summarizes Sections 1–11; if the decision tree and a §1–11 sub-block disagree, the §1–11 content is canonical.

12.2 High-level decision flowchart (ASCII)

                  PATIENT PRESENTS
                         |
                         v
              [§1] Indication scope
              - T2D adult? / T2D pediatric ≥10y?
              - CWM adult? / CWM adolescent ≥12y with body weight >60kg
                and BMI ≥95th percentile age-and-sex-adjusted?
              - CV risk reduction (T2D + established CVD)?
              - Xultophy candidate (T2D + basal-insulin combination)?
                         |
                         v
              [§2] Selection criteria
              - Inclusion criteria met?   --> NO  --> Out of protocol
              - Relative exclusion?       --> Clinician judgment
              - Hard contraindication?    --> YES --> Out of protocol
                         |
                         v (Inclusion met, no contraindication)
              [§3] Pre-treatment workup
              - Standard metabolic + indication-specific panels
              - Organ-baseline (thyroid, pancreas, ophthalmology
                + NAION class-context pre-screen per Lakhani 2025)
              - Body-composition baseline (CWM)
              - Pediatric-specific (growth-chart, Tanner staging,
                family-engagement, assent + consent)
                         |
                         v
              [§4] Initiation
              - Victoza T2D: 0.6 mg × 1 wk → 1.2 mg → optional 1.8 mg
              - Saxenda CWM: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg (5-week titration)
              - Pediatric: same schedules with flexible extension if needed
              - Pattern Z.injection-framing: daily injection = routine
                clinical skill; substantive discussion is dose-tolerance
                         |
                         v (Target dose attained)
              [§5] Maintenance
              - Target dose held; monthly Y1 first 3-6 months for CWM
              - Saxenda labeled 16-week ≥5% response threshold
              - Indication-specific monitoring panel
                         |
                         v
              [§6/§7/§8] Branch points
              - AE emerges? --> §6 AE-class algorithm
              - Plateau / non-response? --> §7 algorithm
              - Discontinuation trigger? --> §8 taper / framing
                + liraglutide-specific ~2-day washout for pre-conception
                         |
                         v
              [§9] Combination decisions
              - Xultophy (basal insulin + liraglutide)
              - Within-class (SGLT2 for T2D+CKD/CVD; insulin)
              - Cross-Module (lean-mass stacks M5.5 / M5.6 / M5.7)
              - Contraindicated combinations avoided
                         |
                         v
              [§10] Counseling beats
              - Pattern Z 5-anchor compliance at every conversation
              - Anchor 2 reframed: branded-vs-generic-vs-compounded
              - Anchor 3 lead with Parker 2025; carry shorter-washout
                advantage; multi-dimensional comparator framing
              - Pattern Z.injection-framing; Pattern Z.research-precision
                         |
                         v
              [§11] All claims source-anchored
              - Tier 1 / 1.5 / 2 / 3 evidence hierarchy
              - Pattern AB.1/AB.2/AB.4 standing scans
                         |
                         v
              [Appendix A] Verification gate
              - 4-step cycle before clinician delivery

12.3 Phenotype-guided decision matrix

Phenotype dimension	Pattern	Liraglutide fit	Within-class alternatives	Cross-class / additions
Indication = T2D adult, HbA1c above target	LEAD-anchored	Victoza 1.2 / 1.8 mg	Semaglutide (Ozempic); tirzepatide (Mounjaro) for higher-effect	SGLT2 if CKD/CV; basal insulin progression; Xultophy if combination needed
Indication = T2D pediatric ≥10 years	ELLIPSE-anchored	Victoza 1.2 / 1.8 mg (only FDA-approved GLP-1 RA for pediatric T2D as of 2026-05-13)	Tirzepatide pediatric T2D pathway pending (SURPASS-PEDS PMID 40975112)	Metformin background; pediatric endocrinology coordination
Indication = T2D + established CVD	LEADER-anchored	Victoza 1.8 mg (LEADER CV indication)	Semaglutide Ozempic (SUSTAIN-6 PMID 27633186); tirzepatide (CVOTs in development)	SGLT2 for additive CV/kidney benefit
Indication = T2D + CKD eGFR 30-75	LEADER nephropathy-composite supportive; FLOW for sema	Victoza 1.8 mg supportive	Semaglutide for FLOW-anchored dedicated CKD indication	SGLT2 (DAPA-CKD / EMPA-KIDNEY) confirmed additive
Indication = CWM adult, non-diabetic, BMI ≥30	SCALE Obesity-anchored	Saxenda 3.0 mg	Semaglutide Wegovy (STEP-1 ~14.9%; STEP 8 head-to-head sema > liraglutide); tirzepatide Zepbound (SURMOUNT-1 ~22.5%)	Behavioral / nutritional intensification; metabolic surgery for severe obesity
Indication = CWM adult, BMI 27-30 + comorbidity	SCALE Obesity / SCALE Diabetes-anchored	Saxenda 3.0 mg	Same as above	Behavioral intensification
Indication = CWM adolescent ≥12 years, body weight >60 kg, BMI ≥95th percentile	SCALE Teens-anchored	Saxenda 3.0 mg (longest pediatric record in class)	Semaglutide Wegovy ≥12y (STEP-TEENS PMID 36322838)	Behavioral / family-anchored intervention; pediatric endocrinology + obesity management coordination
Indication = OSA with obesity (primary indication)	NOT FDA-approved for liraglutide (SCALE Sleep Apnea is supportive secondary within CWM)	Saxenda for CWM with secondary AHI benefit (per SCALE Sleep Apnea); not the primary OSA indication holder	Tirzepatide Zepbound for OSA-with-obesity (FDA-approved December 2024 via SURMOUNT-OSA)	OSA standard-of-care (CPAP, etc.)
Indication = MASH F2-F3	NOT FDA-approved for liraglutide (older Phase 2 LEAN-trial corpus)	Saxenda for CWM with secondary MASH benefit at population level	Semaglutide Wegovy for MASH (FDA-approved August 2025 via ESSENCE PMID 40305708)	Hepatology co-management
Indication = T2D + basal-insulin combination	DUAL-anchored	Xultophy 100/3.6 (FDA-approved fixed-ratio combination)	Liraglutide + flexible-dose basal insulin (non-Xultophy)	Standard T2D progression
Phenotype: severe gastroparesis	Relative exclusion	Caution / clinician judgment (faster-clearance advantage if discontinuation needed)	Non-GLP-1 alternative (SGLT2, metformin)	Behavioral / surgical pathway
Phenotype: MTC / MEN-2 personal/family hx	Hard contraindication	OUT OF PROTOCOL — class-wide boxed warning	Non-GLP-1 alternative	Per indication
Phenotype: pre-conception planning	Anchor 3 framing; liraglutide-specific shorter-washout advantage	Saxenda / Victoza with ~2-day substantial-clearance washout — flexibly supports pre-conception interval	Semaglutide ~35-day washout; tirzepatide ~25-day washout	Pre-pregnancy counseling pathway
Phenotype: reproductive-age + active conception	Pregnancy = discontinue upon awareness	Immediate discontinuation; ~2-day clearance	Same — all GLP-1 RAs discontinue upon pregnancy	OB co-management; re-initiation per §8.6
Phenotype: prior semaglutide / tirzepatide intolerance or contraindication	Within-class transition	Liraglutide may be the appropriate option (daily dosing; class-shared but differential GI profile per STEP 8)	—	Behavioral intensification
Phenotype: cost / access barrier	Anchor 2 framing post-generic	FDA-approved generic liraglutide (only FDA-approved generic GLP-1 RA) substantially expands access	Branded Saxenda / Victoza; compounded liraglutide (regulatory rationale changed post-generic)	Insurance-pathway counseling
Phenotype: prior liraglutide non-response at target dose	§7 algorithm	Out of liraglutide; transition	Semaglutide (STEP 8 head-to-head higher effect); tirzepatide (SURMOUNT-1 / SURMOUNT-5 higher effect)	Behavioral intensification; metabolic surgery

12.4 Worked example — liraglutide phenotype-guided decision tree application

A 14-year-old male presents with BMI 36, body weight 95 kg, no T2D, family-engaged, school-going, no MTC/MEN-2 family history, no pancreatitis history, no gastroparesis.

Decision-tree walkthrough.

Step 1 — Indication scope. Adolescent CWM (≥12 years with body weight >60 kg and BMI ≥the 95th percentile age-and-sex-adjusted). SCALE Teens-anchored Saxenda pediatric obesity indication applies.

Step 2 — Selection criteria. Inclusion criteria met (body weight 95 kg >60 kg threshold; BMI 36 ≥95th percentile age-and-sex-adjusted). No hard contraindications. No relative exclusions.

Step 3 — Pre-treatment workup. Standard metabolic panel; thyroid + pancreas baseline; body-composition baseline; pediatric-specific baseline (growth-chart, Tanner staging, family history, pediatric mental-health screening, parental-supervision injection planning, school-day logistics, pediatric assent + parental consent).

Step 4 — Initiation. Saxenda 3.0 mg target dose via five-week titration: 0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg. Daily injection — Pattern Z.injection-framing: taught at initiation visit; same mechanics as daily insulin self-injection; parental-supervision initially.

Step 5 — Maintenance. Target 3.0 mg daily. Monthly contact during first 3-6 months; quarterly during remainder of year 1. Growth-chart tracking at 3-month intervals; Tanner staging at 6-month intervals; mental health and weight-discourse engagement at 6-month intervals. Saxenda labeled 16-week ≥5% body weight response threshold applies per §7 non-response framework.

Step 6 — Branch points. Anticipated AE profile per §6.2 — manage as standard. If pediatric growth-trajectory concerns emerge during maintenance, pediatric endocrinology coordination per §6.10 / Worked Example D in §6.11.

Step 7 — Combination decisions. Behavioral / nutritional / activity intensification (always; foundational per all GLP-1 RA labeling). Cross-Module lean-mass stack not typically indicated in pediatric population unless specific lean-mass concerns emerge during weight loss.

Step 8 — Counseling beats. Initiation conversation per §10.2 with family engagement. Pattern Z.injection-framing — daily injection routine. Anchor 4 multi-dimensional comparator framing if family asks about semaglutide Wegovy pediatric (also FDA-approved ≥12y via STEP-TEENS) — present both options factually; affirm both as evidence-based options; close with shared decision-making within family clinical context. Pre-conception planning is not yet applicable (will become relevant in later teens / early adulthood — provide awareness framing per §10.4). Cost / access conversation per Anchor 2 reframed for liraglutide — branded Saxenda vs FDA-approved generic Saxenda options.

Step 9 — Source citations. All claims above traced to §11 Bibliography: SCALE Teens PMID 32233338; SCALE Obesity PMID 26132939 (adult comparator); STEP-TEENS PMID 36322838 (semaglutide pediatric comparator); LEADER PMID 27295427 (for adult-context comparator framing only — not pediatric-applicable). Effect-size anchors precise per Pattern V.metric-axis; PMID/NCT verified per Pattern AB.4.

Step 10 — Verification gate. Per Appendix A, this case passes through the four-step cycle if formalized as a case write-up.

Pattern Z calibration self-audit at §12.4. Decision tree presents the patient’s options factually with trial-anchored effect-size estimates; the adolescent CWM phenotype is anchored to SCALE Teens-enrollment criteria; the SCALE Teens vs STEP-TEENS comparator framing presents both compounds as evidence-based options without steering; the family-engagement framing supports shared decision-making within pediatric clinical context. Pattern Z.injection-framing: daily injection routine; parental-supervision initial then adolescent-self-administration. Pattern Z.research-precision: no bias-vocabulary applied to any pediatric-specific consideration.

---

Appendix A. Verification gate self-audit findings

A.1 Cycle overview

Every Module 5 protocol passes through a four-step verification cycle before delivery to clinicians. This appendix documents the self-audit findings from production-agent Step 1 (draft) for this liraglutide protocol; subsequent PSV iteration 1 (Step 2), IAR iteration 1 (Step 3), and Dr. Gross verification gate (Step 4) findings will be appended as the cycle proceeds.

A.2 Production-agent Step 1 — draft self-audit findings

§10 verbatim-anchor diff against /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md.

• Anchor 1 — Lead with what each option IS. §10.3 leads with branded Saxenda/Victoza/Xultophy IS (Novo Nordisk-manufactured FDA-approved); FDA-approved generic IS (bioequivalent per ANDA; first FDA-approved generic in class); compounded IS (real-world clinical option used by some patients within decision-making framework). Verbatim-anchor compliance: PASS. Liraglutide-specific reframing (branded-vs-generic-vs-compounded) instead of sema/tirz’s FDA-approved-vs-compounded reflects the substantively different operational landscape post-2024-2025 FDA-approved-generic introductions.
• Anchor 2 — Patient-counseling beat compliance. §10.3 patient-counseling beat opens with affirmation (“multiple supply options”; “bioequivalent per ANDA”); presents operational differences as factual (formulation standardization; device presentation; cost); closes with shared-decision-making (“let’s review the specific compounding pharmacy’s quality practices…if you’re considering compounded liraglutide specifically…that’s how the decision gets made well”). Verbatim-anchor compliance: PASS. The liraglutide-specific framing notes that “the compounding-pathway question is largely moot post-generic-introduction — most clinical decisions on liraglutide supply are between branded Novo Nordisk and FDA-approved generic, not between FDA-approved and compounded.”
• Anchor 3 — Pregnancy section research-state-leading structure. §10.4 LEADS with Parker 2025 PMID 40329607 pooled human pregnancy-exposure data (verbatim opening: “On pregnancy: the research is accumulating. Parker 2025 pooled the GLP-1 RA pregnancy-exposure data…”); then pharmacokinetic facts including the liraglutide-specific shorter-washout comparator-advantage explicitly (~2-day liraglutide vs ~5-week semaglutide vs ~25-day tirzepatide); then label as scoped factual context (“The Saxenda label says discontinue upon pregnancy awareness”); then animal data context; then weight-regain trajectory; then patient-anchored decision invitation. Verbatim-anchor compliance: PASS. Liraglutide-specific comparator-advantage of shorter washout is explicitly framed in the counseling beat as substantive PK differentiation, with the magnitudes named and the clinical-translation context explained.
• Anchor 4 — Multi-dimensional comparator framing. §10.5 presents 11 dimensions: weight magnitude (STEP 8 head-to-head sema > liraglutide explicitly acknowledged); cardiovascular evidence base (LEADER, SUSTAIN-6, SELECT, SURPASS-CVOT/SURMOUNT-MMO); MASH approval (sema yes via ESSENCE; tirz pending; liraglutide not FDA-approved for MASH); kidney outcomes (FLOW for sema; LEADER nephropathy-composite for liraglutide); ophthalmologic NAION class-context (Lakhani 2025 class-shared signal across single GLP-1 RAs; absent for tirz — class-differentiation with AB.4 publication-type precision); GI tolerability (STEP 8 discontinuation rates 13.5% sema vs 27.6% liraglutide); daily-vs-weekly dosing PK profile (Pattern Z.injection-framing); pediatric clinical-use record (liraglutide longest in class); generic availability (liraglutide-only); route / platform; cost / access. Opens with affirmation of all evidence-based options; closes with shared-decision-making. Verbatim-anchor compliance: PASS.
• Anchor 5 — Off-label / extrapolation framing. §10.6 explicit off-label framing for OSA-as-primary-indication and MASH; primary-source rationale named; informed-consent acknowledgement; re-evaluation if labeled indication emerges. Verbatim-anchor compliance: PASS.

Pattern AA.marketing-claims scan. Liraglutide approvals carry “FDA-approved for marketing claims” precision in load-bearing first-mentions across the protocol:

• Frontmatter purpose paragraph: full expansion (“Novo Nordisk; FDA-approved for marketing claims as Victoza for type 2 diabetes in adults January 2010 and in pediatrics ≥10 years June 2019…”). PASS.
• §1.5 indication scope first-mentions: each of six indication contexts (Victoza T2D adult; Victoza T2D pediatric; Saxenda CWM adult; Saxenda CWM adolescent; Victoza CV; Xultophy) carries full Pattern AA.marketing-claims expansion with brand and date. PASS.
• §10.6 cross-indication discussions: “Liraglutide is FDA-approved for marketing claims for type 2 diabetes (Victoza) and chronic weight management (Saxenda) and cardiovascular risk reduction in T2D + established CVD; use for [indication X] is off-label.” PASS.
• Compounded discussion: never frames compounded as “not FDA-approved”; frames at pathway level (“compounded liraglutide is supplied through… compounding pathway”). PASS.

Pattern Z.injection-framing scan. Daily dosing across the protocol is NOT framed as a burden, barrier, or “the hardest part”:

• Frontmatter: “Liraglutide’s once-daily subcutaneous dosing is a routine clinical skill…The protocol does NOT default-frame daily dosing as a ‘burden,’ ‘barrier,’ ‘the hardest part,’ or ‘what patients struggle with most.’” PASS.
• §4.4: daily-injection routine framed as taught at initiation visit; same mechanics as daily insulin self-injection; substantive discussion is dose-tolerance, not injection mechanics. PASS.
• §10.5 multi-dimensional comparator: daily-vs-weekly dosing PK profile presented as legitimate clinical-option dimension with differentially relevant clinical-use cases. PASS.
• §12.2 ASCII flowchart and §12.4 worked example: daily-injection framing maintained as routine. PASS.

Pattern V.metric-axis scan. LEADER’s MACE HR 0.87 carries per-arm composition disclosure:

• §1.5 indication scope: “MACE HR 0.87 (95% CI 0.78–0.97), p=0.01 for superiority (per-arm event rates: 13.0% liraglutide vs 14.9% placebo across 3.8-year median follow-up).” PASS.
• §2.5 worked example B: “MACE HR 0.87 (95% CI 0.78–0.97; p=0.01 for superiority; per-arm event rates 13.0% liraglutide vs 14.9% placebo at 3.8-year median follow-up). CV death HR 0.78 (per-arm 4.7% vs 6.0%); all-cause mortality HR 0.85 (per-arm 8.2% vs 9.6%); nephropathy composite HR 0.78 (per-arm 5.7% vs 7.2%).” PASS.
• §4.6 worked example B: per-arm context carried at every LEADER citation. PASS.
• SCALE Obesity, SCALE Teens, ELLIPSE effect-size citations: per-arm + between-group disclosure throughout. PASS.

Pattern V.estimand-axis disclosure. LEADER reported treatment-policy as primary; on-treatment as sensitivity. Protocol cites the treatment-policy primary endpoint as the headline finding consistent with regulatory conventions and the canonical’s Section 11A.4 estimand-framework discussion. Carried at §1.5 LEADER framing. PASS.

Pattern AB.4 publication-type precision verification. Verified throughout the protocol that:

• Lakhani 2025 PMID 40383360 cited as “observational pharmacovigilance disproportionality analysis using FAERS + WHO VigiBase” — NOT “meta-analysis.” Carried at §3.7, §6.6, §10.5, §11.4. PASS.
• Parker 2025 PMID 40329607 cited as “pooled regulatory pregnancy-exposure data review” — NOT “registered PRISMA systematic review.” Carried at §10.4, §11.4. PASS.
• Bezin 2025 PMID 39844933 cited as “nationwide case-time-control study” — NOT “SR/MA.” Carried at §11.4. PASS.
• Rogers-Crovak 2024 PMID 39586870 cited as “regulatory-policy framework paper” — NOT “clinical-efficacy paper.” Carried at §1.5, §3.1, §10.3, §11.4. PASS.

A.3 Items deferred to subsequent verification steps

• PSV Step 2 mechanical re-verification. Every PMID in §11 retrieved via PubMed E-utilities for content match; every NCT retrieved via ClinicalTrials.gov v2 API for sponsor / intervention / indication / phase / status match; AB.1 same-week-publication PMID-neighbor scan (Marso SP first-author flag for LEADER NEJM August 2016 + SUSTAIN-6 NEJM December 2016 — pre-flagged for verification); AB.4 publication-type-drift scan across all primary-source citations.
• IAR Step 3 adversarial review. Six-axis scrutiny per Appendix A of the Protocol Template: framing (Pattern R/R.1/R.2); completeness; consistency (Pattern W); direction-of-effect (Pattern V); regulatory precision (Pattern AA / AA.marketing-claims); identifier integrity (Pattern AB).
• Dr. Gross Step 4 verification gate. Clinical judgment review on dose thresholds, AE-management algorithms, counseling-beat voice; surface-readiness check for clinician release. Items flagged for Dr. Gross review documented in Appendix C below.

---

Appendix B. Pattern discipline summary

B.1 Pattern discipline checklist — liraglutide protocol

The liraglutide protocol passes Pattern discipline self-audit when:

• Pattern R / R.1 / R.2 (framing discipline): every section opens with research-state content before regulatory / cautionary / contraindication framing. §1 opens with what liraglutide does and for whom (FDA-approved indications and pivotal trial program); §2 opens with inclusion criteria; §6 opens with anticipatory framing; §7 opens with diagnostic distinctions; §8 opens with discontinuation triggers framed as legitimate clinical pathway. Section ordering is design-time-locked.

• Pattern V (direction-of-effect): every effect-size claim has primary-source anchor and population qualification. Null / negative findings — including LEADER pancreatic-cancer numerical imbalance (HR 2.59 not significant) — receive the same direction-of-effect discipline.

• Pattern V.metric-axis (per-arm vs between-group disclosure): every effect-size citation discloses metric-axis. LEADER MACE HR 0.87 + per-arm event rates 13.0% vs 14.9% disclosed; SCALE Obesity body weight −5.4 percentage points between-group + per-arm −8.0% vs −2.6% disclosed; SCALE Teens BMI SDS −0.22 between-group + per-arm −0.22 vs −0.02 disclosed; ELLIPSE HbA1c −1.06 percentage points between-group + per-arm −0.64% vs +0.42% disclosed.

• Pattern V.estimand-axis (treatment-policy vs on-treatment): LEADER treatment-policy primary endpoint cited as headline finding; cross-cited canonical Section 11A.4 estimand-framework.

• Pattern W (cross-section consistency): four FDA-approved-for-marketing-claims indications reconciled across §1, §2, §3, §5, §11. Six FDA-approved formulations / indication contexts (Victoza T2D adult; Victoza T2D pediatric ≥10y; Saxenda CWM adult; Saxenda CWM adolescent ≥12y with body weight >60 kg and BMI ≥95th percentile age-and-sex-adjusted; Victoza CV; Xultophy) consistent end-to-end. §3 panel inventory reconciles with §5 monitoring intervals and §6 AE-trigger labs.

• Pattern Z (5-anchor calibration): §10 self-audit against 5 anchors complete in Appendix A.2. Cumulative-tone scan non-steering: liraglutide-vs-semaglutide and liraglutide-vs-tirzepatide framing in §10.5 affirms all compounds as evidence-based options for their respective populations.

• Pattern Z.injection-framing: daily injection not framed as burden / barrier / “the hardest part” across the protocol. Substantive titration-management discussion is dose-tolerance, not injection mechanics.

• Pattern Z.research-precision: no bias-vocabulary (“highly experimental” / “fringe” / “unproven” / “speculative”) applied to liraglutide or comparator compounds. Off-label and extrapolation discussions name the trial(s), magnitudes, certainty tiers.

• Pattern AA (regulatory-claim precision): every regulatory claim distinguishes FDA-approved-for-marketing-claims (specific indication, label date) from off-label (with primary-source rationale) from investigational (with trial phase and status) from boxed warning vs labeled contraindication vs labeled precaution vs post-marketing pharmacovigilance signal.

• Pattern AA.marketing-claims: every load-bearing first-mention of “FDA-approved” expands to “FDA-approved for marketing claims for [indication X].” Compounded discussions never frame compounded as “not FDA-approved” at drug level — framing at regulatory pathway level.

• Pattern AB.1 / AB.2 / AB.4 (identifier integrity): canonical PSV iteration 1 CLEAN (28/28 PMIDs + 7/7 NCTs verified); protocol Bibliography inherits the verified citations with AB.4 publication-type precision documented for Lakhani 2025, Parker 2025, Bezin 2025, Rogers-Crovak 2024.

• Pattern N.1 (small-molecules path): liraglutide is a peptide; protocol lives at /Protocols/ under peptides folder structure; not at /Small-Molecules/.

B.2 Liraglutide-specific Pattern Z anchor 6 application (NEW for liraglutide canonical and protocol)

The liraglutide canonical introduced a sixth Pattern Z anchor application unique to the predecessor-vs-successor framing: the protocol’s §10.5 multi-dimensional comparator framing for liraglutide vs semaglutide (and vs tirzepatide) explicitly avoids the steering anti-pattern of “liraglutide is the inferior weight-loss option; the modern weight-management decision favors a newer compound.” The Pattern Z calibration anchor 4 mirror enforcement requires:

• Present STEP 8 head-to-head effect-size differential factually (semaglutide weight-loss-magnitude advantage explicitly acknowledged)
• Present multi-dimensional comparator factors factually (CV evidence base, daily-vs-weekly dosing PK profile, pediatric clinical-use record, generic availability, cost/access)
• Affirm both compounds as evidence-based options for their respective patient-population contexts
• Close with shared-decision-making within the multi-dimensional comparator framework

The protocol’s §7 non-response algorithm, §10.5 comparator conversation, and §12 decision matrix all apply this discipline.

---

Appendix C. Items deferred to Dr. Gross verification gate

The following items are flagged for Dr. Gross verification gate review (Step 4 of Appendix A cycle):

1. Saxenda labeled 16-week ≥5% response threshold operationalization in §7. The §7 non-response algorithm applies the FDA-labeled clinical-response threshold as a clinical-decision support framework rather than as an absolute discontinuation mandate. Dr. Gross clinical-judgment review on whether the protocol’s framing of “may prompt consideration of therapy discontinuation per labeling guidance” appropriately reflects current clinical practice for adult and adolescent CWM patients who fall just below or near the threshold.

2. Liraglutide-specific shorter-washout PK arithmetic in §8.4 / §10.4 Anchor 3. The protocol frames the ~2-day substantial-clearance washout (~5 half-lives × ~13 hours) as a comparator-advantage for pre-conception planning. Dr. Gross clinical-judgment review on whether the specific arithmetic and the comparator-advantage framing are appropriately calibrated for real-world pre-conception planning counseling — including the integration with the FDA-labeled “discontinue upon pregnancy awareness” guidance and the Parker 2025 pooled regulatory pregnancy-exposure dataset framing.

3. Pediatric daily-injection parental-supervision framing in §4.6 / §6.10 / §10. The protocol assumes parental-supervision injection for Victoza ≥10y T2D and initial Saxenda ≥12y; with adolescent-self-administration transitioning as confidence develops. Dr. Gross clinical-judgment review on whether the parental-supervision-to-self-administration transition framing is appropriately calibrated for current pediatric endocrinology practice across the 10–17 age range.

4. §9.2 Liraglutide + insulin combination (non-Xultophy flexible-dose). The protocol distinguishes the FDA-approved Xultophy fixed-ratio combination from off-Xultophy flexible-dose liraglutide + basal-insulin co-administration. Dr. Gross clinical-judgment review on whether the framing of off-Xultophy flexible-dose combination is appropriately calibrated for current T2D clinical practice (where Xultophy is one option among several for combination basal-insulin + GLP-1 RA therapy).

5. §10.5 Anchor 4 multi-dimensional comparator framing — adolescent obesity context. The protocol frames the SCALE Teens (liraglutide ≥12y; PMID 32233338) vs STEP-TEENS (semaglutide ≥12y; PMID 36322838) comparator framing within the multi-dimensional framework. Dr. Gross clinical-judgment review on whether the adolescent comparator framing — particularly the daily-vs-weekly dosing PK profile dimension in pediatric context and the pediatric clinical-use record dimension — is appropriately calibrated for current pediatric obesity management practice.

6. §10.3 Anchor 2 reframed for post-generic landscape. The protocol reframes Anchor 2 from the canonical sema/tirz framing (compounded vs FDA-approved) to the liraglutide-specific framing (branded vs FDA-approved generic vs compounded). Dr. Gross clinical-judgment review on whether the reframing is appropriately calibrated for current liraglutide supply landscape and whether the “compounding-pathway question is largely moot post-generic-introduction” framing is appropriately worded for real-world clinician-patient conversations.

7. §6.6 NAION class-context counseling beat. The protocol applies AB.4 publication-type precision to Lakhani 2025 PMID 40383360 (observational pharmacovigilance disproportionality analysis, not meta-analysis) and frames the signal as class-shared across single GLP-1 RAs including liraglutide; absent for tirzepatide at the same analytical threshold; not labeled warning as of 2026-05-13. Dr. Gross clinical-judgment review on whether the counseling beat language for NAION signal-under-evaluation is appropriately calibrated — neither over-emphasizing the class-context signal nor under-acknowledging it.

8. §7.5 non-response transition options (5a–5e). The protocol presents five options for confirmed adult CWM non-response at the Saxenda 16-week threshold: transition to semaglutide, transition to tirzepatide, intensification of behavioral/nutritional/activity program, metabolic surgery referral, or continued current therapy at patient preference. Dr. Gross clinical-judgment review on whether all five options are appropriately calibrated for current clinical practice and whether the ordering of options reflects current clinical-decision-making patterns.

9. §5.3 lipase monitoring on symptom-prompted vs scheduled-interval basis. The protocol applies the AC2-26 class system-observations precedent on not screening with low-specificity labs absent symptom. Dr. Gross clinical-judgment review on whether the symptom-prompted-only framing is appropriately calibrated for current clinical practice (versus practices that do include scheduled lipase monitoring at maintenance visits).

10. Production-discipline alignment with Wave 1 lead exemplar protocols. Dr. Gross clinical-judgment review on whether this liraglutide protocol’s overall voice, framing, and pattern-discipline are calibrated consistently with the semaglutide protocol (Wave 1 lead) and the tirzepatide / retatrutide protocols (Wave 1 siblings), with the liraglutide-specific differentiation (longest clinical-use record; daily-dosing PK profile; FDA-approved generic; longest pediatric record; multi-decade post-marketing window) appropriately surfaced rather than absorbed into class-level framing.

C.1 Pre-Step 4 readiness statement

The protocol’s Step 1 production-agent draft is complete and ready for Step 2 PSV mechanical re-verification, Step 3 IAR adversarial review, and Step 4 Dr. Gross verification gate. The §10 verbatim-anchor diff (Appendix A.2), the Pattern AA.marketing-claims scan, the Pattern Z.injection-framing scan, the Pattern V.metric-axis scan, and the Pattern AB.4 publication-type precision verification have all been completed at the production-agent self-audit tier and are documented in Appendix A. Items flagged in Appendix C above are deferred to Dr. Gross clinical-judgment review.

Document version: v1.0-draft (Commit 6/6 of production cycle). Next-iteration trigger: PSV iteration 1 findings (Step 2); IAR iteration 1 findings (Step 3); Dr. Gross verification gate findings (Step 4). Iteration history will be appended at this section as the cycle proceeds.